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OBJECTIVE: To evaluate the humoral and cellular immune response against bone 
associated antigens when delivered in a vaccine, and to evaluate the immunomodulation on 
the aforementioned immune response with the addition of adipose-derived mesenchymal 
stromal cells (AD-MSCs).  
 
ANIMALS: 68 C57BL/6 mice 
 
PROCEDURES: Femur fragments harvested from Balb/C or C57BL/6 mice were 
resuspended in PBS and cationic liposomal DNA complexes (CLDC) to create an allograft or 
autograft vaccine, respectively. A positive control vaccine was created utilizing bovine 
alkaline phosphatase (ALP) resuspended in PBS and CLDC. Twenty C57BL/6 mice were 
divided into four treatment groups: non-vaccinated (n=5), ALP vaccine recipients (n=5), 
allograft bone vaccine recipients (n=5), or autograft bone vaccine recipients (n=5). Forty-
eight C57BL/6 mice were divided into the same 4 vaccine treatment groups (n=16), and 
received either intravenous AD-MSCs (n=8) or a subcutaneous injection of AD-MSCs (n=8). 
All mice received an initial vaccine on Day 1 and a booster vaccine on Day 7, followed by 
euthanasia on Day 21. Blood was collected on Day 1 and Day 7 just prior to vaccination, and 
on Day 21 just prior to euthanasia. Serum was subjected to an antibody detection ELISA to 
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evaluate the humoral response. Spleens were collected and flow cytometry was used to 
evaluate T cell proliferation as an indicator of the cellular immune response.  
 
RESULTS: The bone vaccines did no elicit a detectable humoral immune response to the 
total bone antigen vaccine used in this model. The addition of AD-MSCs had no effect on the 
lack of a detectable humoral immune response. The T cell response towards a bone antigen 
was dampened in mice previously vaccinated with a bone vaccine. This effect was most 
pronounced when looking at the T cell response towards an allograft bone antigen in mice 
previously vaccinated with an allograft bone vaccine, particularly with the addition of AD-
MSCs. 
 
CONCLUSIONS AND CLINICAL RELEVANCE: The bone vaccine model used in this study 
allowed evaluation of the humoral and cellular immune response towards bone associated 
antigens. The model suggests that recipients of an allograft bone vaccine will dampen the T 
cell proliferation seen upon second exposure to the bone antigens. This model could be 
used in future vaccine studies looking at the effect of vaccinating mice with a bone vaccine 
prior to undergoing a limb-salvage procedure. If efficacious, the bone vaccine model may 
provide a new treatment option for decreasing the risk of transplant rejection following 
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 Osteosarcoma is the most common primary malignant bone tumor in both human 
and canine patients, making up 85% of all skeletal malignancies (20). It has a bimodal age 
distribution with an average onset occurring during the teenage years or over 60 in 
humans, and a median age of 7 in canines (14, 20). The majority of osteosarcoma tumors 
arise in the appendicular skeleton near the metaphysis of long bones; a region 
characterized by abundant levels of trabecular bone and decreased levels of cortical bone, 
as compared to the adjacent diaphysis. The onset of osteosarcoma is associated with rapid 
bone turnover and increased osteoblastic activity. The 5-year survival rate for human 
patients with localized osteosarcoma ranges from 60-70% when treatment includes 
chemotherapy. The 5-year survival decreases to 20% when metastatic disease is present 
due to limited efficacy of current treatment protocols in controlling the progression of the 
disease (22). The median survival for dogs treated with both chemotherapy and surgery is 
nine to eleven months, with a 20% 2-year survival rate (8). Micro-metastasis is present in 
90-95% of canine patients at the time of diagnosis and one-third of human patients will 
develop metastatic disease (2, 8). Without chemotherapy, 90% of canine patients will 
develop metastatic disease by 1 year, and 80% of humans will develop metastatic disease 
by 2 years, with the lung being the primary metastatic location for both species (20). 
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Current protocols for treating osteosarcoma in dogs include both palliative and curative-
intent therapies.  
 Palliative therapies are aimed at increasing the quality of life of the patient, but have 
no effect on survival time. Common palliative protocols include amputation or radiation 
therapy, and most commonly target bone cancer pain. Radiation therapy is considered the 
most effective palliative treatment and is used to alleviate the osteolytic bone pain that 
accompanies osteosarcoma. Osteosarcoma bone pain is attributed to the high density of 
nociceptors, or pain receptors, present at the periosteal surface and in the medullary 
cavity. Chemical mediators released from tumor cells with invasive malignant osteoblast 
growth can stimulate the nociceptors, causing intense pain for the patient (4). 
Furthermore, the positive modulation of neurotrophins, a group of proteins aimed at 
increasing development and function of neurons, can result in nociceptor sensitization to 
outside stimuli. The dysregulated osteoclast activity present in primary or metastatic bone 
disease can induce an increase in acidity within the bone, causing the sensitized 
nociceptors to increase expression of acid-sensing receptors, leading to activation of the 
nociceptors and severe pain within the bone (7, 20). Radiation therapy is known to induce 
apoptosis of diseased osteoblasts and osteoclasts (20). It has been hypothesized that the 
inhibition of osteoclast activity by radiation and other palliative therapies such as 
bisphosphonates will increase the pH of the bone microenvironment, thereby decreasing 
the stimulation of the acid-sensing receptors on nociceptors and reducing overall bone 
cancer pain (4). Of the canine patients presenting with osteosarcoma, 74-96% tend to 
experience a median pain-free time interval of 53-130 days following a standard 2 to 4 
treatment fraction protocol, with each treatment delivering 6 to 10 Grey fractions of 
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radiation (11, 20). While palliative therapies can be successful at managing bone cancer 
pain and increasing quality of life, they are not able to control progression of the metastatic 
disease. The delivery of chemotherapy in conjunction with radiation therapy has been 
shown to delay the onset of metastatic disease, but this combination does not function as a 
curative-intent therapy. Radiation therapy alone in canine patients yields a mean survival 
time of 4.1-10.4 months (11).  
 Curative-intent therapies target the local tumor, as well as the systemic disease in 
the hopes of prolonging survival time for the patient. The standard protocol for curative–
intent therapy is amputation or limb salvage of the affected limb to remove the local tumor, 
followed by chemotherapy to target the micrometastasic disease. Surgery alone will rid the 
patient of the primary tumor, however is not considered a curative-intent therapy. Human 
patients have a survival rate of 5 to 23% at 5 years following amputation alone, and a study 
looking at the outcome of amputation alone in 19 canines showed a mean survival time of 
218 days (10). Canine patients are able to rapidly compensate with three limbs as long as 
no preexisting orthopedic or neurologic conditions that could severely impact ambulation 
are present (20). Human patients respond well to amputation and are able to walk with the 
use of prosthetics. An inefficient gait and alteration of ideal mechanical and anatomical 
alignment due to loss of the knee joint can be seen in human patients having an above-the- 
knee amputation as opposed to a below-the-knee amputation, however an overall rapid 
compensation to limb loss is observed (9). While amputation is still a prevalent treatment 
for patients with osteosarcoma, limiting factors such as severe pre-existing orthopedic 
disease or a lack of social acceptance towards amputation requires the need for a different 






 The limb-salvage procedure was developed as an alternative to amputation, 
and can employ segmental bone autograft or allograft, massive endoprostheses or 
combinations. In canine patients, ideal candidates for the limb-salvage procedure include 
patients presenting with osteosarcoma that is confined to the limb and less than 50% of the 
bone is affected. Furthermore, an ideal candidate would also present without pathologic 
fracture of the bone (20). Commonly, a fresh-frozen allograft is harvested from a donor, 
and is cut to fit the defect during surgery. Once placed, the graft is stabilized with a dynamic 
compression plate. (20).  Recovery after a limb-spare procedure is rapid, and good limb use 
can be seen within 10 days post-operatively for canine patients and 6-8 weeks for human 
patients. While not widely recognized, the use of an allograft is accompanied with the 
presence of transplantation immunity, which can be a contributing factor to allograft 
failure (5). While the allograft limb-salvage procedure does prevent the need for 
amputation, massive allograft reconstruction is accompanied with a high failure rate of 
60% at 10 years for human patients and 50% at 2 years for canine patients. Furthermore, 
30% of human patients and 50% of canine patients will develop complications within the 
first 1-3 years post surgery, including infection, local recurrence, and implant failure (9,20). 
Canines have an infection rate of 40-50%, despite the intra-operative use of antibiotics 
(20).  
 
An autograft can be used in the limb-salvage procedure, and is obtained from the 
same individual undergoing the procedure. This is most commonly seen in an ulna 
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transposition limb salvage procedure performed in canines, in which the ipsilateral distal 
ulna is used to reconstruct a distal radial defect. Due to the use of autologous bone, the 
chance of infection and transplantation immunity is negated, and the healing period is 
accelerated as compared to patients receiving an allograft. However, the transposed ulna is 
smaller in size compared to the surrounding radius, so the risk of biomechanical failure is 
increased with this procedure (20).  
 




 In order to better understand the factors contributing to massive allograft failure, 
Sharon Stevenson conducted a study to evaluate the recipient biologic response to 
allografts and autografts in canine patients (5).  A successful graft will induce osteogenesis, 
or the formation of new bone that will allow graft incorporation into host bone. This 
process of forming new bone can be referred to as osteoinduction, and involves bone 
morphogenic protein (BMP)- stimulated differentiation of mesenchymal cells into 
osteoblasts. Results from the study by Stevenson, et al show that BMP is present in both 
fresh autografts and modified allografts, but is eliminated with heat treatment, such as 
autoclaving the graft. Massive cortical grafts undergo incorporation into host bone, which 
is characterized by a multi-phase process involving inflammation, osteogenesis and 
remolding, and development of a mechanically efficient bone, however the cortical allograft 
will forever remain a mix of necrotic, non-viable bone and host bone. The initial 
inflammatory phase of the graft incorporation process is due to the host immune system 
launching an acute inflammatory response to the trauma caused by surgery, regardless of 
6 
the type of graft placed. This acute inflammatory response will subside over the first week 
post-operation and allow for an increase in osteoclastic activity to repair bone. The 
osteoinduction process will continue for several weeks, and it is during this time that the 
host immune system will recognize foreign antigens present on the donor allograft bone 
(5).  
 Stevenson, et. al compared the rate of bone incorporation between massive cortical 
autografts and allografts in a canine model. They found that resorption of cortical bone 
grafts is dictated by the presence of osteoclasts and will increase for 6 weeks post-
operation and undergo a gradual decline afterwards. Massive allograft transplants have a 
higher risk of poor revascularization and host-graft incorporation as compared to an 
autograft. These investigators hypothesized that poorer incorporation seen with massive 
cortical allograft transplant as compared to autograft transplant is in part due the host 
immune response mounted against the foreign donor antigens present on the allograft. The 
delayed incorporation results in a significantly weaker bone construct as compared to an 
autograft, construct and contributes to a rapid failure rate. In attempts to eliminate the host 
immune response against an allograft, Stevenson, et. al looked at the effect of freezing on 
allograft incorporation and immune response, and found that, while the initial immune 
response was dampened in groups receiving the frozen allograft compared to the groups 
receiving a fresh cortical allograft, bone formation was still significantly delayed in patients 
receiving a frozen graft and bone strength was considerably weaker for longer periods of 
time when compared to autograft (5). While the best outcome of host-graft incorporation is 
seen following the transplant of a cortical autograft, clinically, massive cortical allografts 
are more readily available in the form of cadaveric bone, and more feasible for large 
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reconstructive surgeries. While freezing of the allograft bone diminishes the immune 
response, it does not completely eliminate the host immune response to donor bone 
antigens. Therefore, modulation of allograft immunogenecitiy could be useful to increase 






 Transplant rejection is a well-described phenomenon in whole organ 
transplantation, however, the same processes occur with fresh tissue grafts. Transplant 
rejection occurs when the host immune system recognizes alloantigens present on the 
donor tissue. These alloantigens are proteins that vary between individuals and are 
therefore recognized by the immune system as being foreign to the recipient. Foreign 
pathogens are internalized by host cells, which will modify the pathogen protein into 
peptide fragments, or alloantigens, through a method known as antigen processing. 
Specialized glycoproteins known as major histocompatibility complex (MHC) molecules 
bring these fragments to the cell surface for circulating T cells to recognize (12).  
 MHC molecules are encoded for in the host genome major histocompatibility gene 
complex, and play a major role in the immune response towards transplanted tissues. The 
MHC complex is high polymorphic, resulting in multiple gene variants present in one 
population. In humans, the MHC genes are referred to as the human leukocyte antigen, or 
HLA genes. These genes can vary between individuals, which is why the donor and 
recipient must be MHC matched before a transplant. Differences in HLA genes between 
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donor and recipient result in rapid transplant rejection due to host T cells recognizing the 
donor MHC molecules as being foreign, a phenomenon known as an alloreaction (12). 
 An alloreaction is the T cell recognition of a foreign MHC molecule by the allelic 
polymorphism present. While it was first believed that the foreign MHC molecule was 
enough to elicit a T cell response, studies now show that the T cells recognize the foreign 
peptide:foreign MHC complex through the cross-reactivity of the T cell receptor (TCR) to 
the foreign peptide:MHC complex. While host T cells undergo positive selection in the 
thymus to prevent reaction with self-MHC molecules, they are inadvertently primed to 
cross-react with any type of MHC molecule that varies from the self-MHC. Furthermore, 
TCRs are genetically encoded to inherently recognize an MHC complex, which increases the 
frequency of alloreactions. TCRs have evolved to recognize foreign peptide:MHC complexes 
through two different methods: peptide dependent and peptide independent recognition.  
Peptide dependent recognition occurs when the foreign peptide fits well in the TCR 
peptide-binding groove, causing binding to occur even if the foreign MHC molecule does 
not fit well with the receptor. Peptide independent recognition occurs with the foreign 
MHC molecule fits well with the TCR, so binding occurs regardless of the foreign peptide 
present in the MHC:peptide complex. Both of these recognition methods can play a part in 
the alloreactivity of a foreign tissue transplant, and will result in an immune response 
being mounted against the transplant that eventually leads to transplant rejection (12,15). 
T cells are only able to elicit an immune response towards the transplant once they 
recognize a foreign alloantigen, so the MHC:peptide complex is crucial. MHC molecules are 
divided into two different classes, MHC Class I and Class II. These classes dictate the type of 
foreign peptide that will bind to the MHC molecules, and they determine the type of T cell 
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that will be activated. MHC Class I molecules bind foreign peptides made in the cytosol and 
will activate host CD8+ T cells. MHC Class II molecules will bind foreign peptides from 
intracellular vesicles, and will activate CD4+ T cells. In the case of foreign antigens released 
from a transplant, the host circulating antigen-presenting cells (APCs) will engulf the 
foreign antigen and degrade the protein into peptides in the intracellular vesicle system. 
MHC Class II molecules will bind these peptides and activate CD4+ T cells. These peptides 
can also bind to MHC Class I molecules through cross-presentation, a process that 
transplants antigens from the vesicular system of the cell to the cytosol through 
retrotranslocation. Once in the cytosol, the peptides can bind to MHC Class I molecules and 
activate CD8+ T cells.  
 While common protocol in major organ transplant procedures include the matching 
of donor and recipient for the major histocompatibility complex, this protocol is not 
considered essential for massive cortical bone transplants. This is primarily because 
cortical allografts are considered to be acellular. Nonetheless, research suggests that MHC 
matching of donor and recipient does impact allo-osseous integration. Strong, et. al looked 
at the effect of MHC matching of osseous allograft transplants in a human model after 
previous animal models suggested that there is a correlation between graft outcome and 
“the degree of genetic disparity between donor and recipient” at the MHC locus (18). He 
found that the use of an allograft resulted in a recipient sensitization towards the MHC 
molecules on the graft bone, as measured by anti-HLA Class I antibodies present in the 
serum. Higher levels of anti-donor HLA antibodies present were correlated to poorer graft 
outcome, as previously seen in animal models and with major organ transplants in humans. 
(18).  Despite these findings, current clinical practice does not involve MHC matching of 
10 
massive cortical bone allograft between donor and recipient. This is partly because of the 
limited availability of allograft bone, and partly because massive cortical allografts are 
frozen prior to implantation which has previously been shown to diminish host immune 
response to donor bone.  The lack of access to readily available technologies to better 
match allografts with recipients is also a limitation to the use of routine graft typing.  
However, as previously shown by Stevenson et al. , frozen cortical allografts heal more 
slowly and with less new bone formation than autograft.  Thus, new approaches to allow 
better control of the allograft rejection process could significantly improve the overall 
utility of allografts for reconstruction of bony defects or limb amputations.   
 




 Modulation of the immune system to improve allograft healing following a massive 
bone transplant may improve allograft-host bone incorporation. This concept seems logical 
especially when one considers is that even patients receiving matched grafts can 
experience a transplant rejection. Welter, et. al showed that, while MHC matched allografts 
have higher levels of remodeling and revascularization compared to MHC mismatched 
allografts, graft rejection is still possible through the presence of mismatched minor 
histocompatibility antigens. These antigens are a result of differences in genetic loci 
besides the MHC loci between donor and recipient. The loci encoding for the minor 
histocompatibility antigens can produce proteins containing polymorphic peptides that are 
recognized by the recipient as a minor histocompatibility antigen. The recipient T cells will 
mount an immune response against all cells expressing these minor histocompatibility 
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antigens, which will effectively target and destroy all the cells present in the graft. Due to 
only identical twins being considered to have both matched major and minor 
histocompatibility antigens, the use of potent immunosuppressive drugs following 
transplants are a necessity (5). 
 Welter, et.al further examined the use of Cyclosporin A, a potent 
immunosuppressive drug, with a mismatched allograft in a canine model. This was a short-
term study using nonvascularized cortical grafts. Purpose-bred beagles were all typed for 
both MHC Class I and Class II antigens at the dog leukocyte antigen (DLA) loci, and were 
either considered matched for both or mismatched for both. Dogs received either a sham 
operation; an autograft; an allograft that was DLA Class I and Class II matched; an allograft 
that was DLA Class I and Class II mismatched; or an allograft that was DLA Class I and Class 
II mismatched, as well as cyclosporin for 30 days beginning at one day pre-operation. Dogs 
were euthanized at 3 months post-operation, and resorption scores, bone strength and 
stiffness, and histology, were evaluated. There was no difference seen in resorption scoring 
between the group receiving an autograft and the group receiving mismatched allografts 
and cyclosporin with all animals having slight to moderate erosion. The groups receiving 
matched allografts or mismatched allografts saw a resorption score of severe erosion to 
resorbed areas, with no difference between the two groups. Bone strength and stiffness 
were evaluated by mechanical testing of with a material testing machine that twisted the 
bones to failure. Autografts and the mismatched allografts treated with cyclosporin had the 
similar outcomes of high strength and stiffness. Mismatched allografts were weaker than 
the autografts, and a small difference (p=0.07) in strength and stiffness was noted between 
the autograft and the matched allograft. Of the four groups, the autograft had the highest 
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area of bone and the lowest level of porosity on histological findings. The autografts were 
also completely re-vascularized. The matched allografts had extensive levels of resorption 
and bone remodeling, some level of blood vessels being visible in all vascular spaces, but 
also had high levels of porosity. The mismatched allografts were largely resorbed with high 
porosity and fragmentation of the graft. Furthermore, a large amount of fibrous tissue 
surrounded the graft, and there was delayed blood vessel presence. The mismatched 
allografts treated with cyclosporin were histologically similar in appearance to the 
autografts, and experienced full revascularization, although higher levels of porosity 
compared to the autograft were seen.  
 This study hypothesized that the addition of cyclosporin increased the efficacy of 
incorporation and outcome of allografts by either dampening the immune response long 
enough to allow for incorporation of the graft to reach a level that would sequester the 
alloantigens away from circulating T cells, or the immune system was dampened to the 
point of allowing for tolerance of the graft. However, future studies showed that antibodies 
against the graft were made after discontinuation of cyclosporin treatment. Furthermore, 
the effects of cyclosporin on bone resorption were reversed within days of finishing 
treatment. This study illustrates the fact that the immune system does play a role in 
successful allograft incorporation but brings to light a clinical dilemma that still exists. 
Chronic immunosuppression with potent drugs such as cyclosporin is not ideal. Other 
immunomodulators that could provide the same level of local immunosuppression would 








 Mesenchymal stromal cells (MSCs) are a population of adult stromal cells that have 
differentiated past the level of embryonic stem cells (1). These are multipotent cells 
characterized by their ability to differentiate down osteogenic, chondrogenic, and 
adipogenic lineages. While originally isolated from bone marrow, MSCs can be isolated 
from a variety of tissues, including adipose tissue. Mesenchymal stromal cells have been 
frequently referred to as ‘mesenchymal stem cells’, resulting in Horwitz et al to publish a 
paper in 2005 clarifying the correct nomenclature for MSCs. They declared the plastic 
adherent cells isolated from the stromal compartment of tissues, such as adipose, bone 
marrow, etc. should be referred to as ‘mesenchymal stromal cells’, a term which indicates 
the general cell type being described, and infers a heterogeneous cell population. 
Furthermore, Horwitz et al acknowledged that certain subsets of mesenchymal stromal 
cells may be termed ‘mesenchymal stem cells’ as long as they were a homogeneous cell 
population with stem cell activity (6). The National Institutes of Health describe stem cells 
to be a population of unspecialized cells that are capable of self-renewal, and can be 
induced to differentiate down a specific cell lineage (17).  The Mesenchymal and Tissue 
Stem Cell Committee of the International Society for Cellular Therapy defined 
mesenchymal stromal cells to be cells fulfilling three major criteria: 1. They must be plastic-
adherent in standard culture conditions, 2. They must contain a specific cell marker profile, 
including expression of specific markers such as CD73 and lacking specific markers such as 
CD14, and 3. They must be able to differentiate into osteoblasts, adipocytes, and 
chondroblasts in vitro (3).  
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 MSCs possess potent immunomodulatory abilities, and are able to partially avoid 
allorecognition by the host immune system. They can alter both the innate and adaptive 
immune response by inducing either anti-inflammatory or pro-inflammatory effects 
depending on signals they receive from the surrounding environment (1). Within hours of 
an initial inflammatory response towards a pathogen or in response to tissue injury, toll-
like receptors (TLRs) recognize non-self molecular patterns on infected or damaged cells, 
and initiate the release of inflammatory mediators (12). These mediators will recruit 
macrophages and neutrophils to the site of infection or injury, resulting in a localized 
inflammatory environment. These TLRs can also activate resident MSCs, which, upon 
activation, will increase secretion of growth factors and chemokines necessary to recruit 
more neutrophils and lymphocytes and propagate the pro-inflammatory response. Studies 
have shown that in the presence of pro-inflammatory cytokines such as interferon-gamma 
(IFN-γ), tumor necrosis factor (TNF), and interleukin-1β (IL-1β), MSCs will increase the 
expression of specific TLRs that sensitize them to the pro-inflammatory environment. 
Initial exposure to TLRs that support a pro-inflammatory response, like TLR 4, cause MSCs 
to adopt a proinflammatory phenotype known as MSC 1. This MSC 1 subset will allow an 
increase of T cell proliferation by lowering levels of nitric oxide (NO) secretion and by 
increasing secretion of chemokines needed to attract lymphocytes to the local 
inflammatory environment and increase the overall response in early-stage inflammation 
(1).  
 Prolonged interaction with the pro-inflammatory TLR ligands, however, will cause a 
decrease in expression of TLR4, and an increase in expression of TLR3, an anti-
inflammatory propagator. MSCs primed with TLR3 will adopt an anti-inflammatory 
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phenotype known as MSC 2. MSC 2 cells will secrete factors such as tumor growth factor-β 
(TGF- β) that promote regulatory T cells (Tregs) to dampen the pro-inflammatory 
response, and MSC 2 cells will increase levels of NO, further inhibiting T cell proliferation. 
While the exact stimuli and mechanism by which MSCs can switch between an MSC 1 and 
MSC 2 phenotype are not completely understood, it is hypothesized that expression of 
specific TLRs and levels of NO play a key role (1). 
 Additionally, studies have shown interferon-gamma (IFN-γ) augments the 
immunosuppressive capabilities of MSCs by directly or indirectly altering the T cell 
response. Upregulation or deregulation of MSC inhibitory factors by IFN- γ results in 
decreased T cell activation and will induce T cells to switch from a pro-inflammatory to an 
anti-inflammatory phenotype. Additionally, a substantial increase in Tregs and T cell 
negative signaling is observed with high concentrations of IFN- γ. However, some 
conflicting data has shown that allogeneic MSC may have increased immunogenicity 
properties in the presence of IFN- γ, which would promote a pro-inflammatory 
environment. Therefore, it is imperative to look at differing properties between allogeneic 
and autologous MSCs in the presence of cytokines such as IFN- γ to determine their 
immunomodulatory effects and explore their potential use in therapeutics (16). 
 Bernardo et. al  used a murine graft-versus-host disease (GvHD) model to look at the 
effect of delivering MSCs at varying time points after a bone marrow transplant. MSCs 
delivered the same day as the transplant had no effect on suppressing the GvHD, whereas 
MSCs delivered 3, 8, or 20 days after transplant successfully dampened the GvHD 
progression and decreased symptoms associated with the disease. Furthermore, MSCs that 
were pretreated with IFN-γ before administration prevented GvHD fatalities. These results 
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suggest that the level of pro-inflammatory cytokine exposure play a role in whether MSCs 
take on a pro-inflammatory or anti-inflammatory phenotype (1).  
 




 Due to their ability to differentiate down an osteogenic lineage into osteoblasts, 
emerging studies continue to look at the benefit of mesenchymal stem cells on allograft 
incorporation. Nather, et al. looked at the effect of autogenous bone marrow derived 
mesenchymal stem cells (BM-MSCs) on the level of host-graft union, resorption, new bone 
formation, and osteocyte production in an allograft using a rabbit model. Rabbits received 
either a non-vascularized autograft, a frozen allograft, or a frozen allograft seeded with BM-
MSCs. They found that at 12 weeks, union at both host-graft junctions was seen in all 
animals receiving an autograft transplant, but union was not seen in any animals receiving 
an allograft transplant. Host-graft union for the animals receiving an allograft was seen in 
50% of the animals at 16 weeks, and in all animals at 24 weeks. However, this delayed 
union response was diminished in animals receiving an allograft loaded with MSCs; 
complete host-graft union for these animals was seen at 12 weeks. There was no significant 
difference in the level of bone resorption at 12 weeks between animals receiving an 
autograft and animals receiving an allograft seeded with MSCs. The animals receiving an 
allograft alone had a significant increase in resorption levels compared to the other two 
groups. The autograft recipients had the highest level of new bone formation at 12 weeks, 
and had identical levels of formation at weeks 16 and 24 as those seen in the recipients of 
allografts loaded with MSCs. Recipients of allografts alone had significantly lower levels of 
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new bone formation as compared to the other groups. The highest level of osteocytes, 
which indicate fully formed bone, was significantly higher in the recipients of the allograft 
loaded with MSCs as compared to both the allograft and autograft recipients at 12, 16, and 
24 weeks (13). Results of this study suggest the addition of mesenchymal stem cells to 
allografts will increase graft incorporation by helping increase new bone formation, yield 






 Aforementioned studies show that the success of allograft transplantation is 
dependent of levels of host-graft incorporation, new bone formation, and revascularization 
of the graft. However, a host immune response directed towards the alloantigens present 
on a MHC mismatched allograft can impede successful incorporation, contributing to 
eventual graft failure. The addition of immunosuppressive drugs following a mismatched 
allograft transplant result in incorporation, new bone formation, and revascularization 
levels nearly identical to those seen in a matched MHC autograft transplant, suggesting that 
immunomodulation may be an important determinant of allograft transplant success. 
Clinically, it is not ideal to place a patient on chronic immunosuppressive medication. The 
immunomodulatory agent is one that could effectively modulate the local immune 
response towards the transplant without causing systemic immunosuppression. 
Additionally, an immunomodulator that could have a potent, long term effect without 
having to be administered chronically would increase the quality of life of the patient, and 
would decreased added health risks of being on chronic immunosuppressives.   
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 Mesenchymal stem cells can influence the immune system through various signaling 
and activation pathways. Moreover, MSCs have been shown to increase the incorporation 
and success of a mismatched allograft. The research described in the following chapters 
was initiated to begin to address the question of whether or not the increased success 
when using local administration of MSCs with a cortical allograft is due, at least in part, to 
the immunomodulation of the host immune system by the mesenchymal stem cells. This 
body of work describes 1) an experiment utilizing a novel bone vaccine that suggests 
adipose derived mesenchymal stem cells have no detectible effect on the humoral immune 
response towards total bone antigen delivered in a vaccine,  2)  the effect of mesenchymal 
stem cells on the cellular immune response towards an allograft or autograft bone vaccine 
and whether the route of administration (intravenous or local ) influences this effect,  and 
3) the effect of mesenchymal stem cells on the cellular immune response towards a 
massive cortical allograft or autograft transplant.  
 This goal of this research was to evaluate the influence on the host immune 
response elicited by an allograft or autograft either alone or when accompanied with 
mesenchymal stem cells. Understanding how mesenchymal stem cells influence the 
immune system following an allograft transplant will aid in future studies looking for the 












The Effect of Adipose Derived Mesenchymal Stromal Cells and Vaccines Prepared 
from Allogeneic Bone Tissues On The Humoral and Cellular Host Immune Responses 








 Massive bone allografts are utilized to reconstruct large bone defects after tumor 
resection or trauma. Traditionally, allografts are obtained from deceased, non-related 
tissue donors, sterilely harvested, stripped of soft tissues and frozen to diminish 
antigenicity. Due to lack of availability of matched tissue and the paucity of cellular 
material on the allograft, massive cortical bone allografts are not are not matched for major 
histocompatibility antigens with the recipient. Limb-salvage treatments utilizing massive 
allografts have a 60% failure rate at 10 years in human patients and a 50% failure rate at 
one year for canine patients (9). Studies performed by Sharon Stevenson in the 1980’s 
evaluated healing outcome in canines receiving either a matched or mismatched 
vascularized and nonvascularized frozen large cortical grafts, and found that there was 
improved graft incorporation when the graft donor and host were matched for major 
histocompatibility antigens. In 1990, Welter, et.al investigated whether modulation of the 
immune system would improve allograft healing following a massive cortical allograft 
transplant and allow for better incorporation. They found that recipients of a mismatched 
allograft treated daily with a potent immunosuppressant (Cyclosporin A) resulted in higher 
levels of new bone formation and lower levels of fracture and resorption compared to 
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recipients of a mismatched allograft alone. These positive results changed with the 
discontinuation of Cyclosporin A resulting in decreased new bone formation and increased 
levels of fracture and resorption. Based up on previous work, it is known that the poor 
healing seen after mismatched large frozen cortical allograft transplants are partly 
immune-mediated, and can be contributed to T cell recognition of graft alloantigens (7,8).   
 The use of mesenchymal stromal cells (MSCs) following major organ transplantation 
had been widely investigated in the hope of finding a new standard of immunosuppressive 
treatment. While current immunosuppressive drugs greatly decrease the risk of graft 
rejection, long-term use is not advantageous. Mesenchymal stromal cells are not only able 
to avoid recognition by the host immune response due to low surface levels of major 
histocompatibility complex (MHC) Class I molecules and absent levels of MHC Class II 
molecules, but they are able to modulate T cell proliferation to propagate either a pro-
inflammatory and anti-inflammatory response based on the environment they are 
introduced to (1).  Furthermore, the regulation of the immune system can be highly specific 
due to the ability of MSCs to home to sites of injury and inflammation.  
 The objective of this study was to evaluate the humoral and cellular immune 
response against allograft bone versus autograft bone when delivered as a vaccine, to 
determine whether or not the addition of adipose-derived mesenchymal stromal cells (AD-
MSCs) would dampen the immune response towards an allograft bone vaccine. A 
secondary objective was to determine if there was a difference in the level of 
immunosuppression observed in mice receiving intravenously delivered MSCs as 
compared to mice receiving subcutaneously injected MSCs. To accomplish these objectives 
we developed a murine bone vaccine model to mimic the immune response seen following 
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a limb-salvage procedure. We hypothesized that: 1) An allograft-derived bone vaccine 
would elicit a greater humoral immune response as compared to an autograft-derived bone 
vaccine in a murine model; 2) An adipose-derived mesenchymal stromal cells (AD-MSCs) 
would dampen the recipient humoral immune response against donor bone-associated 
antigens, with intravenously administered MSCs having a more potent immunomodulatory 
effect than a subcutaneous delivery of MSCs; and 3) T cell proliferation would be 
suppressed in mice receiving a vaccine with AD-MSCs compared to mice a receiving a 
vaccine alone.  
 








 All animals were obtained from the National Cancer Institute (NCI) or National 
Institute of Health (NIH). Female BALB/C mice and female C57B/6 mice arrived at 6-8 
weeks of age, and were allowed to acclimate for one week before use. The handling, 
treatment, and euthanasia of mice followed a Colorado State University Institutional 
Animal Care and Use Committee (IACUC) approved protocol.  
 
Allograft and Autograft Collection 
 
 
 Bones used for the allograft vaccine were obtained from the femurs of BALB/C mice. 
Femurs were collected under sterile conditions in a laminar flow hood immediately 
following humane euthanasia. All instruments used were sterilized prior to use. Femurs 
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were collected, scraped with a scalpel blade to remove all periosteum, and placed into 
cryovials.  Cryovials were immediately placed into a container with liquid nitrogen to flash-
freeze the bones. Bones were stored at -80°C for a minimum of one week before further 
processing.  Bones used in the autograft vaccine were obtained from C57Bl/6 mice in the 
same manner as described for the allograft bone collection.  
 
Bone Vaccine Preparation 
 
 
 The donor femurs were removed from the -80°C storage and were immediately 
placed into a liquid nitrogen container. A mortar and pestle were placed in ethanol for 10 
minutes and used to smash the bones into a powder. The final concentration of bone 
powder in the vaccine was 10μg/mL.  
 The bone powder and freshly made cationic liposomal DNA complex (CLDC) 
adjuvant was re-suspended in sterile PBS and stored at -20°C until use (9). Final bone 
vaccines contained bone dust of the allograft (BALB/C) bone or an autograft (C57Bl/6) 
bone; a CLDC adjuvant; and sterile PBS.   
 The allograft and autograft treatment groups were compared against a positive 
control vaccine containing alkaline phosphatase (ALP) (Phosphatase, Alkaline from bovine 
intestinal mucosa, Sigma-Aldrich P7640-500MG). The final ALP concentration in the 




 Serum (0.1 ml) was collected from the tail vein on days 1 and 7 before 
administration of the vaccine. On Day 21, mice were anesthetized, and blood was collected 
via cardiac puncture just prior to euthanasia. Blood was placed into serum separator tubes 
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(BD Microtainer® Serum Separator Tubes, REF 365956), which were spun down in a 
micro-centrifuge (Fisher Scientific accuSpin Micro 17) at 7 x 1,000g for 5 minutes. Serum 




   C57Bl/6 mice (n=20) were treated with an initial vaccine injection on Day 1, 
followed by a booster vaccine injection on Day 7. Mice were randomly assigned to receive 
an ALP vaccine (n=5), an allograft vaccine (n=5), an autograft vaccine (n=5), or were non-
vaccinated (n=5). Mice were anesthetized, and a 0.1mL vaccine was injected 
subcutaneously through a 14gauge needle.  
 Mice (n=48) were randomly assigned to receive a vaccine with either intravenously 
delivered (IV) MSCs (n=24) or with subcutaneous MSCs (n=24). Recipients within each 
MSC delivery group received an ALP vaccine (n=8), an allograft vaccine (n=8), an autograft 
vaccine (n=8), or were non-vaccinated (n=8). 
 
Adipose Tissue Harvest for Preparation of MSC 
 
 Adipose tissue was collected from the abdominal fat pads of C57BL/6 mice using 
sterile instruments under a laminar flow hood. Fat was isolated, minced, and resuspended 
in 1mg/mL of collagenase with an antibiotic/antimycotic solution. Cells were incubated at 
37°C for 30 minutes before MSC media (antibiotic/antimycotic solution, 15% FBS, MEM 
vitamins, and MEM nonessential amino acids) was added. Cells were washed, resuspended 
in MSC media, and plated in flasks that were stored at 37°C.  
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Adipose-Derived Mesenchymal Stem Cell Collection and Storage 
 
 Cells were allowed to incubate at 37°C until reaching a minimum of 80% confluency. 
Cells were washed and trypsinized before being transferred to a 50mL conical tube. The 
cells were resuspended in PBS-Heparin (0.1mL Heparin in 9.9mL sterile PBS) with a final 
volume of 5x105 cells/100μL PBS-Heparin. MSCs in unused flasks were frozen and stored 
for later use Cells in flasks that were not used for treatment were washed, trypsinized, and 
spun like mentioned before, and were resuspended in freeze media (20% DMSO, 40% 




 During injections, the MSC-PBS-Heparin suspension was stored in a 37°C water 
bath. For mice receiving an intravenous Ad-MSC injection, mice were placed under a heat 
lamp for 20 minutes, placed into a restrainer and 0.1mL of the MSC-PBS/Heparin solution 
was injected into the tail vein using an insulin needle. Mice received two tail vein injections 
of 5x105 MSCs/0.1mL 48 hours apart beginning on Day 1, and two injections 48 hours 
apart beginning on Day 7. The injections on Day and Day 7 were given immediately after 
vaccination.   
 Mice that received a subcutaneous injection of MSCs received one subcutaneous 
injection of 1x106 MSCs/0.1mL PBS-Heparin on Day 1 and one injection on Day 7. A 0.1mL 
injection of MSCs was delivered subcutaneously between the shoulder blades using an 
insulin needle immediately following vaccination. 
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 Bone protein from C57BL/6 mice was isolated using TRIzol Reagent (TRIzol 
Reagent, Life Technologies 15596-026) and used as the antigen in the antibody detection 
ELISA. Femurs were collected from C57BL/6 mice in a sterile manner and stored at -80°C 
prior to use.  Femurs were immediately placed into liquid nitrogen, freeze fractured, and 
crushed into a powder. TRIzol reagent was added at 1mL/50mg of protein, and the sample 
was homogenized using a power homogenizer (Fisher Scientific PowerGen 1000). The 
homogenized sample was incubated for 5 minutes at room temperature and chloroform 
(Chloroform, 99.9+%, A.C.S. HPLC grade, Aldrich Chemical Co, Inc. 67-66-3) was added at 
0.2mL per 1mL of TRIzol Reagent, and then centrifuged in a Hermle Labnet Z-383K High 
Performance Centrifuge at 12,000 x g for 15 minutes at 4°C. The upper aqueous phase was 
removed, and 0.3mL of 100% ethanol per 1mL of TRIzol Reagent was added. The sample 
was spun at 2,000xg for 5 minutes at 4°C, and the supernatant was transferred to a new 
tube. Isopropanol (2-Propanol HPLC Grade, Fisher Scientific A451-4) was added to the 
supernatant at 1.5mL isopropanol per 1mL TRIzol Reagent and the sample was incubated 
for 10 minutes at room temperature, spun at 12,000 x g for 10 minutes at 4°C, and the 
supernatant was removed. The protein pellet was washed with 2mL of a 0.3M guanidine 
hydrochloride in 95% ethanol wash solution per 1mL of TRIzol Reagent, incubated for 20 
minutes at room temperature and then spun at 7500 x g for 5 minutes at 4°C. The wash 
solution was removed and 2mL of 100% ethanol was added to the protein pellet. The 
solution was vortexed and then incubated at room temperature for 20 minutes. The sample 
was spun at 7500 x g for 5 minutes at 4°C, the ethanol wash was removed, and the protein 
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pellet air-dried for 10 minutes before 200μL of 1% SDS was added. The solution was 
pipetted up and down until the pellet was resuspended, spun at 10,000 x g for 10 minutes 
at 4°C and the supernatant containing the protein was transferred to a new tube. The 
protein yield was determined with a BCA Protein Assay Kit (Pierce 23225). The protein 
yield from the TRIzol extraction method was determined with a BCA Protein Assay Kit 





 Immediately after euthanasia, spleens were collected under sterile conditions in a 
laminar flow hood for the purpose of evaluating the cellular immune response to total bone 
antigens by measuring T cell proliferation present in the spleen cells. Spleens were placed 
into petri dishes containing 1-2mL HBSS media (HBSS, 1x with calcium and magnesium, 
CORNING cellgro REF 21-020-CV) and subjected to a single-cell suspension protocol. 
Briefly: the spleen and media were pushed through a cell strainer; spun in a centrifuge 
(Beckman Coulter Allegra™ 6R) at 1200 rpm for 5 minutes; resuspended in 2mL of ACK 
Lysing Buffer (Lonza BioWhittaker® Catalog No: 10-548E) for 5 min; resuspended in HBSS 
and spun at 1200 rpm for 5 minutes; and cells were resuspended in 1mL of freeze media 
and stored at -80°C. 
 
Serum Analysis for IgG Antibody Levels 
 
 
 Serum samples were subjected to an antibody-detection ELISA. Briefly: a Nunc-
Immuno Maxisorp 96-well plate (Nunc #442404, Fisher 12-565-135) was coated with 
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C57BL/6 bone protein suspended in carbonate buffer at 5 μg/mL. The plate was covered 
and incubated overnight at 4°C. A 5% PBS-milk blocking buffer was used and the plate was 
incubated at room temperature for 60 minutes. Serial dilutions of the samples from 1:10 to 
1:10,000 were performed. Blanks were 3% BSA-PBS with no sample. An anti-IgG detection 
antibody (ImmunoPure® Goat Anti-Mouse IgG (H+L), Pierce Prod# 31430) was diluted 
1:500 in 5% PBS-Milk and added before the plate was incubated at room temperature for 
60 minutes in the dark. A TMB substrate (3, 3’, 5, 5’-Tetra Methylbenzidine (TMB) Liquid 
Substrate System for ELISA, Sigma-Aldrich T0440-1L) was brought to room temperature 
during the 60-minute incubation time, and was added to each well. Color was allowed to 
develop in the dark for two minutes, and a 1N HCl stop solution was then added to each 
well. The plate was immediately read at 450nm in a BioTek Synergy HT plate reader. 
Absorbance readings were analyzed with Gen5 2.00 Software.  
 
Statistical Analyses 
 The raw optical density (OD) values of the 1:10 dilution in the antibody detection 
ELISA were analyzed to look at differences in antibody production between treatment 
groups. Differences in T cell proliferation levels between different treatment groups were 
also analyzed. All analyses were performed with a 2-way ANOVA followed by a Bonferroni 
post-test. A p-value of less than 0.05 was considered statistically significant for all analyses, 
and raw p-values are reported. Statistical analyses were performed using GraphPad Prism 








Among animal receiving vaccines (no Ad-MSCs) recipients of an ALP vaccine had a 
significantly higher antibody response on Day 21 compared to recipients of an autograft 
bone vaccine (Figure 2.1). No other differences were noted.   
A. B  
 
 
Among mice receiving both a vaccine and intravenously –delivered Ad-MSCs, there were no 
significant differences in ALP antibody response observed between treatment groups on 
Day 1 or Day 7. On Day 21, mice receiving both ALP vaccine and intravenously –delivered 
Ad-MSCs had greater antibody production when compared to recipients of an allograft or 

























































Figure 2.1 Antibody Response Towards Bone Antigen in Vaccine Recipients. Graph 
A depicts the antibody response towards a bone antigen in recipients of an allograft or 
autograft bone vaccine compared to a non-vaccinated mouse. Graph B depicts the 
differences in antibody response seen between non-vaccinated animals and recipients 









vaccinated group that did not receive MSCs. The same trend was noted in recipients of 
subcutaneous MSCs (Figure 2.2).  
 
A.  B.     
C.  
 
Differences in antibody response within each treatment group receiving a vaccine were 
evaluated to examine any immunomodulatory effect of MSC administration with the 
different vaccines, as well as to evaluate if there was any MSC immunomodulatory effect on 
non-vaccinated mice in order to ascertain the non-vaccine induced MSC effect on the 
immune system. On Day 21, non-vaccinated recipients had a significantly more robust 
antibody response compared to non-vaccinated recipients that received MSCs. On Day 1, 
recipients of an allograft bone vaccine co-administered with IV MSCs had a significantly 
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Figure 2.2 Antibody Response in Vaccine Recipients With the Addition of MSCs. 
Graph A depicts the antibody response towards a total bone antigen in recipients of IV 
delivered MSCs with the various treatment groups. Graph B depicts the antibody 
response in recipients of subcutaneous MSCs with the various treatment groups. Graph 
C shows the antibody response towards total bone antigen in recipients of the ALP 
(positive control) vaccine.   
*p-value<0.05   **p-value<0.005 
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less robust antibody response (p <0.05) compared to recipients of an allograft bone vaccine 






T Cell Proliferation 
 
 T cell proliferation in response to a negative control, an allograft bone antigen, and 
an autograft bone antigen were evaluated in recipients of an ALP vaccine (n=5), an allograft 
vaccine (n=5), an autograft vaccine (n=5), non-vaccinated mice (n=5), and recipients of the 
Figure 2.3 Antibody Responses Within ALP Vaccine, Allograft Bone Vaccine, and 
Autograft Bone Vaccine Treatment Groups Recipients of an allograft bone vaccine 
with IV MSCs had a significantly less robust antibody response on Day 1 compared to 
recipients of an allograft bone vaccine alone. No other differences within treatment 
groups were reported. *p-value<0.05 
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aforementioned treatment groups with IV MSCs (n=8 per group) and with subcutaneous 
MSCs (n=8 per group).  
 Recipients of an allograft bone vaccine with IV MSCs and with subcutaneous MSCs 
had a significantly less potent T cell proliferation response to an allograft bone antigen 
compared to the amount of proliferation found in non-vaccinated animals.  No differences 
in T cell proliferation were observed between recipients of an allograft bone vaccine upon 




 No differences in T cell proliferation were noted in recipients of an autograft bone 
vaccine with IV MSCs and with subcutaneous MSCs in response to an allograft bone antigen 
compared to the response found in non-vaccinated animals. The same result was observed 
in response to an autograft antigen (Figure 2.5).   
 
Figure 2.4 T Cell Proliferation in Recipients of an Allograft Bone Vaccine. The first 
graph depicts T cell proliferation response upon in vivo re-exposure to allograft bone 
protein in recipients of an allograft bone vaccine. This response is compared against the 
response in a non-vaccinated mouse after in vivo re-exposure to an allograft bone 
protein, as well as the response in non-vaccinated mice that are not re-exposed in vivo 
to any bone protein. A significantly less potent T cell proliferation response to an 
allograft bone protein is observed in recipients of an allograft bone vaccine with IV 
MSCs and with subcutaneous MSCs compared to non-vaccinated mice. No differences in 
T cell proliferation in response to an autograft bone protein were observed. Error bars 















 The role of T-cells in acute graft rejection, as well as the effect of the initial, antigen-
independent, inflammatory response present after a transplant, have been examined as key 
players in amplifying and propagating the graft-specific adaptive immune response (7). 
Studies using T-cell deficient mice that received mismatched skin or cardiac allografts 
looked at the effect of adoptive T cell transfer after grafts were allowed to heal. With the 
Figure 2.5 T Cell Proliferation in Recipients of an Autograft Bone Vaccine. The first 
graph depicts T cell proliferation upon exposure to an allograft bone antigen in 
recipients of an autograft bone vaccine. This response is compared against the response 
in a non-vaccinated mouse after exposure to an allograft bone antigen, as well as in non-
vaccinated mice that are not exposed to any antigen. No significant differences in T cell 
proliferation in response to an allograft bone antigen or an autograft bone antigen were 
observed. Error bars depict SD.  
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addition of T cells, acute rejection of the graft was seen, even in mismatch grafts that were 
considered well-healed, with normal histological appearance (1, 4, 7).  
 The T cell immune response can be stimulated either through a direct pathway or an 
indirect pathway of antigen presentation. In the direct stimulation of T cells, the 
polymorphic donor’s MHCs present on the graft are recognized by host T cells thereby 
stimulating naïve T cell activation and proliferation into effector T cells targeted against the 
graft. The indirect pathway of antigen presentation T cell occurs when donor graft cells 
with intact MHCs are secreted into the periphery, internalized by host antigen presenting 
cells, and presented to naïve T-cells, which results in increased activation and proliferation 
of T cells (4). While cross-over of pathway activation can occur during an immune 
response, there is no doubt that the antigen presentation by MHCs is essential for 
activation of T cell proliferation. 
 As part of the primary immune response, T cells are activated against a specific 
antigen, and divide into CD4+ and CD8+ subsets to effectively target and kill infected cells 
while activating B cells to produce antibodies against the foreign antigen. The primary 
immune response will also induce the production of memory T cells, which are primed 
against the foreign antigen, and are capable of mounting a faster and greater immune 
response upon second exposure to the specific antigen (5). 
 The antigen-independent proinflammatory events that occur in response to trauma 
and/or surgery may propagate the T-cell response towards the graft. Inflammatory 
mediators are partly responsible for the expression of toll-like receptors (TLRs) that, once 
stimulated by a foreign peptide, will increase production of proinflammatory cytokines and 
chemokines, as well as increase antigen presentation to T cells (6, 7). A pro-inflammatory 
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environment induces upregulation of MHC molecules on antigen presenting cells, thereby 
increasing the opportunity for T cells to encounter a MHC molecule presenting peptide 
from the graft (2).  
 Allograft rejection can be due to a collaborative response between the host immune 
system and the transplant site environment. The allograft itself is capable of stimulating a 
T-cell immune response by antigen activation of T-cells through either a direct or indirect 
pathway. The direct pathway of T cell activation involves recipient T cells recognizing 
intact, donor MHC:peptide complexes present on donor cells. T cells can also recognize 
antigen via an indirect pathway in which recipient antigen presenting cells will process 
donor MHC molecules into peptides, and present the MHC:peptide complex to recipient T 
cells (4). The antigen presentation is enhanced by the TLRs present in response to surgery-
induced inflammation at the allograft transplant site.  
The novel bone vaccine model used in this study was an attempt to mimic the 
immune response seen in a clinical setting following massive cortical allograft 
transplantation in order to investigate the humoral and cellular immune response towards 
a bone antigen. The overall increase in antibody production observed in response to the 
ALP vaccine support the concept of a vaccine model to evaluate the humoral immune 
system toward a single bone antigenic protein. However, the lack of statistically significant 
differences in antibody response towards a bone vaccine was unexpected.  It is possible 
that the amount of complex bone antigen delivered in the allograft and autograft bone 
vaccines was not sufficient to elicit a strong humoral immune response. Each mouse 
received 0.1μg of bone in the vaccine; so future studies looking at increasing this 
concentration might yield more detectable differences.  Nonetheless, these data suggest 
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little to no humoral response towards the total bone antigen mixture delivered in the 
vaccines. Additionally, the administration of Ad-MSCs, whether delivered subcutaneously 
or intravenously, did not alter this outcome.  
 Evaluation of the Ad-MSC immunomodulation of the cellular immune response did 
reveal a suppressive effect on T cell proliferation levels in recipients of a vaccine with 
MSCs.  This effect was most pronounced in recipients of an allograft bone vaccine and Ad-
MSCs when spleen cells were exposed to an allograft bone antigen. T cell proliferation 
suppression by Ad-MSCs was less pronounced when cells were exposed to an autograft 
bone antigen. Additionally, this suppression was not as pronounced in recipients of an 
autograft vaccine when exposed to an allograft bone antigen or an autograft bone antigen. 
When considered as a whole, these data support the hypothesis that Ad-MSCs do suppress 
cellular immunity towards allograft bone antigens. 
  An additional unexpected observation was noted during the analysis of the T cell 
proliferation following re-exposure to the bone antigens. Wherein one would normally 
expect re-exposure to an antigen via vaccine to enhance the immune response to a 
particular antigen, we noted that T cell proliferation towards the allograft bone antigen was 
dampened in animals previously vaccinated with an allograft bone vaccine. This effect was 
most profound when the allograft bone vaccine was given with MSCs. This suggests that 
vaccinating against a total allograft bone antigen may in fact decrease the immune 
response to the allograft, especially with the addition of MSCs.  The high failure rate 
associated with massive cortical allograft transplants is partly immune mediated, and 
previous studies have shown this immune response is in part due to T cells activated by the 
host immune system to target the non-self mismatched major histocompatibility complex 
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molecules present on the donor bone. However, recipients of a bone vaccine had a 
dampened T cell response upon re-exposure to the bone antigen. These findings provide an 
avenue to explore future methods aimed at dampening the immune response against a 
massive cortical allograft transplant. Investigating whether vaccination with a bone vaccine 
prior to a massive cortical allograft transplant could lead to novel ways of dampening the 
host immune response towards the donor bone and lead to overall higher allograft 







 The employment of a massive cortical allograft for limb-salvage is widely performed 
in clinical settings with little concern for the matching of donor and recipient MHC 
complexes. Failure of an allograft to incorporate into host bone is partly immune-mediated. 
We developed a novel vaccine model to mimic the immune response seen towards a 
massive cortical allograft in a clinical setting. We have shown that the administration of ad-
MSCs modulate the cellular immune response to allograft bone antigen has little effect on 
the humoral immune response in this model. However, there is some immunomodulation 
of the cellular immune response with the addition of MSCs as seen in the T cell 
proliferation response to an antigen. Lastly, data presented herein suggests a possible new 
avenue to explore to diminish immune response following massive allograft transplant 
through prior vaccination of the patient with the allograft. A future vaccine study looking at 
this potential mechanism is needed to determine if the suppression of T cell proliferation 
present in vaccinated animals is related to clinically improved graft incorporation. If 
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successful, vaccination with an allograft bone antigen could yield a potential new 


































Massive Cortical Allograft Transplants Result in Increased Antigen Presentation and 







 Mesenchymal stem cell (MSCs) modulation of the host immune response is partly 
dependent on the cytokine profile of the surrounding environment. Initial exposure to pro-
inflammatory cytokines such as interferon-gamma (IFN-Υ) will activate MSCs to up-
regulate expression of specific toll-like receptors (TLRs) that are involved in maintaining 
an inflammatory immune response through the increased proliferation of T cells. However, 
the MSC immune modulation is equipped with a self-regulatory mechanism to prevent a 
hyperimmune response. With extended exposure to pro-inflammatory cytokines, MSCs will 
decrease expression of pro-inflammatory TLRs and increase expression of anti-
inflammatory TLRs (7).  
 A pro-inflammatory, primary cell-mediated immune response is characterized by 
increased T cell proliferation into CD4+ and CD8+ T cells. CD4+ T cells are involved in the 
humoral immune response that results in increased macrophage and neutrophil migration 
to sites of infection or injury, as well as the activation of B cells to produce antibodies 
against a foreign antigen. CD8+ T cells are involved in the cellular immune response that 
targets and kills infected cells (4).  
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 An anti-inflammatory immune response involves a decrease in pro-inflammatory 
cytokines and the increased expression of CD4+ T regulatory cells (Treg cells) that are 
responsible for dampening and eventually eliminating the immune response (5).  
 Mesenchymal stem cells have been shown to suppress T cell proliferation both in 
vivo and in vitro; however, the level of suppression is dependent on the environment 
surrounding the MSC-T cell interaction. Interferon-gamma (IFN-γ) is a regulatory protein 
that is produced in response to T cell activation by an alloantigen. High levels of IFN-γ in an 
inflammatory environment have been shown to induce the production of indoleamine 2,3-
dioxygenase (IDO) as a self-regulatory mechanism to prevent a hyperinflammatory 
response. IDO mainly functions as an enzyme to catalyze tryptophan, one of the body’s 
essential amino acids that play a role in the induction of Foxp3+ T regulatory cells. IDO also 
possess a non-enzymatic, signaling function in dendritic cells (DC) that, when activated, 
will convert the DC phenotype to that of a regulatory DC, and tipping the immune response 
towards a tolerogenic response (4).  MSCs exposed to high levels of IFN-γ are induced to 
increase production of IDO and other immunosuppressive cytokines such as tumor growth 
factor β (TGF-β), which may explain how MSCs help suppress the immune response seen in 
transplant rejection.  
 Santoni, et. al. looked at the effect of the addition of mesenchymal stem cells 
following a massive cortical allograft transplant in a murine model to evaluate new bone 
formation in mice receiving an allograft compared to an autograft. C57BL/6 mice received 
either an allograft from a Balb/C mouse; an allograft coated with a fibrin carrier; an 
allograft with a fibrin carried coated with adipose-derived MSCs (AD-MSCs); or an allograft 
followed by intravenous(IV) injection of AD-MSCs. All animals were compared against mice 
40 
receiving the same treatment with an autograft instead of an allograft. They hypothesized 
that the addition of AD-MSCs would decrease the immune response towards the allograft 
bone and allow levels of new bone formation and incorporation similar to levels seen 
following an autograft transplant. A pairwise analysis looking at the effect of treatment on 
new bone formation found that the highest level of new bone was found in groups receiving 
intravenous MSCs. Within the autograft treatment group, the mice receiving an autograft 
with IV MSCs had a significantly higher amount of new bone formation as compared to the 
group receiving an autograft with a fibrin carrier (p=0.01) and to the group receiving an 
autograft only (p=0.04). However, no statistically significant differences in new bone 
volume were seen in within the allograft treatment group.  
 The purpose of this study is to determine the MSC immunomodulation on the 
cellular immune response towards a massive cortical allograft transplant by evaluating T 
cell proliferation in the spleens collected from the study conducted by Santoni, et. al. We 
hypothesized that 1) Spleens from the mice receiving an allograft bone transplant will have 
higher levels of T cell proliferation as compared to mice receiving an autograft transplant. 
And 2) T cell proliferation in mice receiving an allograft or autograft transplant with MSCs 
will be less than that of mice receiving an allograft or autograft transplant alone, but that 
the autograft transplant groups will still have lower levels of T cell proliferation as 











 All animals were obtained from the National Cancer Institute (NCI) or National 
Institute of Health (NIH). Female Balb/C mice and female C57BL/6 mice arrived at 6-8 
weeks of age, and were allowed to acclimate for one week before use. The handling, 
treatment, and euthanasia of mice followed a Colorado State University Institutional 




   C57BL/6 mice used in a previous study were treated with an initial vaccine 
injection on Day 1, a booster vaccine injection on Day 7, and were euthanized on Day 21. 
Mice (n=20) were randomly assigned to receive an ALP vaccine (n=5 ), an allograft vaccine 
(n=5), an autograft vaccine (n=5 ), or were non-vaccinated (n= 5). Mice were anesthetized, 
and a 0.1mL vaccine was injected subcutaneously through a 14gauge needle.  
 A second group of mice (n=48) were randomly assigned to receive a vaccine with 
either intravenously delivered (IV) MSCs (n=24) or with subcutaneous MSCs (n=24). 
Recipients within each MSC delivery group received an ALP vaccine (n=8), an allograft 





 Immediately after euthanasia, spleens were collected under sterile conditions in a 
laminar flow hood for the purpose of evaluating the cellular immune response to total bone 
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antigens by measuring T cell proliferation present in the spleen cells. Spleens were placed 
into petri dishes containing 1-2mL HBSS media (HBSS, 1x with calcium and magnesium, 
CORNING cellgro REF 21-020-CV) and subjected to a single-cell suspension protocol. 
Briefly: the spleen and media were placed into a cell strainer and mashed; spun in a 
centrifuge (Beckman Coulter Allegra™ 6R) at 1200 rpm for 5 minutes; resuspended in 2mL 
of ACK Lysing Buffer (Lonza BioWhittaker® Catalog No: 10-548E) for 5 min; resuspended 
in HBSS and spun at 1200 rpm for 5 minutes; and cells were resuspended in 1mL of freeze 
media and stored at -80°C. 
 
CFSE Staining of Spleen Cells 
 
 Spleen cells were placed in a 37°C water bath to thaw, then added to warmed 
complete growth media and incubated for fifteen minutes. Cells were pelleted out and 
resuspended in PBS at a final concentration of 1x106 cells/mL. 
 Carboxyfluorescein succinimidyl ester (CFSE) was added at 0.4μL CFSE per 1mL PBS 
and the cells were incubated at 37°C for ten minutes. Cells were washed with MEM media 
(MEM, 1x w/ Earle’s salts & L-glutamine Cat. No. 10-010-Cx Cellgro), and resuspended in 
MEM at 4x105 cells/200μL MEM for plating.  
 
Spleen Cell Antigen Exposure  
 Antigens were added to a 96-well, flat-bottomed plate (Costar 9018 EIA/RIA plate 
96 well flat bottom high binding certified, Corning Incorporated)  at 50μL/mL MEM. All 
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spleen samples were co-cultured with Balb/C bone protein, C57BL/6 protein, and media. 
All samples were plated in triplicate. Samples were incubated at 37°C for 72 hours. 
 
Cell Staining for Flow Cytometry 
 
 After 72 hours of incubation, plates were spun at 1800rpm for 3 minutes, the 
supernatant was removed and stored at -20°C., and the cell pellet was resuspended in FACS 
(Fluorescence-Activated Cell Sorting) buffer (1x PBS, FBS, and Sodium Azide) before being 
transferred to a 96-well, round bottom plate (96 well U-Bottom Plate, Tissue Culture, 
Treated by Vacuum Gas, Plasma Polystyrene, Non-pyrogenic REF 353077 Falcon). Non-
stimulated spleen cells were plated at 4x105cells/well for compensation wells. 5μL of 
mouse block (normal mouse serum, human IgG, FCR antibody) was added to each sample 
well. Antibody cocktails were made at a 1:200 dilution with 50μL/sample well, with anti-
mouse CD4, CD3, and CD8 antibodies being used(Anti-mouse CD4 eFluor® 450 REF 48-
0042-82 eBioscience, APC-AlexaFluor® 750 Conjugated Anti-mouse CD3e Cat #27-
0032082 eBioscience, Anti-mouse CD8a (Ly-2) PE-Cy7 Cat# 25-0081-81, eBioscience). The 
compensation cocktail was made at a 1:200 dilution of CD3 Biotin (Biotin Conjugated Anti-
mouse CD3e Cat# 13-0033-82 eBioscience) in FACs buffer. 50μL of the antibody cocktail 
was added to each sample well, 50μL of the compensation cocktail was added to each 
compensation well, and 50μL of FACs buffer was added to the blank compensation well. 
The plate was incubated in the dark for 20 minutes at room temperature. A 1: 500 solution 
of streptavidin conjugate in FACS buffer was prepared and added to the respective 
compensation wells at 50μL /well. The plate was incubated for 15 minutes at room 
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temperature in the dark before samples were resuspended in 200μL of FACs buffer and 
transferred to flow tubes. Samples were run on a Cyan Flow Cytometry Machine and data 




 Levels of T cell proliferation, CD4+ cell frequency, and CD8+ cell frequency were 
evaluated for all samples. Differences between groups were determined using an ANOVA 
and a Bonferroni multiple comparison post-test. A p-value of less than 0.05 was considered 
statistically significant for all analyses, and raw p-values are reported. Statistical analyses 
were performed using GraphPad Prism Version 5 for Windows.  
 Levels of T cell proliferation were evaluated for all spleen samples using FlowJo 





T Cell Proliferation 
 
 Levels of T cell proliferation in response to an allograft bone antigen and an 
autograft bone antigen were evaluated in all transplant recipients. The T cell proliferation 
level in all treatment groups was compared against the level found in recipients of an 
autograft alone. The mice in this treatment group only received self-bone and the bone 
transplant surgery, so they should experience the lowest levels of T cell proliferation.  
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 Overall, the presence of AD-MSCs in an allograft transplant had no effect on T cell 
proliferation when exposed to an allograft bone antigen or and autograft bone antigen.  
Additionally, there was no significant difference in T cell proliferation levels found in 






 The presence of AD-MSCs in an autograft transplant had no effect on T cell 
proliferation levels when exposed to an allograft bone antigen or an autograft bone antigen.  
 
Figure 3.1 T Cell Proliferation Responses to Allograft and Autograft Bone Antigens 
in Recipients of an Allograft Transplant. T cell proliferation in recipients of an 
allograft only, an allograft with MSCs in fibrin, and an allograft with IV delivered MSCs 
was compared against T cell proliferation seen in recipients of an autograft. No 
significant differences in T cell proliferation levels with exposure to an allograft bone 
antigen or an autograft bone antigen were observed between treatment groups in 
recipients of a massive cortical allograft transplant.  
Error Bars depict SD. 
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 Contrary to our hypothesis, T cell proliferation in recipients of either a massive 
cortical allograft or autograft transplant was not affected by the presence of AD-MSCs. Data 
from this study suggests that the MSCs have a minimal effect on the T cell proliferation in 
response to a massive cortical allograft transplant. These results could also suggest that T 
cell proliferation is not a key player in massive cortical allograft failure. The humoral 
response to a transplant may have a bigger role in transplant failure in vivo. Additionally, 
transplant failure is normally associated with a chronic inflammatory response towards the 
donor tissue that prolongs over an elongated period of time (4). The immune response in 
this in vivo study was only measured at six weeks, so long-term immune response 
alterations were not evaluated. The addition of MSCs in vivo may still have 
Figure 3.2 T Cell Proliferation Responses to Allograft and Autograft Bone Antigens 
in Recipients of an Autograft Transplant. A.T cell proliferation was compared 
between recipients of an allograft bone vaccine, an allograft bone vaccine with MSCs 
delivered in fibrin, or an allograft bone vaccine with IV delivered MSCs. B.T cell 
proliferation was compared between recipients of an autograft bone vaccine, an 
autograft bone vaccine with MSCs delivered in fibrin, or an autograft bone vaccine with 
IV delivered MSCs.   
Error Bars depict SD. 
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immunomodulatory effects that lead to increased bone healing, but these effects may occur 
immediately after transplant or over a longer period of time. However, the presence of 
MSCs with a transplant has been shown to increase new bone formation. These results 
suggest that the new bone healing in vivo promoted by the presence of MSCs is not 
primarily due to modulation of the T cell immune response, however this does not rule out 
other immunological effects. The addition of MSCs may promote new bone healing due to a 
local effect elicited by the MSCs.  
 The mechanisms of bone healing are widely studied, especially in cases of fracture 
repair. Fracture repair is carried out in four phases. The immediate phase involves 
formation of a hematoma around the fracture site. The early inflammatory phase is 
characterized by the recruitment of immune cells to the fracture site, and high levels of T 
cells and pro-inflammatory cytokines are observed. The regenerative phase is marked by 
the bridging of the fracture with new bone, which is then remodeled into mature bone 
during the final remodeling phase. Studies looking at the effects on non-steroidal anti-
inflammatory drugs (NSAIDs) on fracture healing have shown that the initial pro-
inflammatory phase following fracture is key for new formation and fracture healing. 
NSAIDs act on the cyclo-oxygenase, or COX pro-inflammatory pathway that is responsible 
for converting arachidonic acid into cycloendoperoxides that include prostanglandins, 
thromboxanes, and prostacyclin. The cycloendoperoxides are key factors needed for the 
pro-inflammatory immune response seen after cell membrane disruption, and are 
necessary for adequate fracture repair. Prostaglandin E2, one of the factors produced via 
the COX pathway, is known to enhance bone resorption by increasing the proliferation and 
activity of osteoclasts, as well as stimulating new bone formation by increasing the 
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replication and differentiation of osteoblasts. Interruption of this pro-inflammatory 
response, and more specifically, the Prostaglandin E2 response, by NSAIDs administered 
within the first two weeks after injury has ben shown to result in impaired fracture healing 
(1). 
 A study by Namgil, et al. looked at the effect of MSCs with NSAIDs by culturing 
canine bone marrow MSCs in osteogenic media to promote osteoblast differentiation of the 
MSCs. A COX-2 specific pro-inflammatory response was induced, and cells were treated 
with NSAIDs for 48 hours. At 24 hours, there was a significant drop in the Prostaglandin E2 
levels, as well as a subsequent decrease in the MSC osteogenic process. However, at 48 
hours, the Prostaglandin E2 levels had rebounded in the presence of MSCs, and there was a 
subsequent increase in the MSC osteogenic process. The researchers suggested that MSCs 
might have some inherent ability to compensate for the anti-inflammatory NSAID activity 
through regulation of Prostaglandin E2 levels to promote new bone formation (2).  
 The minimal effects of MSCs on T cell proliferation observed in the in vivo study 
differ from what was observed in the bone vaccine study. Spleen cells from recipients of a 
massive cortical allograft or autograft transplant experienced minimal changes in T cell 
proliferation with the addition of MSCs upon re-exposure to a bone antigen, whereas 
spleen cells from recipients of a bone vaccine with MSCs had a dampened T cell 
proliferation response. This would suggest that previous exposure to low levels of the bone 
antigen might induce tolerance towards that antigen. Mice that were vaccinated received 
two different exposures to the bone antigen at a low enough concentration to potentially 
induce a tolerogenic immune response, as compared to recipients of an allograft or 
autograft that could potentially induce an immune response towards the bone.  
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 Future studies looking at the evaluation of MSC immunomodulatory effects in vivo 
at different time points following a massive cortical allograft transplant are needed to 
determine the extent of MSC effects on the cellular immune response. Additionally, future 
studies looking at the effects of prior exposure to a foreign bone antigen via vaccination on 
the overall outcome of a massive cortical allograft transplant are imperative in the search 




 The addition of MSCs following a massive cortical allograft transplant has been 
shown to increase new bone formation. One of the potential mechanisms of this 
phenomenon may be attributed to the immunomodulatory properties of MSCs. The 
presence of MSCs may lead to new bone formation via the MSCs acting in a more local 
effect. MSCs will directly increase bone healing by differentiating into bone cells, and 
through paracrine effects. They could be enhancing the initial pro-inflammatory healing 
response that is seen with allograft transplant and with fracture repair, and is necessary for 
adequate new bone formation.  
 Examination of the MSC immunomodulatory effect on T cell proliferation in vivo 
suggest that MSCs may not modulate the immune response towards a massive cortical 
allograft or autograft primarily by affecting T cell proliferation. However, in the in vivo 
study, this response was measured at one point in time; a longitudinal study looking at the 
immunomodulatory effects of MSCs on T cell proliferation are needed to determine if these 
results are true at other time points following massive cortical allograft transplants. 
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Additionally, this study evaluated the effect of MSCs on the cellular immune response 
towards a foreign bone antigen via evaluation of T cell proliferation, so other 
immunological effects by MSCs cannot be ruled out. The use of MSCs in promoting new 
bone formation following a massive cortical transplant should continue to be explored, 











































 The work detailed in this thesis was performed to aid in the exploration of a 
successful treatment protocol following the employment of a massive cortical allograft in a 
limb-salvage procedure. Current treatment protocols are accompanied by a high graft 
failure rate due to low levels of revascularization, new bone formation, and host-graft 
incorporation. These low levels have been deemed to be partly immune-mediated, so the 
use of immunosuppressives following allograft transplant are being evaluated. While 
immunosuppressive drugs such as Cyclosporin A effectively increase the success of an 
allograft, termination of the drug treatment results in eventual graft failure. Clinically, it is 
not advantageous to place a patient of immunosuppressives, so a different way of 
modulating the immune response towards the allograft is imperative. 
 In chapter two, we used a vaccine model to mimic the immune response seen 
towards an allograft as compared to an autograft in order to look at the effect of adipose-
derived mesenchymal stromal cells on the humoral and cellular immune response towards 
the graft. We found that administration of MSCs had little to no detectable effect on the 
humoral immune response towards the total bone antigens delivered in the vaccine. 
However, the MSCs do have some effect on the cellular immune response, as observed with 
dampened levels of T cell proliferation in recipients of a vaccine with either IV or 
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subcutaneously delivered MSCs. Additionally, we found that administration of an allograft 
vaccine will lead to a dampened T cell proliferation level observed with exposure to an 
allograft bone antigen, particularly when the vaccine is given with MSCs.  
 In chapter three, we evaluated the effect of mesenchymal stem cells on the cellular 
immune response in an in vivo model to see if the results seen in the vaccine study were 
comparable as the results seen with an in vivo model. Answers to this question could help 
shed light on the increased level of new bone formation observed in recipients of a massive 
cortical allograft or autograft with the addition of MSCs. Contrary to our hypothesis that 
MSCs would dampen the cellular immune response towards the graft and thereby allow 
increased new bone formation, we saw little to no effect of the MSCs on the cellular 
immune response elicited towards a massive cortical allograft or autograft transplant. 
These results suggest that the new bone formation promoted by the presence of MSCs is 
not due primarily to immunomodulation of the T cell proliferation response by MSCs. 
These results could also be due to the bone antigens eliciting a low T cell response in the 
recipients. However, in the in vivo study, this response was measured at one point in time, 
so other immunological effects by MSCs cannot be ruled out. Additionally, recipients of a 
massive cortical allograft or autograft transplant had no prior exposure to a bone antigen, 
unlike recipients of a bone vaccine. This prior exposure may be a key player in the MSC 
immunomodulation of the T cell proliferation response seen in recipients of a bone vaccine, 







 Further studies are needed to determine the effect of MSC administration following 
a massive cortical allograft transplant. While the MSCs had little to no effect on the T cell 
proliferation response in the in vivo study, other immunological effects elicited by the 
presence of MSCs should still be considered and explored. The effect of prior exposure to 
the bone antigen via a bone vaccine may play a role in the MSC immunomodulation of the T 
cell response, and could explain why the different results were observed in the in vivo 
study and in the vaccine study. In order to adequately compare these two results, an in vivo 
model looking at recipients of an initial vaccine with MSCs on Day 1, a booster vaccine with 
MSCs on Day 7, and a massive cortical allograft or autograft transplant on Day 21 compared 
to recipients of a transplant and MSCs alone is needed. The T cell proliferation in this model 
could be evaluated and correlated to levels of healing in order to determine if the prior 
exposure to a bone antigen and the presence of MSCs will dampen T cell proliferation in 
response to an allograft and autograft and allow for better levels of graft healing.  
 Additionally, a vaccine study is imperative in answering whether or not vaccination 
with an allograft bone antigen prior to a massive cortical allograft transplant will yield a 
better clinical outcome. While mice in this study received two vaccines, we would like to 
determine the number of vaccines and the time interval for administration that is most 
efficacious in promoting a positive clinical outcome. Timing of the first vaccination also 
needs to be explored. In cases of trauma patients, there is minimal time to administer the 
vaccine prior to a massive limb reconstruction surgery. Looking at the effects of vaccination 
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prior to the surgery compared to vaccination at the time of surgery could yield insights to 
the feasible use of this vaccination therapy in a clinical setting. 
 Our knowledge regarding an ideal treatment that would allow for increased massive 
cortical allograft success is still limited. The work described here shows that a total bone 
antigen is capable of inducing an immune response. The administration of MSCs has 
minimal to no effect on the humoral immune response in this vaccine model, however 
there is some effect on the cellular immune response. Unfortunately, this MSC 
immunomodulation of the cellular immune response is not seen in an in vivo massive 
cortical allograft transplant model. The work described here is a small step in 
understanding the response to a massive cortical allograft transplant in the hopes that one 
day this process will be better understood and result in a treatment protocol yielding high 
levels of host-graft incorporation and new bone volume, thereby increasing the overall 
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Allograft and Autograft Bone Harvest 
 Bones used for the allograft vaccine were obtained from Balb/C mice, with both 
femurs from each mouse collected. Mice were heavily anesthetized with isoflurane and 
oxygen, and euthanized via cervical dislocation. Femurs were collected under sterile 
conditions in a laminar flow hood. All instruments used were sterilized prior to use. 
Femurs were isolated, scraped with a fresh scalpel blade to remove all periosteum, and 
placed into cyrovials. Cyrovials were immediately placed into a container with liquid 
nitrogen to flash-freeze the bones. Bones were stored at -80°C for a minimum of one week 
before further processing.  
 Bones used in the autograft vaccine were obtained from C57BL/6 mice in the same 
manner as described for the allograft bone collection.  
 
Bone Powder Collection 
 The donor femurs were removed from the -80°C storage and were immediately 
placed into a liquid nitrogen container. A mortar and pestle were placed in ethanol for 10 
minutes and used to smash the bones into a powder. The bone powder was weighed and a 
final concentration of bone powder in the vaccine was 10μg/mL.  
 Donor femurs used in vaccines given to MSC recipients were removed from the -
80°C storage and immediately placed into a liquid nitrogen container. Bones were placed in 
a sterile metal container, and a hammer was used to smash the lid and crush the bones into 
a powder. The bone powder was weighed and a final concentration of 10μg/mL was used 




 Mice cages were placed on a heating pad under a heat lamp for a minimum of 20 
minutes before beginning the blood draws. Mice were placed in a restraining tube 
underneath the heat lamp, and 0.1mL of blood was collected from the tail vein on Day 1 and 
Day 7 before administration of the vaccine. On Day 21, mice were heavily anesthetized, and 
blood was collected via cardiac puncture just prior to euthanasia. Blood was placed into 
serum separator tubes (BD Microtainer® Serum Separator Tubes, REF 365956), which 
were spun down in a micro-centrifuge (Fisher Scientific accuSpin Micro 17) at 7 x 1,000g 




 C57BL/6 mice were treated with an initial vaccine injection on Day 1, followed by a 
booster vaccine injection on Day 7. Mice were anesthetized under oxygen and isoflurane, 
and a 0.1mL vaccine was injected subcutaneously through a 14gauge needle on the 
craniodorsal aspect between the shoulder blades. 
 
Spleen Collection 
 Immediately after euthanasia, spleens were collected under sterile conditions in a 
laminar flow hood. Mice were sprayed with 75% ethanol, and spleens were removed with 
sterile instruments. Spleens were placed into petri dishes containing 1-2mL HBSS media 
(HBSS, 1x with calcium and magnesium, CORNING cellgro REF 21-020-CV) and subjected to 
a single-cell suspension protocol. A cell strainer was placed on a 15mL conical tube, and the 
spleen and media were dumped into the cell strainer and mashed with a 3mL syringe 
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plunger. The conical tubes were spun in a centrifuge (Beckman Coulter Allegra™ 6R) at 
1200 rpm for 5 minutes and the cell pellet was then resuspended in 2mL of ACK Lysing 
Buffer (Lonza BioWhittaker® Catalog No: 10-548E) for 5 min. HBSS was added to the tube 
and spun at 1200 rpm for 5 minutes. Cells were resuspended in 1mL of freeze media, 
transferred to a cyrovial, and stored at -80°C. 
 
Bone Protein Extraction 
 
 Bone protein from C57BL/6 mice was isolated using TRIzol Reagent (TRIzol 
Reagent, Life Technologies 15596-026). Femurs were collected from C57BL/6 mice in a 
sterile manner and stored at -80°C prior to use.  
 Femurs were immediately placed into liquid nitrogen, freeze fractured, and crushed 
into a powder. TRIzol reagent was added at 1mL/50mg of protein, and the sample was 
homogenized using a power homogenizer (Fisher Scientific PowerGen 1000). The 
homogenized sample was incubated for 5 minutes at room temperature and chloroform 
(Chloroform, 99.9+%, A.C.S. HPLC grade, Aldrich Chemical Co, Inc. 67-66-3) was added at 
0.2mL per 1mL of TRIzol Reagent, and then centrifuged in a Hermle Labnet Z-383K High 
Performance Centrifuge at 12,000 x g for 15 minutes at 4°C. The upper aqueous phase was 
removed, and 0.3mL of 100% ethanol per 1mL of TRIzol Reagent was added. The sample 
was spun at 2,000xg for 5 minutes at 4°C, and the supernatant were transferred to a new 
tube. Isopropanol (2-Propanol HPLC Grade, Fisher Scientific A451-4) was added to the 
supernatant at 1.5mL isopropanol per 1mL TRIzol Reagent and the sample was incubated 
for 10 minutes at room temperature, spun at 12,000 x g for 10 minutes at 4°C, and the 
supernatant was removed. The protein pellet was washed with 2mL of a 0.3M guanidine 
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hydrochloride in 95% ethanol wash solution per 1mL of TRIzol Reagent, incubated for 20 
minutes at room temperature and then spun at 7500 x g for 5 minutes at 4°C. The wash 
solution was removed and 2mL of 100% ethanol was added to the protein pellet. The 
solution was vortexed and then incubated at room temperature for 20 minutes. The sample 
was spun at 7500 x g for 5 minutes at 4°C, the ethanol wash was removed, and the protein 
pellet air-dried for 10 minutes before 200μL of 1% SDS was added. The solution was 
pipetted up and down until the pellet was resuspended, spun at 10,000 x g for 10 minutes 
at 4°C and the supernatant containing the protein was transferred to a new tube. The 
protein yield was determined with a BCA Protein Assay Kit (Pierce 23225).  
 
BCA Protein Assay 
 A BCA Protein Assay Kit (Pierce 23225) was used to determine the protein 
concentration extracted from the TRIzol reagent protein extraction protocol. 10mL of 
Reagent A was added to 200μL of Reagent B to form a working reagent. Contents of an 
albumin standard were diluted in sterile PBS to create 8 protein standards at the following 
dilutions:  0, 0.125, 0.25, 0.5, 0.75, 1.0, 1.5, and 2.0mg/mL. The working reagent was added 
to a 96-well flat bottom plate (Costar EIA/RIA plate 96-well flat bottom high binding 
certified plate #90128) at 200μL/well. The standards were plated in triplicate at 
25μL/well. Protein samples were added at a 1:10 and 1:25 dilution and plated in triplicate. 
The plate was placed on a plate shaker for 30 seconds and incubated at 37°C for 30 




Mouse IgG2a Ready-SET-Go! ELISA 
 A Mouse IgG2a Ready-SET-Go! ELISA was purchased from eBioscience (Catalog #88-
50420). A 96-well flat bottom plate (Costar EIA/RIA plate 96-well flat bottom high binding 
certified plate #90128) was used. The Coating Buffer (1x) provided was diluted at a 1:10 
dilution in sterile PBS (10x). Capture antibody (250x) was diluted in the coating buffer at a 
1:250 dilution. 100μL of the capture antibody: coating buffer dilution was added to each 
well, the plate was sealed with a plate cover, and incubated at 37°C overnight.  
 A blocking buffer was prepared by diluting the Assay Buffer A Concentrate (20x) in 
deionized water at a 1:10 dilution. The plate was washed twice with 0.05% PBS-Tween, 
with 1 minute of soaking time allowed for each wash. 250μL of Blocking Buffer was added 
to each well and the plate was incubated overnight at 4°C. 
 A standard was prepared by reconstituting mouse IgG2a standard in distilled water 
for a concentration of 50ng/mL. The standard was allowed to reconstitute for 30 minutes. 
The detection antibody (250x) was diluted in Assay Buffer A (1x) at a 1:250 dilution. The 
plate was washed twice as done in the previous wash step. Two-fold serial dilutions of the 
standards with Assay Buffer A were performed to make the standard curve. This was done 
by added 100μL of Assay Buffer A (1x) to all standard wells. 100μL of reconstituted 
standard was added in duplicate to well A1 and A2. Well contents were mixed via pipetting, 
and 100μL were transferred to wells B1 and B2, respectively. This procedure was repeated 
5 times. The Assay Buffer A (1x) was added to all blank wells at 100μL/well, and added to 
sample wells at 50μL/well. Samples were pre-diluted I Assay Buffer A (1x) at a 1:10 
dilution, and 50μL of this dilution was added to the sample well. The Detection Antibody 
was added to all wells at 50μL/well, and the plate was covered and incubated at room 
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temperature for 3 hours. The plate was washed as previously done for 4 washes. 100μL of 
the Substrate Solution was added to each well, and the plate was incubated at room 
temperature for 15 minutes. 100μL of Stop Solution was added to each well, and the plate 
was read at 450nm.  
 
Antibody Detection ELISA 
 A Nunc-Immuno Maxisorp 96-well plate (Nunc #442404, Fisher 12-565-135) was 
coated with an antigen resuspended in bicarbonate buffer at 5μg/mL, with 50μL added to 
each well. The plate was covered with a plate sealer and incubated overnights at 4°C. 
 The plate was washed three times with 0.05% PBS-Tween. A 5% PBS-milk blocking 
buffer was made, and 250μL was added to each well. The plate was incubated for 60 
minutes at room temperature. Sample dilutions were prepared by diluting samples in 3% 
BSA-PBS (Bovine Serum Albumin Fraction V 100g BP1605-100, Lot 067027 Catalog #9048-
46-8, Fisher Scientific). The first dilution (1:10) was made by adding 6μL of sample to 54μL 
of 3% BSA-PBS, and samples were added to the first row of the plate. The rest of the plate 
was coated with 54μL of 3% BSA-PBS, and 6μL of the 1:10 dilution was transferred to the 
second row. Serial dilutions were performed in a similar matter and ranged from 1:10 to 
1:10,000 for each sample. Tips were changed between each dilution. Blank wells contained 
3% BSA-PBS. The plate was sealed and incubated at room temperature for 90 minutes. The 
plate was then washed three times with 0.05% PBS-Tween. An anti-IgG antibody 
(ImmunoPure® Antibody Goat Anti-Mouse IgG (H+L), Pierce Prod# 31430) was diluted 
1:500 in 5% BSA-PBS, and 50μL was added to each well. The plate was incubated for 60 
minutes and room temperature and the TMB substrate (3, 3’, 5, 5’-Tetra Methylbenzidine 
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(TMB) Liquid Substrate System for ELISA, Sigma-Aldrich T0440-1L) was brought to room 
temperature during this incubation period.  
 The plate was washed three times with 0.05% PBS-Tween, and 50μL of the TMB 
substrate was added to each well. Color was allowed to develop for two minutes before 
50μL of a 1N HCl stop solution was added to each well. The plates were read at 450nm.  
 
Adipose Tissue Harvest 
 Adipose tissue was collected from the abdominal fat pads of C57BL/6 mice using 
sterile instruments under a laminar flow hood. Fat was isolated and placed in a petri dish 
containing HBSS. Spleens were minced with a scalpel blade, and resuspended in 1mg/mL of 
collagenase with an antibiotic/antimycotic solution in a 50mL conical tube. Cells were 
incubated at 37°C for 30 minutes before MSC media was added. Cells were spun at 
2000rpm for 5 minutes, resuspended in MSC media, and spun once more. Cells were 
resuspended in MSC media and plated in flasks that were stored at 37°C.  
 
Adipose-Derived Mesenchymal Stem Cell Collection 
 Cells were allowed to incubate at 37°C until reaching a minimum of 80% confluency, 
as measured by visual inspection under a microscope. Cells were washed with HBSS, and 
trypsin was added to the flasks and allowed to sit at room temperature for 5 minutes. The 
sides of the flasks were vigorously tapped to cause cells to lift off the flask, and the cell-
trypsin solution was transferred to a 50mL conical tube. The tube was spun at 1220 for 5 
minutes, and the cells were resuspended in PBS-Heparin (0.1mL Heparin in 9.9mL sterile 
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PBS) with a final volume of 500,000 cells/100μL PBS-Heparin for injection. MSCs in unused 
flasks were frozen and stored for later use. 
 
Cryopreservation and Storage of MSCs 
 Cells in flasks that were not used for treatment were washed, trypsinized, and spun 
like mentioned before, and were resuspended in freeze media. Cells were transferred to 
cryovials and stored at -80°C.   
 
Spleen Thawing Protocol 
 Cryovials containing the single-cell spleen suspension were thawed quickly in a 
37°C water bath. Contents of the cyrovials were transferred to a 15mL conical tube 
containing 10mL of warmed complete growth media. Cells were gently mixed in the tube 
and incubated at 37°C for 15 minutes, with the tube lid left slightly loose. Cells were 
pelleted via centrifugation at 1220rpm and 25°C for 30 minutes. Media above the pellet 
was decanted and cells were counted and resuspended in sterile PBS at 1x106cells/mL.  
 
CFSE Staining 
 Conical tubes containing the spleen cells resuspended in sterile PBS at 
1x106cells/mL were spun at 1200g for 5 minutes. The PBS was decanted off, and cells were 
resuspended in 2mL of sterile PBS. Cells were counted, and resuspended in sterile PBS for a 
final concentration of 1x106cells/mL. Carboxyfluorescein succinimidyl ester (CFSE) 
(CellTrace™ CFSE Cell Proliferation Kit Catalog #C34554) was added at 0.4μL CFSE per 
1mL sterile PBS added to the spleen cells. The cells were incubated at 37°C for 10 minutes, 
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and then the conical tube was filled to 20mL with MEM. Tubes were placed on ice for 5 
minutes, and then spun at 1200rpm for 5 minutes. Pellets were washed twice with MEM, 
and cells were counted. The cells were resuspended in MEM at 4x105cells/200μL MEM for 
plating.  
 
Spleen Cell Antigen Exposure 
 A 96-well flat bottom plate (Costar EIA/RIA plate 96-well flat bottom high binding 
certified plate #90128) was used for spleen cell antigen exposure. Antigens were diluted in 
MEM at 0.01μL/50μL. 50μL of this solution was added to all antigen-spleen sample wells. 
50μL MEM was added to non-stimulated spleen sample wells. 100μL of the spleen cells was 
added to each well, and plates were incubated at 37°C for 72 hours.  
 After 72 hours, plats were spun at 1800rpm for 5 minutes, and the supernatant was 
transferred to cryovials and stored at -20°C. Cells were resuspended in FACS buffer and 
transferred to a 96-well round bottom plate (96 well U-Bottom Plate, Tissue Culture, 
Treated by Vacuum Gas, Plasma Polystyrene, Non-pyrogenic REF 353077 Falcon) for flow 
cytometry staining.  
 
Flow Cytometry Staining 
 Unstained spleen cells were added to the plate for color compensation wells. One 
well was plated for every antibody color used, as well as one blank well for a negative 
compensation well. Plates were spun at 1800rpm for 3 minutes, and the FACS buffer was 
flicked off. 5μL of mouse block was added to each sample well, and plates were stored in a 
drawer. An antibody cocktail was made with a 1:200 dilution of antibody in FACS buffer. 
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CD3, CD4, and CD8 antibodies were used (Anti-mouse CD4 eFluor® 450 REF 48-0042-82 
eBioscience, APC-AlexaFluor® 750 Conjugated Anti-mouse CD3e Cat #27-0032082 
eBioscience, Anti-mouse CD8a (Ly-2) PE-Cy7 Cat# 25-0081-81, eBioscience). The 
compensation cocktail was made with a 1:200 dilution of CD3 Biotin (Biotin Conjugated 
Anti-mouse CD3e Cat# 13-0033-82 eBioscience) in FACS buffer. Cocktails were vortexed 
for 5 seconds. 50μL of the antibody cocktail was added to each sample well, 50μL of the 
compensation cocktail was added to the color compensation wells, and 50μL of FACs buffer 
was added to the negative compensation well. Plates were incubated at room temperature 
for 20 minutes in the dark. Plates were washed two times, with one wash being: adding 
200μL FACS to each well, spinning the plates at 1800rpm for 5 minutes, and flicking off the 
FACS buffer. Plates were stored in a drawer and streptavidin cocktails were made. One 
1.5mL ependorf tube was used for each individual streptavidin (Streptavidin FITC 
Catolog#11-4317-87 eBioscience, Streptavidin APC REF#17-4317-82 eBioscience, 
Streptavidin eFluor®450 REF#48-4317-82 eBioscience, Streptavidin PE REF#12-4317-87 
eBioscience). 500μL of FACS buffer was added to 1μL of the streptavidin. 50μL of the 
streptavidin cocktail was added to the respective color compensation well. 50μL of FACS 
was added to all sample wells and to the negative compensation well. Plates were 
incubated at room temperature for 15 minutes in the dark. The wash step was performed 
as done before for a total of one wash. 200μL of FACS buffer was added to each well, and 






 Femurs harvested from Balb/C and C57BL/6 bones were freeze-fractured and 
placed into homogenizer tubes containing 500μL of lysis buffer before being placed into a 
power homogenizer.  The homogenized lysate sample was placed in a sonicator for 3-
second bursts with 20 seconds between each burst. This was done three times. The lysate 
sample was transferred to ependorf tubes, placed in a sonicator as done previously, and 
then spun at 4°C for 5 minutes in a micro-centrifuge. A BCA Protein Assay Kit (Pierce 
23225) was used to determine the bone protein concentration for the Balb/C lysate sample 
and for the C57BL/6 lysate sample.  
 
Western Blot Sample Preparation 
 Balb/C lysate samples were mixed with SDS 6x buffer and deionized water at: 15μL 
bone lysate, 11μL SDS 6x buffer, and 40μL water. C57BL/6 lysate was mixed at: 54.2μL 
bone lysate, 11μL SDS 6x buffer, and 0.8μL water.  A final loading concentration of 
20mg/mL bone protein was achieved with the above solutions. Solutions were made in 
ependorf tubes, and boiled for 5 minutes.  
 
Western Blot 
 20μL of the bone lysate sample were added to their respective gel wells, and 5μL of 
the protein standard (Precision Plus Protein™ Standards Kaleidoscope™ Bio-Rad #161-
0375) was added to the standard wells. The charge of the loading system was set to 180 
volts and ran for 41 minutes. A tupperware was filled with 2 blot papers and 4 sponges, 
and soaked with transfer buffer. Four box containers were filled with: transfer buffer, 
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transfer buffer, milliQ water, and filtered methanol, respectively. A PVDF transfer 
membrane (Immun-Blot® PVDF Membrane) was placed in the methanol box for 30 
seconds and transferred into the milliQ box for 2 minutes. The SDS gel was carefully 
removed from its plastic casing and placed into the first box containing transfer buffer. The 
blot papers were moved into the second box containing transfer buffer, and allowed to sit 
for 5 minutes, along with the SDS gel. After 5 minutes, the blot papers, gel, and sponges 
were assembled in the following order and loaded into a blot module (XCell Sure Lock™): 
sponge, sponge, blot paper, gel, blot paper, sponge, and sponge. The blot module was run at 
30 volts and 0.17Amps for 40 minutes.  
 Pooled serum from five recipients of an allograft bone vaccine was placed into a 50 
mL conical tube. The same was done with pooled serum from five recipients of an autograft 
bone vaccine. Both tubes were filld to the 5mL line with a TBST blocking buffer, resulting in 
a 1:1 dilution of serum: buffer. A third 50mL conical tube was filled to the 5mL line with the 
blocking buffer and 2μL of tubulin was added to serve as a loading control. The three tubes 
were stored at 4°C. 
 A container was filled with blocking buffer, and the blot paper was placed in the 
container after being removed from the blot module. The container was placed on a gentle 
rocker for 1 hour. The liquid was then dumped off, and the gel was cut into three pieces 
along the middle of the 2 protein standard wells. One gel piece was placed into the 50mL 
conical tube containing the pooled allograft serum. One gel piece was placed into the 50mL 
conical tube containing the pooled autograft serum. One gel piece was placed in the loading 
control 50mL conical tube. Gel pieces were placed so they were stuck to the side of the 
tube. The tubes were placed in a spinning carousal and stored at 4°C overnight.   
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 The gel pieces were removed and placed into a container filled with 1x TBST and 
placed on a slow rocker for 5 minutes. The liquid was dumped off and new 1x TBST was 
added before the container was placed on the slow rocker for 5 minutes. The liquid was 
changed 2 times for a total of 3 washes. After the last wash, the container was filled with 
blocking buffer and 10μL of anti-mouse IgG secondary antibody was added for a 1:2000 
dilution. The container was placed on a slow rocker for 1 hour, and the wash step was then 
repeated three times.  
 A Super Signal West Dura Extended Duration Substrate Kit (Thermo Scientific 
Product 34075) was used to prepare the blot papers for analysis in a Bio Rad Molecular 




 The pooled serum from recipients of either an allograft vaccine or an autograft 
vaccine used in the Western Blot was incubated with 50,000 cells of the K7M2 murine 
osteosarcoma line with a 1:100 final dilution of serum in blocking buffer for 30 minutes. 
Non-stimulated cells were suspended in FACS. Cells were plated on a 96-well round bottom 
plate (96 well U-Bottom Plate, Tissue Culture, Treated by Vacuum Gas, Plasma Polystyrene, 
Non-pyrogenic REF 353077 Falcon). A donkey-anti mouse IgG antibody with fluorescent 
tag (Fluorescein [FITC]-conjugated Affini Pure F(ab’)2 Fragment Donkey anti-mouse IgG 
(H&L), JacksonImmuno Code # 715-096-150) was added to each serum: cell well at a 1:100 
dilution in FACS buffer. Cells were incubated for 20 minutes, resuspended in FACS buffer, 
and run through a CyAn ADP DakoCytomation flow cytometry machine with Summit 
V4.3.02 Build 2451 software. The flow data was analyzed using FlowJo vX0.7. A K7M2 cell 
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gate was established on all samples and the mean intensity of the FITC channel was 
evaluated to look at the number of staining events as an indirect measure of the amount of 
antibody bound to the cell. A histogram of FITC expression in the cells only sample was 
used to create a lower threshold expression level of 1% to account for random binding. 
FITC histograms of the other cell populations were created to look at the percentage of cells 




Cationic Liposomal DNA Complex (CLDC)  
 
37.5μL DOTAP Liposomal Transfection Reagent 





Equal amount of CLDC resuspended in sterile PBS 
Antigen at 10μg/mL concentration 
 
 
Bone Vaccine Antigens 
 
Balb/C bone dust  
C57BL/6 bone dust 




980mL PBS (1x) 
20mL FBS 
0.5g Sodium Azide 








1L low glucose DMEM (Corning Cellgro DMEM 11885) 
150mL FBS (Atlas Fetal Bovine Serum Lot F12073011) 
20mL MEM Vitamins 
10mL Antibiotics/Antimycotics (Gemini Bio-Products Lot 30009111) 












50mL Atlas FBS Serum 
5mL Antibiotic/Antimycotics (Gemini Bio-Products Lot 30009111) 
500mL MEM (Corning Cellgro MEM, 1x [minimum essential medium eagle] with Earle’s 
Salts and L-glutamate, lot 10010266 REF 10-010-CV) 





Resuspended lyophilized mouse serum (Jackson ImmunoResearch) in 5mL deionized 
water 
83μL human IgG 






1N HCl Stop Solution 
 
9mL 37% hydrochloric acid 





10μL Tris-HCl 1M pH 7.5 
50μL 3M NaCl 
10μL Tritan 100x 
0.3mL deionized water 
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1μL sodium orthovaninate 
3.48μL PMSF protease inhibitor 10mg/mL 
7μL Proteinase Inhibitor Cocktail 7x 
*Kept on ice 
 
 
TBST Blocking Buffer 
 
100mL 1x TBST 


































































































































































































































































































































































































































































292.1 4.13 55.4 37.1 
292.2 1.66 15.9 57.1 
292.3 1.35 34 33.3 
 2.38 35.1 42.5 
292.4 3.96 55.7 14.1 
292.5 45.7 97.5 5.8 
 24.83 76.6 9.95 
292.7 12.7 86 20.3 
292.8 28.6 89.6 20.4 
292.9 1.44 13.3 16.7 
 14.24666667 62.96666667 19.13333333 
293.1 1.53 16.5 32.3 
    
293.4 28.7 21.2 28 
    
293.7 2.5 3 20 
    
296.1 2.25 31.2 58.8 
    
296.4 29.7 36.9 28 
    
296.7 0.77 38.3 44.4 
    
721.1 1.36 57.8 59.7 
721.2 14.8 57.1 42.5 
721.3 19.6 60.5 32 
 11.92 58.46666667 44.73333333 
721.4 25 58.4 20.1 
721.5 31.9 61.3 20 
721.6 33.8 60.8 20.3 
 30.23333333 60.16666667 20.13333333 
721.7 8.49 47 43.2 
721.8 1.79 31.1 52.7 
721.9 0.76 21.6 50 
 3.68 33.23333333 48.63333333 
722.1 7.47 60.2 31.1 
722.2 2.51 30.1 31.8 
722.3 5.8 50.5 34.6 
 5.26 46.93333333 32.5 
722.4 5.86 41.3 29.8 
722.5 5.89 48.9 23.4 
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722.6 2.02 17.5 21.4 
 4.59 35.9 24.86666667 
722.7 1.67 11.8 50 
722.8 1.53 20.7 41.2 
722.9 1.91 13.6 37.5 
 1.703333333 15.36666667 42.9 
756.1 0.82 73.6 65.4 
756.2 1.06 67.9 66.3 
 0.94 70.75 65.85 
756.4 0.38 62.5 63.3 
    
756.7 1.16 81.4 68.6 
    
765.1 0.61 74.4 22.4 
765.2 4.86 76 22.6 
765.3 2.44 56.7 29 
 2.636666667 69.03333333 24.66666667 
765.4 7.4 60.5 13.7 
765.5 4.52 67.2 15 
 5.96 63.85 14.35 
765.7 0.61 47.7 28.6 
765.8 1.34 49.6 19 
765.9 1.78 55.4 31.1 
 1.243333333 50.9 26.23333333 
775.1 10.1 85.8 4.33 
    
775.7 1.08 42.4 36 
 
 
Samples # Lymphocytes CD3+ CD3 Proliferation 
297.1 0.8 36.6 46.7 
    
297.4 2.02 46 4.35 
    
297.7 0.57 31.7 15.4 
    
298.1 1 35.8 31.6 
    
298.4 3.2 67.5 24.1 
    
298.7 0.97 43.2 28.1 
    
723.1 0.16 20 0 
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723.4 2.32 85 7.81 
    
723.7 3.23 83.8 14.4 
    
758.1 1.14 11.5 33.3 
    
758.7 0.67 5 0 
    
761.1 1.23 47.5 32.1 
761.2 0.73 17.9 40 
   36.05 
761.4 6.36 79 18.9 
    
761.7 1.45 1.69 100 
761.8 0.81 26.3 50 
   75 
770.1 0.12 13.3 50 
770.2 0.24 17.2 20 
770.3 0.12 26.7 50 
   40 
770.4 17.7 90.4 19.1 
770.5 42.5 92.6 19.9 
770.6 33.5 89.6 33.4 
   24.13333333 
770.7 0.88 60.2 43.1 
770.8 0.1 27.8 30 
770.9 0.32 6.45 50 
   41.03333333 
772.1 21.1 95.6 13.6 
    
772.4 13.5 93.3 25.5 
    
772.7 1.1 50.9 26.7 
772.8 0.91 16.7 0 
772.9 0.84 0 0 
   8.9 
781.2 36.4 88.3 43.5 
782.1 33.3 89.7 40.6 
782.3 40.1 90.4 55.5 
   46.53333333 
782.4 35.4 87.7 41.6 
782.5 38.1 92.2 41.3 
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782.6 34.9 88.1 24.8 
   35.9 
782.7 29.6 88.9 47.4 
782.8 33 85.8 42.6 
782.9 10.6 79 48.3 
   46.1 
 
 
Samples # Lymphocytes CD3+ CD3 Proliferation 
751.1 0.2 25 14.3 
751.2 0.64 35.9 3.57 
751.3 0.28 13.5 14.3 
   10.72333333 
751.4 0.45 80.4 8.89 
751.5 0.78 85.1 11.2 
   10.045 
752.1 0.68 87.8 4.17 
752.2 0.66 92.5 2.7 
   3.435 
752.4 0.58 31.6 28 
752.5 1.44 78.9 9.3 
   18.65 
753.1 0.23 73.3 13.6 
753.2 0.24 83.9 15.4 
753.3 0.21 61.5 12.5 
   13.83333333 
753.4 0.28 88.6 0 
753.5 0.19 87.5 9.52 
753.6 0.22 81.5 4.55 
   4.69 
754.1 0.84 85.4 2.27 
754.2 0.72 88.8 5.06 
754.3 0.67 87.7 2.82 
   3.383333333 
754.4 0.86 93.3 5.15 
754.5 0.81 88 2.27 
   3.71 
756.2 17.2 96.7 6.08 
756.3 21.3 97.1 6.88 
   6.48 
756.4 21.7 97.9 4.64 
756.5 28.7 97.4 7.01 
756.6 32 97 5.61 
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   5.753333333 
757.1 9.18 83.9 5.55 
757.2 11.8 82.1 7.1 
757.3 11.5 80.9 8.15 
   6.933333333 
757.4 21.1 84.6 7.43 
757.5 16.6 81.7 7.16 
757.6 22.4 83.1 8.59 
   7.726666667 
760.1 50.4 96 13.7 
760.2 45.3 95.7 12.3 
760.3 45.6 95.8 12.6 
   12.86666667 
760.4 66.9 97.2 10.7 
760.5 66.8 96.9 12.4 
760.6 59.1 96.5 11.9 
   11.66666667 
761.1 41.6 92.2 14.9 
761.2 43.5 93 14.9 
761.3 38.3 92.9 14.8 
   14.86666667 
761.4 50.9 96.4 12.4 
761.5 50.5 95.5 12.4 
761.6 57.2 95.8 13.3 
   12.7 
764.1 14.3 98.5 1.18 
764.2 6.09 97.3 1.32 
764.3 15.7 98.7 0.52 
   1.006666667 
764.4 34.7 98.7 0.65 
764.5 39.6 98.7 0.63 
764.6 30.7 98.5 0.8 
   0.693333333 
951.1 8.73 96.1 7.37 
951.2 8.91 96 6.22 
   6.795 
951.4 4.96 94.7 4.17 
951.5 3.9 87.1 3.41 
   3.79 
959.1 56 98.9 4.02 
959.2 52.4 98.9 2.13 
959.3 46.9 99.3 2.66 
   2.936666667 
110 
959.4 70 98.8 2.72 
959.5 65.7 98.7 2.41 
959.6 66.1 98.7 2.54 
   2.556666667 
972.1 3.38 70 15 
972.2 2.66 64.2 19.4 
972.3 3.14 68.9 15.3 
   16.56666667 
972.4 4.07 74.4 16.1 
972.5 3.12 68.9 15.4 
   15.75 
981.1 41.3 98.1 6.93 
981.2 39.9 97.9 6.13 
981.3 37.4 98.1 6.65 
   6.57 
981.5 37.3 99 5.08 
981.6 62.4 99.1 4.88 
   4.98 
982.1 6.08 34.4 7 
982.2 6.44 30 8.97 
982.3 7.49 33.3 7.59 
   7.853333333 
982.4 7.2 31.6 4.73 
982.5 10.5 30.2 3.93 
982.6 10.6 29.4 12.2 
   6.953333333 
985.1 36.1 93.7 16.8 
985.2 42.1 94.2 17.3 
985.3 45.7 93.8 17.5 
   17.2 
985.4 61 95.9 13.1 
985.5 54.3 94.9 15.7 
985.6 61.9 96.3 13 








726.1 1.48 49.2 46.7 
726.2 1.65 54.9 38.5 
762.3 1.49 56.3 58.6 
   47.93333333 
726.4 2.2 73 32.3 
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726.5 1.7 63.3 52.6 
   42.45 
726.7 1.18 60.6 50 
726.8 0.56 21.7 46.7 
   48.35 
728.1 38.4 98.3 15 
728.2 41.8 98.8 16.8 
728.3 39.1 98.6 13.1 
   14.96666667 
728.4 47.7 98.7 17.1 
728.5 46.5 99.1 14.6 
728.6 48.3 98.7 15.6 
   15.76666667 
728.7 42.5 99 16.9 
728.8 41.9 98.9 17.8 
728.9 46.6 99 18.9 
   17.86666667 
886.1 77.1 99.9 11.8 
886.2 56.8 99.7 11.2 
886.3 63.9 99.9 12 
   11.66666667 
886.4 64.7 100 11.9 
886.5 64.1 99.9 14.1 
886.6 63.1 99.8 12.7 
   12.9 
886.7 66.8 99.9 13.9 
886.8 68 99.9 11.9 
886.9 59.3 99.8 7.03 
   10.94333333 
887.1 64 99.8 3.7 
887.2 66.8 99.9 5.24 
887.3 65.3 99.8 5.26 
   4.733333333 
887.4 60 99.7 5.83 
887.55 53.4 99.5 2.62 
887.66 66.5 99.9 2.31 
   3.586666667 
887.7 65.4 99.9 1.97 
887.8 49.6 99.5 3.07 
887.9 44.8 99.4 3.22 
   2.753333333 
926.1 3.05 93.5 33.1 
926.2 3.6 90.4 32.7 
112 
962.3 4.19 89.2 30.8 
   32.2 
926.4 4.3 94.7 42.4 
926.5 0.65 89.9 50.7 
926.6 3.65 87.2 45.9 
   46.33333333 
926.7 5.48 92.4 39.8 
926.8 3.44 92.1 43.9 
926.9 0.71 45.2 59.6 
   47.76666667 
927.1 28.6 98.2 30.5 
927.2 33.5 99.1 31.4 
927.3 36 98.8 33.5 
   31.8 
927.4 24.6 98.5 31 
927.5 21.8 97.9 30.7 
927.6 39.7 98.9 29 
   30.23333333 
927.7 28.2 99.2 26.6 
927.8 5.35 95.7 42.1 
928.9 33.8 98.9 31.1 
    33.26666667 
948.1 3.61 94.5 22.7 
948.2 3.92 89.2 25.4 
   24.05 
948.4 4.06 91.2 27.2 
948.5 4.62 92.5 30.1 
   28.65 
948.7 1.51 68.3 33.1 
948.8 4.54 91.8 23.8 
   28.45 
954.1 39.1 99.3 22.2 
954.2 39.2 99.2 20.7 
954.3 37.5 99 20.9 
   21.26666667 
954.4 46.2 99 21 
954.5 44.7 99.3 19.4 
954.6 46 99.3 21.1 
   20.5 
954.7 0.38 55.7 47.6 
954.8 34.8 99.5 4.07 
954.9 42.5 99 10.9 
   20.85666667 
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976.1 48.9 99.8 5.12 
976.2 54.9 99.9 5.88 
976.3 49.9 99.9 6.01 
   5.67 
976.4 53.9 100 6.46 
976.5 44 99.6 7.42 
976.6 52.1 99.9 6.61 
   6.83 
976.7 50.7 99.8 6.22 
976.8 49.6 99.8 12.1 
976.9 46.5 99.4 12.7 
   10.34 
977.1 41.5 99 15.6 
977.2 47.9 99.4 14.2 
977.3 51.3 99.8 13 
   14.26666667 
977.4 61.1 99.9 12.2 
977.5 50.4 100 12 
977.6 51 99.5 13.2 
   12.46666667 
977.7 57.9 99.9 11.2 
977.8 54.1 99.8 12.8 
977.9 49.5 99.3 10.5 





Lymphocytes CD3+ CD3 Proliferation 
692.1 33.5 98.6 12.6 
692.2 36.4 98.7 12.5 
692.3 33.3 98.9 11.4 
   12.16666667 
692.4 13.8 96.7 11.5 
692.5 41.9 98.9 11.3 
692.6 41.9 98.4 12.1 
   11.63333333 
692.7 33.2 98.6 11.3 
692.8 34.4 98.7 14 
692.9 38.6 98.6 12.8 
   12.7 
693.1 47.4 97.4 15.3 
693.2 41.9 97 14.9 
693.3 40.4 97.2 15 
114 
   15.06666667 
693.4 46.3 97 14.8 
693.5 48.7 97 15.8 
693.6 49.1 97.4 13.7 
   14.76666667 
693.7 41.4 96.9 15.1 
693.8 41.2 97.2 16.4 
693.9 49.2 96.5 15.9 
   15.8 
694.1 48.6 97.8 15.5 
694.2 47.1 97.1 15.6 
694.3 46.4 98.1 15.1 
   15.4 
694.4 52.2 98.2 14.9 
694.5 48.1 97.2 17.2 
694.6 49.4 97.5 16.3 
   16.13333333 
694.7 46.6 98 12.7 
694.8 45.5 97.5 16 
694.9 45.5 97.4 15.2 
   14.63333333 
729.1 5.92 83.9 19.1 
729.2 5.18 81.3 22.3 
   20.7 
729.4 4.59 84 22.7 
729.5 0.31 0 0 
   11.35 
729.7 4.41 82.2 26.7 
729.9 5.03 84.7 23.9 
   25.3 
738.1 24.2 98.4 16.5 
738.2 27.6 98.1 19.4 
738.3 28.7 98.1 18 
   17.96666667 
738.4 25.2 98.1 17.9 
738.5 25.5 97.9 15.4 
738.6 28.6 98.2 18.2 
   17.16666667 
738.7 30.8 98.3 18.8 
738.8 28 98.5 20.2 
738.9 31.3 98.2 20.7 
   19.9 
758.1 56.5 97 18 
115 
758.2 59.3 97.3 18 
758.3 59.2 97.2 18.2 
   18.06666667 
758.4 52.7 98.2 17.3 
758.5 55.2 98.1 15.6 
758.6 59.6 98 18.7 
   17.2 
762.1 42.2 94.3 27.4 
762.2 43.5 91.9 30.3 
762.3 43 92.9 29.1 
   28.93333333 
762.4 53.9 94.8 25.1 
762.5 54.6 94 27.3 
762.6 55.5 94.1 28.3 
   26.9 
881.1 55.8 92.2 33.1 
881.2 55.4 89.9 37.1 
881.3 51.4 88.9 40 
   36.73333333 
881.4 50.5 90.3 37.7 
881.5 53.6 91.5 36.8 
881.6 48.4 90.9 37.9 
   37.46666667 
881.7 45.9 89.9 40.2 
881.8 46.1 90.4 38.3 
881.9 47.5 91.1 36.7 
   38.4 
883.1 40.5 95.8 23.4 
883.2 43.3 96.2 22.7 
883.3 43.9 95.2 24.3 
   23.46666667 
883.4 42.2 95.7 25 
883.5 43.6 96.3 26 
883.6 46.7 95.2 27.7 
   26.23333333 
883.7 45.8 95.8 25.5 
883.8 43.5 95.8 24.3 
883.9 46.1 94.5 26.1 
   25.3 
888.1 58.6 94.8 23.5 
888.2 57.3 94.7 24.1 
888.3 56.2 94.6 24.1 
   23.9 
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888.4 63.6 94.3 25.2 
888.5 66 94.1 25.1 
888.6 63.1 94.2 25.1 
   25.13333333 
888.7 21.7 94.8 23.1 
888.8 53.9 95.3 22.7 
888.9 66.9 94.6 21.2 
   22.33333333 
931.1 51 94.5 31.5 
931.2 42.7 94.6 31.5 
   31.5 
931.4 49.3 94.3 31.2 
931.5 51.7 93.6 34.1 
   32.65 
931.7 42.9 95 33.1 
931.8 45.4 94.7 31.2 
   32.15 
933.1 39.1 97.7 24.3 
933.2 39.6 97.8 23.6 
933.3 35.5 97.6 21.9 
   23.26666667 
933.4 46.6 97.7 21.3 
933.5 37.3 97.7 22.7 
933.6 42.6 97.9 23.1 
   22.36666667 
933.7 36.9 97.6 24.8 
933.8 42.1 97.9 22.2 
933.9 40.4 97.9 22.4 
   23.13333333 
949.1 2.17 78.9 26.3 
949.2 2.32 75.5 26.8 
949.3 2.28 74.5 21.7 
   24.93333333 
949.4 1.63 75.1 25 
949.5 2.8 74.6 23.8 
   24.4 
952.1 31.4 72.6 49 
952.2 26.9 72.3 47.4 
952.3 33.9 72.3 49.5 
   48.63333333 
952.4 24.3 69 49.2 
952.5 24.2 70.4 48.9 
952.6 36.2 70.4 48.2 
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   48.76666667 
952.7 0.45 58.5 39.5 
952.8 29 79.4 47.2 
952.9 25.2 79 48.7 
   45.13333333 
953.1 30.7 97 21.3 
953.2 35.8 94.8 21.6 
953.3 35.7 96.3 23.9 
   22.26666667 
953.4 3.59 95.4 24.2 
953.5 42.6 95.9 25.2 
953.6 33.2 96.1 23.2 
   24.2 
953.7 33.2 97 22.1 
953.8 36 96.5 23.5 
953.9 36.5 91.8 25.3 
   23.63333333 
956.1 30.3 92.9 35.6 
956.2 5.69 13.8 42.4 
956.3 26.1 91.3 37.8 
   38.6 
956.4 29.6 91 37.9 
956.5 30.9 91.9 36.2 
956.6 30.7 90.2 37.8 
   37.3 
956.7 22.8 92.3 38.2 
956.8 28.3 91 36.9 
956.9 35.5 92.9 33.1 
   36.06666667 
957.1 2.76 68.9 18.3 
957.2 3.16 54.7 23.4 
957.3 2.93 73.4 25.5 
   22.4 
957.4 2.71 79.3 26.1 
957.5 2.63 74.4 26.4 
   26.25 
957.7 0.33 8.79 66.7 
957.8 3.41 75 32.1 
957.9 1.81 73.2 29.8 
   42.86666667 
969.1 50.4 94.7 21 
969.2 38 93.9 23.4 
969.3 45.5 93.9 24.3 
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   22.9 
969.4 47.2 94.4 20.8 
969.5 33.3 94.4 21.2 
969.6 47 94.2 22.2 
   21.4 
969.7 39.2 94 21.8 
969.8 26.4 92.9 23.7 
969.9 36.6 93.6 22.5 
   22.66666667 
978.1 6.2 85.8 34.6 
978.2 3.9 83.7 32 
978.3 3.73 82.5 39 
   35.2 
978.4 3.61 82.3 34.5 
978.5 5.21 85.3 32 
   33.25 
978.7 3.87 82.9 29.8 
978.8 5.22 84.4 38 
978.9 5.17 84.5 30.1 
   32.63333333 
980.1 38.1 79.9 45.9 
980.2 38.5 80.5 46.2 
980.3 33.9 80.1 44.6 
   45.56666667 
980.4 36 80.1 44.5 
980.5 34.7 81.2 44.8 
980.6 39.6 80.4 46.4 
   45.23333333 
980.7 32.4 78.5 47.9 
980.8 38.6 80.6 47 
980.9 34.6 79.2 45.3 






Lymphocytes CD3+ CD3 Proliferation 
700.1 41.4 98.8 22 
700.2 46.1 99.4 25.6 
700.3 45.5 99.5 21.8 
   23.13333333 
700.4 45.8 99 22.6 
700.5 45.2 98.8 27.8 
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700.6 51.3 99.1 24 
   24.8 
700.7 44.4 99.3 26 
700.8 42.5 99.2 23.2 
700.9 45.2 99.4 21.3 
   23.5 
730.1 3.27 83.3 24.5 
730.2 3.89 77 31.8 
   28.15 
730.4 2.7 75.3 24.8 
730.5 3.95 90.6 19.5 
   22.15 
730.7 3.37 79.3 27.8 
730.8 2.68 64.2 27.4 
   27.6 
732.1 3.58 82.4 18.3 
732.2 2.47 79.2 16.5 
   17.4 
732.4 3.73 76.8 17.6 
    
732.7 4.03 76.5 17 
732.8 3.04 66.2 20.7 
   18.85 
737.1 3.67 62.5 29.2 
737.2 2.15 40.4 42.9 
   36.05 
737.4 2.9 25.4 40 
737.5 3.9 61.2 15.9 
   27.95 
737.7 1.66 16.9 28.6 
737.8 1.79 18 55.6 
   42.1 
739.1 52.1 99.6 10 
739.2 52.4 99.5 11.8 
739.3 48 99.5 11.3 
   11.03333333 
739.4 34.9 97.3 15.8 
739.5 54.7 99.4 11.5 
739.6 52.5 99.6 11 
   12.76666667 
739.7 53.9 99.4 11.7 
739.8 55.6 99.4 12.1 
739.9 53.1 99.6 11.8 
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   11.86666667 
740.1 19.3 99.2 8.77 
740.2 24.5 99.1 13.1 
740.3 23.5 98.9 14.7 
   12.19 
740.4 28.7 99.4 16.6 
740.5 28.8 99.3 16.2 
740.6 26.2 99.1 14.9 
   15.9 
740.7 24.4 98.8 14.9 
740.8 19.8 99 15 
740.9 25.2 98.9 17.3 
   15.73333333 
882.1 50.7 99.8 13.1 
882.2 53.1 99.6 11.6 
882.3 53 99.7 12.6 
   12.43333333 
882.4 53.1 99.7 14.5 
882.5 50.1 99.7 14.1 
882.6 55.3 99.7 14.2 
   14.26666667 
882.7 45.1 99.6 15.9 
882.8 50.3 99.8 12.1 
882.9 46.3 98.5 20.5 
   16.16666667 
884.1 43.9 96.4 23.4 
884.2 44.2 99.1 14.7 
884.3 47 99.7 17.9 
   18.66666667 
884.4 47.7 99.8 16.6 
884.5 42.7 99.1 17.3 
884.6 49.6 99.6 16.9 
   16.93333333 
884.7 39.8 98.6 16.9 
884.8 45.2 99.7 14.9 
884.9 36.6 98.4 16.9 
   16.23333333 
885.1 34.9 98.8 22 
885.2 31.5 99.4 20.6 
885.3 40.3 98.8 20.1 
   20.9 
885.4 23.8 95.5 26.1 
885.5 32.4 99 21.8 
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885.6 33.8 99 23.1 
   23.66666667 
885.7 25.9 97.3 21.7 
885.8 29.7 99 22.7 
885.9 33.7 98.6 20.8 
   21.73333333 
971.1 0.84 22.7 0 
971.2 1.15 8.7 50 
   25 
971.4 1.11 15.2 14.3 
971.5 0.66 16.7 16.7 
   15.5 
971.7 1.17 9.26 0 
971.8 1.3 11.6 0 
   0 
 
 
Samples # Lymphocytes CD3+ CD3 Proliferation 
380.1 27.3 95.9 13.8 
380.2 27.8 94.9 15.9 
380.3 32 95.6 15.6 
   15.1 
380.4 23.4 93.3 14.3 
380.5 34.9 95.8 16.6 
380.6 34.7 95.5 15.2 
   15.36666667 
380.7 25.6 95.3 17.5 
380.8 33.6 96.5 14.7 
380.9 28.7 96 15.8 
   16 
387.1 5.35 91.4 19.8 
387.2 6.64 95.2 15.2 
387.3 3.5 95.6 13.9 
   16.3 
387.4 3.09 23.5 17 
387.5 2.25 74.4 2.99 
387.6 2.46 81.9 19.5 
   13.16333333 
387.7 2.24 94.8 19.1 
387.8 2.64 93.8 12.1 
387.9 3.69 90.9 16.7 
   15.96666667 
411.1 46.1 98.7 12.1 
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411.2 39.4 97.9 13.4 
411.3 41.5 98.5 13.8 
   13.1 
411.4 39.1 96.7 17.3 
411.5 42 98 15.4 
411.6 28.7 89 18.3 
   17 
411.7 39.3 97.2 16 
411.8 36.1 96.6 12.7 
411.9 32.3 94.7 20 
   16.23333333 
417.1 13.5 91.9 25.2 
417.2 13.8 90.8 23.4 
417.3 15.7 93.8 22.9 
   23.83333333 
417.4 22.2 92.3 25.1 
417.5 18.7 88.7 28.4 
417.6 21.4 87.1 32.3 
   28.6 
417.7 27.1 88.9 28 
417.8 18.3 89.5 24.9 
417.9 27 91.7 23.1 
   25.33333333 
641.1 45.8 94.5 20.9 
641.2 36.8 94.2 19.7 
641.3 43 94.5 19.2 
   19.93333333 
641.4 43.7 94.8 18.9 
641.5 44.3 94.9 17.3 
641.6 43.2 95.3 18.4 
   18.2 
641.7 40.3 96.2 18.3 
641.8 42.6 95.5 18.3 
641.9 43.3 94.5 19.6 
   18.73333333 
642.1 50.1 93.7 21.8 
642.2 44.5 93.4 22.4 
642.3 44.5 95.4 19.6 
   21.26666667 
642.4 42.3 94.8 21.8 
642.5 45 93.7 21.9 
642.6 45.8 93.5 23.6 
   22.43333333 
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642.7 43.3 92 23.3 
642.8 46 91.7 22.8 
642.9 43.5 92 22.2 
   22.76666667 
643.1 45.2 82 30.8 
643.2 51.3 84.1 30.4 
643.3 50.3 82.3 28.5 
   29.9 
643.4 45.2 81 35 
643.5 43.2 80.1 33.5 
643.6 46.5 81.3 32 
   33.5 
643.7 49.3 84.8 31.1 
643.8 42.4 83.7 31.1 
643.9 45.9 84.4 31 
   31.06666667 
644.1 31 91.4 29 
644.2 32.7 90 28.6 
644.3 37.1 91.7 28.3 
   28.63333333 
644.4 44.3 91.5 24.3 
644.5 32.8 92.2 24.6 
644.6 25.1 91.4 24.8 
   24.56666667 
644.7 30.2 91.1 29.2 
644.8 28.9 88.8 29.4 
644.9 25.1 92.5 23.9 
   27.5 
780.1 7.34 89.7 14.8 
780.2 9.24 90.5 21 
780.3 8.59 92.8 26.5 
   20.76666667 
780.4 3.77 80.6 5.17 
780.5 4.55 73.8 17.7 
   11.435 
932.1 25.7 96.7 14.7 
932.2 27.9 96.2 17.6 
932.3 26 96.3 16.6 
   16.3 
932.4 28.3 96.7 17.1 
932.5 8.69 72.6 18.6 
932.6 20.3 95.9 15.1 
   16.93333333 
124 
932.7 19 96.4 16.4 
932.8 20.4 95 16.4 
932.9 23.7 97 15 




Samples # Lymphocytes CD3+ 
CD3 
Proliferation 
384.1 4.16 46.8 36.1 
384.2 1.66 31.6 50 
384.3 0.68 9.8 40 
   42.03333333 
384.4 2.16 53.7 45.5 
384.5 1.94 41.9 44.4 
384.6 3.1 66.7 48.4 
   46.1 
384.7 2.23 46.3 36.8 
384.8 2.16 39.4 30.8 
384.9 2.1 51.5 35.3 
   34.3 
394.1 2.37 40.5 33.3 
394.2 2.38 48.2 11.1 
394.3 3.35 51.6 34.4 
   26.26666667 
394.4 1.88 40.5 35.3 
394.5 3.83 35.1 25 
394.6 2.01 62.1 25 
   28.43333333 
394.7 4.31 72.5 20.7 
394.8 5.27 60.8 27.1 
394.9 1.64 37.1 15.4 
   21.06666667 
395.1 37.1 96.3 22.1 
395.2 32.7 97.5 22.2 
395.3 32.5 97.7 21.7 
   22 
395.4 33.9 97.4 19.4 
395.5 33.7 96.4 20.7 
395.6 31.2 96.5 22.5 
   20.86666667 
395.7 27.3 97.1 23.7 
395.8 30.1 96.8 22.1 
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395.9 32.4 96.8 23.1 
   22.96666667 
396.1 5.89 74.2 25.5 
396.2 6.35 76.4 21 
396.3 7.22 76.7 25.9 
   24.13333333 
396.4 6.67 67.9 17.9 
396.5 6.96 80.8 23.7 
396.6 3.54 70.3 29.5 
   23.7 
396.7 5.19 58.2 34.8 
396.8 3.53 47.7 32.3 
396.9 2.82 44.8 23.1 
   30.06666667 
397.1 27.8 96.2 17 
397.2 25 95.5 22.1 
397.3 17.6 94.3 18.6 
   19.23333333 
397.4 18.6 92.8 22.1 
397.5 20.6 95.8 21 
397.6 14.6 94.6 20.1 
   21.06666667 
397.7 17.1 89.6 23.8 
397.8 18.1 95.8 19.2 
397.9 17.6 94.7 21.7 
   21.56666667 
402.1 14.6 76.2 48.4 
402.2 8.71 84.7 49 
402.3 11.8 82.2 43.6 
   47 
402.4 12.9 63.4 49.1 
402.5 8.35 51.9 45.6 
402.6 8.06 92.3 37.9 
   44.2 
402.7 5.91 60.4 42.4 
402.8 7.7 68.9 41.7 
402.9 5.96 80.7 49 
   44.36666667 
407.1 14.6 88.7 21.5 
407.2 18.4 92.2 26.6 
407.3 11.5 89.5 29.3 
   25.8 
407.4 15.9 94 18.5 
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407.5 10.5 91.5 18.7 
407.6 16.4 91.3 24.4 
   20.53333333 
407.7 16 89.1 18 
407.8 18.2 92.8 23.4 
407.9 27 93.3 24 
   21.8 
408.1 22.2 95.2 13.7 
408.2 28.8 96.6 17.1 
408.3 31.9 95.3 17.5 
   16.1 
408.4 27 94.9 15.6 
408.5 19 95.3 12.1 
408.6 26 97.1 11.3 
   13 
408.7 33.3 97 16.7 
408.8 30.2 96.8 19.4 
408.9 29.9 96.7 19.5 
   18.53333333 
412.1 26.3 96.1 15 
412.2 29.6 97.7 18.3 
412.3 27 97.9 16.3 
   16.53333333 
412.4 24.8 98.1 18.2 
412.5 27 97.3 19.7 
412.6 24.7 94.6 16.7 
   18.2 
412.7 21.2 97.4 20.7 
412.8 26.8 88.9 27 
412.9 20.4 95.3 16.7 
   21.46666667 
418.1 7.03 86.2 19.6 
418.2 8.98 90.9 16.1 
418.3 10.8 81 16.7 
   17.46666667 
418.4 8.22 88.3 19 
418.5 9.23 84.8 18.9 
418.6 7.09 86 18.3 
   18.73333333 
418.7 7.82 83.2 16.9 
418.8 10.4 86.5 18.1 
418.9 14.6 92.6 23.8 
   19.6 
127 
Samples # Lymphocytes CD3+ 
CD3 
Proliferation 
381.1 32.2 95.3 32.5 
381.2 32.9 95.8 29.1 
381.3 34.5 96.8 28.9 
   30.16666667 
381.4 34.1 96.4 27.7 
381.5 30 96.6 27.1 
381.6 26.8 94.2 32.3 
   29.03333333 
381.7 25.2 96.7 24.6 
381.8 30 94 26.9 
381.9 31.4 94.9 30.1 
   27.2 
382.1 6.2 81.8 49.6 
382.2 8.64 88 46.7 
382.33 47.7 98.9 15.9 
   37.4 
382.4 9.97 90.6 39 
382.5 9.65 85.8 53.1 
382.6 8.89 89.4 38.2 
   43.43333333 
382.7 9.04 89.1 40 
382.8 7.99 85 34 
382.9 6.26 86.8 35.7 
   36.56666667 
383.1 45.6 99.1 17.9 
383.2 55 99.2 17.4 
   17.65 
383.4 57.5 99.2 14.5 
383.5 48.6 99 21.6 
383.6 58 99.4 21.6 
   19.23333333 
383.7 40.6 95.8 19.8 
383.8 51.7 99.2 15.4 
383.9 50.2 98.8 22.9 
   19.36666667 
385.1 28.7 97.5 24.4 
385.2 24.9 97 26.5 
385.3 24.8 66.5 62.2 
   37.7 
385.4 22.5 92.4 27.6 
385.5 19.7 92.8 25.1 
128 
385.6 29.7 96.7 24.2 
   25.63333333 
385.7 19.7 89.9 19.4 
385.8 13.1 27.2 25.9 
385.9 15 67 17.3 
   20.86666667 
386.1 38.5 94.9 37.7 
386.2 36.1 95.4 38.6 
386.3 36 94.2 39.3 
   38.53333333 
386.4 36.9 86 37.5 
386.5 39.8 95.3 35.9 
386.6 22.5 78.2 35.3 
   36.23333333 
386.7 30.9 94.5 32.7 
386.8 25.6 89.6 38.3 
386.9 25.6 79.6 35.1 
   35.36666667 
391.1 5.68 34.4 21 
391.2 3.63 35.8 16 
391.3 3.54 74.7 18.3 
   18.43333333 
391.4 3.43 66.7 34.2 
391.5 3.45 49.1 30.8 
391.6 1.43 76.9 20 
   28.33333333 
391.7 4.88 52.1 20 
391.8 9.22 76.8 37.1 
391.9 7.1 62.9 30.7 
   29.26666667 
392.1 3.06 60.7 16.2 
392.2 2.8 50 12 
392.3 4.75 24.3 16.2 
   14.8 
392.4 2.38 39.4 38.5 
392.5 2.75 4.63 23.5 
392.6 1.87 41.3 23.1 
   28.36666667 
392.7 5.56 50 23.5 
392.8 1.91 59.5 31.8 
392.9 1.83 49.1 21.4 
   25.56666667 
403.1 16.5 88.2 32.1 
129 
403.2 22.7 91.4 31.6 
403.3 11.7 51.2 64.1 
   42.6 
403.4 18.5 88.5 29.4 
403.5 11.2 85.9 26.4 
403.6 9.85 85.9 29 
   28.26666667 
403.7 24.6 91.4 28.3 
403.8 21.7 92.7 26.9 
403.9 14.4 87 32.3 
   29.16666667 
405.1 20.3 95.5 20.3 
405.2 11.4 97.2 17.4 
405.3 6.02 3.46 75 
   37.56666667 
405.4 23.4 85 21.7 
405.5 19.4 89.1 22.3 
405.6 14.6 74.6 10 
   18 
405.7 15.5 84.8 19.5 
405.8 14.3 88.4 23.6 
405.9 13.1 88.3 23.8 
   22.3 
406.1 10.3 89.6 15.2 
406.2 1.78 66.7 17.5 
406.3 10.4 33.1 42.2 
   24.96666667 
406.4 3.23 57.3 21.3 
406.5 2.85 47.8 21.9 
406.6 2.27 25 28.6 
   23.93333333 
406.7 2.96 66.7 15.9 
406.8 5.14 63.7 16.9 
406.9 6.54 80.2 20.8 









390.1 3.14 28.2 27.3 
390.2 5.15 4.12 0 
   13.65 
130 
390.4 5.86 10.2 22.2 
   22.2 
390.7 2.56 46.2 11 
390.8 1.94 29.6 21.9 
   16.45 
393.1 8.05 59.3 16.9 
393.2 9.03 59.5 21.2 
393.3 7.55 62 16 
   18.03333333 
393.4 7.22 68.3 12.8 
393.5 10.5 54.5 18.4 
393.6 9.06 56.1 11.8 
   14.33333333 
393.7 12.5 49.6 18.8 
393.8 10.9 54.4 32.6 
393.9 11.3 55.1 21.8 
   24.4 
413.1 8.8 44 18.4 
413.2 9.76 68.9 13.4 
413.3 7.81 57.1 12.8 
   14.86666667 
413.4 3.99 37.8 23.2 
413.5 11.1 63.6 25.7 
413.6 11.7 38.5 27.7 
   25.53333333 
413.7 12.3 67.9 19.4 
413.8 15.1 70.3 15.8 
413.9 11.1 62.7 21.5 
   18.9 
419.1 21.3 81.7 14 
419.2 23.6 86.2 13.5 
419.3 25 86.1 9.92 
   12.47333333 
419.4 33.7 88 14.4 
419.5 17.9 69.2 11.3 
419.6 32.3 87.4 16.2 
   13.96666667 
419.7 18.3 55 15.2 
419.8 27 72.5 18.8 
419.9 21.8 76 11.1 
   15.03333333 
926.1 12.5 1.02 50 
926.2 6.66 5.63 12.5 
131 
926.3 4.38 3.42 50 
   37.5 
926.4 5.57 2.5 0 
926.5 4.95 17.6 17.4 
926.6 6.42 8.78 38.5 
   18.63333333 
926.7 5.12 9.6 50 
926.8 5.25 19.7 22.2 
926.9 7.45 4.24 28.6 





Lymphocytes CD3+ CD3 Proliferation 
345.1 27.7 92.7 4.46 
345.2 11.7 84.6 4.76 
345.3 30 91.9 3.7 
   4.306666667 
345.4 26.2 92.1 4.92 
345.5 21.1 90.7 5.53 
345.6 28.3 93.1 3.91 
   4.786666667 
345.7 26.4 91.6 4.41 
345.8 29.4 91.7 4.49 
345.9 29.7 90.1 6.16 
   5.02 
347.1 41.4 96.8 1.76 
347.2 37.9 96.1 2.57 
347.3 32.7 95 3.24 
   2.523333333 
347.4 37.9 96.6 2.09 
347.5 43.6 97 1.89 
347.6 37.7 97 1.28 
   1.753333333 
347.7 31.7 84.8 8.07 
347.8 45.4 96.3 2.17 
347.9 36.9 95.5 2.24 
   4.16 
363.1 40.6 94.3 1.42 
363.2 47.1 96.6 0.48 
363.3 46.2 96.7 0.75 
   0.883333333 
363.4 47.6 96.5 0.34 
132 
363.5 39.2 96.8 0.7 
363.6 45.5 96.4 0.28 
   0.44 
363.7 46.5 96.7 0.3 
363.8 49.8 96.6 0.27 
363.9 48.1 96.8 0.22 
   0.263333333 
364.1 32.6 95.6 0.71 
364.2 25.9 95.3 0.4 
364.3 32 95.2 0.71 
   0.606666667 
364.4 26.4 93 0.087 
364.5 14.5 92.1 0.35 
364.6 25.6 94.2 0.063 
   0.166666667 
364.7 20.5 93.8 0.2 
364.8 26 93.2 0.12 
364.9 25.7 93.8 0.032 
   0.117333333 
365.1 2.63 89.3 0.34 
365.2 3.21 91 0.24 
365.3 3.22 89.7 0.27 
   0.283333333 
365.4 2.82 91.4 0.3 
365.5 3.23 91.3 0.27 
365.6 1.91 92.2 0.88 
   0.483333333 
365.7 3.82 94 0 
365.8 2.97 90.6 0.6 
365.9 2.2 91.3 0 
   0.2 
366.1 4.04 86.5 0 
366.2 6.23 92.5 0.4 
366.3 0.14 60.7 3.36 
   1.253333333 
366.4 5.21 92.5 1.3 
366.5 5.63 94 0.38 
366.6 8.24 93.1 0.75 
   0.81 
366.7 7.92 91.4 0.67 
366.8 9.56 90.4 0.63 
366.9 6.3 90.9 0.86 
   0.72 
133 
374.1 30.5 97 0.98 
374.2 22.6 97.6 1.07 
374.3 35.8 97.5 1.18 
   1.076666667 
374.4 37.5 98.2 0.51 
374.5 31.9 98.2 0.47 
374.6 30.7 97.8 0.81 
   0.596666667 
374.7 28.1 95.6 3.29 
374.8 28.7 94.1 3.98 
374.9 33.1 96.5 2.99 
   3.42 
375.1 37.2 96.3 2.36 
375.2 33.6 95.3 2.74 
375.3 34 94.1 4.19 
   3.096666667 
375.4 36 96.8 1.18 
375.5 33.1 95.8 2.77 
375.6 36.6 95.8 2.83 
   2.26 
375.7 37.1 96.9 1.34 
375.8 35.5 96.2 2.12 
375.9 38.1 95.9 2.05 
   1.836666667 
 
 
Samples # Lymphocytes CD3+ CD3 Proliferation 
331.1 32.4 89.2 25.7 
331.2 34.7 90.8 24.1 
   24.9 
331.4 37.4 89.6 23.9 
331.5 31.3 88.9 23 
   23.45 
331.7 30.8 89.1 23.7 
331.8 32.7 90.7 24.4 
   24.05 
336.1 32.2 92.6 22.4 
336.2 38.9 89.6 26.8 
336.3 31.8 90.8 26.3 
   25.16666667 
336.4 44.7 94.3 21.4 
336.5 39.1 92.6 24.4 
336.6 40.4 92.2 25.6 
134 
   23.8 
336.7 38.8 91.7 25.5 
336.8 26.7 89.5 27.5 
336.9 38 85.5 32.9 
   28.63333333 
337.1 1.61 4.44 43.3 
337.2 28.1 92.7 18.3 
337.3 29.9 84 27 
   29.53333333 
337.4 32.2 89 23.8 
337.5 32.7 87 24 
337.6 31.7 86.5 25.1 
   24.3 
337.7 24.1 62.7 24 
337.8 29 89.7 19.6 
337.9 23.2 89.2 19.2 
   20.93333333 
340.1 18.5 57.4 26.8 
340.2 17.6 60.8 24.1 
340.3 16.4 60.9 24.3 
   25.06666667 
340.4 17 60.2 24.3 
340.5 17.7 60.9 26.5 
340.6 12.7 51.3 25.6 
   25.46666667 
340.7 15.2 54 27.5 
340.8 18.6 57.8 25.6 
340.9 17.3 52.7 27.8 
   26.96666667 
344.1 22.5 82.2 20.7 
344.2 22.1 81 22.4 
344.3 18.6 81.5 22.3 
   21.8 
344.4 23.8 83.3 23.6 
344.5 16.8 74.4 26.2 
344.6 22.3 81.7 21.2 
   23.66666667 
344.7 19.6 82 22.4 
344.8 20 77.8 28.3 
344.9 20.9 81.5 18.9 
   23.2 
346.1 5.86 59 25.3 
346.2 32.5 84 19 
135 
346.3 29.9 83.3 22.8 
   22.36666667 
346.4 31.9 84.7 21.1 
346.5 33 86.1 22.2 
346.6 33.7 83.7 23.6 
   22.3 
346.7 34.7 84.1 24.1 
346.8 34.6 83.8 27.1 
346.9 30 84.6 24.1 
   25.1 
367.1 42.2 89.9 22.3 
367.2 40.3 87.6 23.5 
367.3 42 88.8 24.6 
   23.46666667 
367.4 36.2 87.3 25.3 
367.5 45.7 88 25.1 
367.6 37.8 87.6 22.5 
   24.3 
367.7 42.4 87 24.8 
367.8 44.4 88.9 24.1 
367.9 36.6 86.7 26.2 
   25.03333333 
414.1 31.8 80 34.5 
414.2 25 81.1 35.4 
414.3 24.7 78.9 35.1 
   35 
414.4 20.8 91.5 13.5 
414.5 31.2 82.8 34 
414.6 28.7 78.6 39.3 
   28.93333333 
414.7 25.1 78.1 37.2 
414.8 28.1 80.3 35.9 
414.9 26.2 80.5 34.4 






Lymphocytes CD3+ CD3 Proliferation 
330.1 12.4 71.3 17.6 
330.2 13 67.4 25.7 
330.3 13.7 75.5 13.7 
   19 
136 
330.4 9.91 68.8 24.3 
330.5 7.04 51.4 20.8 
330.6 12.3 76.3 11.6 
   18.9 
330.7 11.6 89.5 6.78 
330.8 8.15 86.2 5.79 
330.9 11.3 86.7 5.4 
   5.99 
332.1 32.2 97.9 6.09 
332.2 31.6 97.6 5.86 
332.3 35.2 97.3 4.33 
   5.426666667 
332.4 38.7 97.4 6.91 
332.5 31 97.8 5.04 
332.6 36.1 97.7 5.47 
   5.806666667 
332.7 29.7 95.6 6.74 
332.8 27.4 96.9 7.17 
332.9 28.7 99.2 0.34 
   4.75 
333.1 22.8 92.6 7.39 
333.2 14.9 85.1 18.1 
333.3 16.7 92.5 5.38 
   10.29 
333.4 15.8 91.9 2.43 
333.5 19.2 90.9 8.31 
333.6 23.6 93.3 6.97 
   5.903333333 
333.7 16.9 92.1 8.14 
333.8 15 90.8 9.96 
333.9 21.1 91.6 7.66 
   8.586666667 
334.1 29.4 95.2 7.14 
334.2 28.2 90.2 14.4 
334.3 29 90.6 13.3 
   11.61333333 
334.4 30.2 88.4 13.5 
334.5 32.9 91 14.1 
334.6 34.4 86.9 16.6 
   14.73333333 
334.7 33.9 88.4 14.2 
334.8 30.4 75.7 29.7 
334.9 27.2 79.6 27.6 
137 
   23.83333333 
335.1 24 46.3 28.1 
335.2 22.6 53.5 23.7 
335.3 21.3 45.4 23.7 
   25.16666667 
335.4 27.7 54.4 29.8 
335.5 24.3 52 31.7 
335.6 29.8 59.2 37.6 
   33.03333333 
335.7 23.8 52.8 22.2 
335.8 26.6 51.9 24.9 
335.9 25.6 45.2 29.6 
   25.56666667 
338.1 26.8 75.3 17.5 
338.2 36.5 70.1 27.2 
338.3 33.7 72.9 33.7 
   26.13333333 
338.4 38.7 67.7 32.9 
338.5 20 79.6 5.71 
338.6 35.3 89.6 12.4 
   17.00333333 
338.7 32.1 86.9 13.5 
338.8 30 91.3 7.21 
338.9 31.5 89.7 10.6 
   10.43666667 
339.1 23.7 72.4 20.9 
339.2 20.1 73.9 17.7 
339.3 20.7 67.6 18.4 
   19 
339.4 23.8 58.5 19.7 
339.5 26.1 63.6 17.2 
339.6 24.7 58.5 21.4 
   19.43333333 
339.7 25.6 48.9 25.7 
339.8 22.9 56.3 21 
339.9 25.3 58.2 20.8 
   22.5 
343.1 25.2 76.2 22.4 
343.2 26.8 75.6 25.4 
343.3 24.9 75.8 24.3 
   24.03333333 
343.4 27.4 78.4 28.7 
343.5 31.1 75.8 28.3 
138 
343.6 31.7 80.1 23.9 
   26.96666667 
343.7 26.1 73.3 21.3 
343.8 30.8 73.5 24.5 
343.9 27.6 80.7 29.9 
   25.23333333 
350.1 17 42.1 29.5 
350.2 18.7 44.9 26.5 
350.3 15.8 55.1 23.3 
   26.43333333 
350.4 21 52.4 26.3 
350.5 19.7 50.9 24.6 
350.6 23.1 49.6 23.2 
   24.7 
350.7 19.9 50.2 22.7 
350.8 20.7 62.1 15 
350.9 20.3 51.5 20.6 
   19.43333333 
357.1 36.9 45.5 27.9 
357.2 25.4 81 11.9 
357.3 41 40.9 32.3 
   24.03333333 
357.4 37.5 57.9 31.8 
357.5 33.9 54 31.1 
357.6 41.7 49.6 31.4 
   31.43333333 
357.7 46 47.6 34.4 
357.8 40.7 46.5 36.2 
357.9 41.7 54.6 30.6 
   33.73333333 
358.1 33.8 89.4 14.8 
358.2 4.66 75.7 14 
358.3 34.9 78.7 17.8 
   15.53333333 
358.4 36.9 91.9 12.6 
358.5 44.2 93 11.2 
358.6 41.6 95.3 9.22 
   11.00666667 
358.7 45 94.7 10.2 
358.8 36.4 98.6 1.7 
358.9 35.2 90.9 3.56 
   5.153333333 
359.1 48.8 82.1 22.5 
139 
359.2 48.3 79.4 19.4 
359.3 43.5 82.4 19.7 
   20.53333333 
359.4 48.5 80 18.8 
359.5 51.3 86 20.2 
359.6 48.7 84.3 21.6 
   20.2 
359.7 48.3 80.8 20.5 
359.8 47.4 80.4 22.3 
359.9 41.8 82.6 18.9 
   20.56666667 
361.1 45.2 90.7 5.8 
361.2 39.2 88.6 6.35 
361.3 37.2 89.2 5.62 
   5.923333333 
361.4 40.6 90.7 4.56 
361.5 40.5 88.9 4.95 
361.6 48.2 91.6 13 
   7.503333333 
361.7 46.8 91.8 13 
361.8 37.5 90.1 15.7 
361.9 39.3 89.3 15.8 
   14.83333333 
368.1 29.7 76.3 27.7 
368.2 27.9 72.6 24.5 
368.3 29.1 76.5 25.7 
   25.96666667 
368.4 32.2 77.9 19.9 
368.5 31 81.4 15.7 
368.6 26.6 74.4 22.5 
   19.36666667 
368.7 25.2 69.9 21.6 
368.8 27.3 75.1 27.7 
368.9 28.6 73.8 20.7 
   23.33333333 
369.1 40.4 90.7 13 
369.2 36.9 88.7 13.8 
369.3 34.8 90.3 14.5 
   13.76666667 
369.4 41.9 80.4 20.9 
369.5 40.1 87.9 15.2 
369.6 41 84.9 16.1 
   17.4 
140 
369.7 40.4 81 19.9 
369.8 37.4 79.3 20.4 
369.9 37.1 84.3 13.9 
   18.06666667 
370.1 28.9 86 4.48 
370.2 25.6 83.8 5.39 
370.3 25.9 82.2 5.84 
   5.236666667 
370.4 30.9 86.5 4.34 
370.5 30.4 73.9 14 
370.6 30.8 84.6 5.44 
   7.926666667 
370.7 27.7 82.1 5.12 
370.8 34.1 83.1 5.11 
370.9 31.5 86 5.05 
   5.093333333 
420.1 16.6 50.7 26.6 
420.2 31.7 71.7 31.1 
420.3 27.5 60.2 27.7 
   28.46666667 
420.4 30.5 79.1 19.7 
420.5 27 87.5 16.9 
420.6 23.6 88.4 19.6 
   18.73333333 
420.7 31.6 35.1 29.4 
420.8 30.2 58.9 23.4 
420.9 28.1 61.2 21.7 
   24.83333333 
421.1 33 68.8 35.1 
421.2 31.5 53.4 26.2 
421.3 28.1 51.8 24.9 
   28.73333333 
421.4 24.4 49.6 29.9 
421.5 36.1 63.8 36.9 
421.6 39.2 39.5 35.4 
   34.06666667 
421.7 34.3 59.2 26.8 
421.8 30.1 63.2 23.6 
   25.2 
 
 
Samples Freq. of CD4+ CD4 Proliferation 
292.1 9.68 4.84 
141 
292.2 14.3 14.3 
292.3 55.6 27.8 
 26.52666667 15.64666667 
292.4 35.9 12.8 
292.5 34 3.39 
 34.95 8.095 
292.7 4.75 0.68 
292.8 7.69 3.17 
292.9 66.7 33.3 
 26.38 12.38333333 
293.1 90.3 45.2 
   
293.4 86.3 34.8 
   
293.7 80 30 
   
296.1 97.1 64.7 
   
296.4 69.5 28.5 
   
296.7 77.8 44.4 
   
721.1 82.9 63.6 
721.2 86.8 50.1 
721.3 72.9 35.2 
 80.86666667 49.63333333 
721.4 72.5 23.6 
721.5 69.2 22.6 
721.6 68.2 23.6 
 69.96666667 23.26666667 
721.7 64.6 40.2 
721.8 81.1 56.8 
721.9 77.3 54.5 
 74.33333333 50.5 
722.1 18.2 12.8 
722.2 27.3 13.6 
722.3 11.5 11.5 
 19 12.63333333 
722.4 56.1 26.3 
722.5 45.3 18.8 
722.6 71.4 14.3 
 57.6 19.8 
722.7 50 33.3 
142 
722.8 94.1 58.8 
722.9 75 37.5 
 73.03333333 43.2 
756.1 83.3 70.5 
756.2 88.8 70.8 
 86.05 70.65 
756.4 93.3 73.3 
   
756.7 93.2 78.8 
   
765.1 81 25.9 
765.2 15.7 6.27 
765.3 37.6 20.4 
 44.76666667 17.52333333 
765.4 40.7 11.4 
765.5 42.5 11 
 41.6 11.2 
765.7 83.3 45.2 
765.8 33.3 15.9 
765.9 50.5 25.2 
 55.7 28.76666667 
775.1 4.69 0.36 
   
775.7 20 8 
 
 
Samples Freq. of CD4+ CD4 Proliferation 
297.1 6.67 n/a 
   
297.4 17.4 n/a 
   
297.7 23.1 n/a 
   
298.1 0 n/a 
   
298.4 16.7 n/a 
   
298.7 12.5 n/a 
   
723.1 0 n/a 
   
723.4 23.4 n/a 
   
143 
723.7 3.67 n/a 
   
758.1 0 n/a 
   
758.7 0 n/a 
   
761.1 0 n/a 
761.2 0 n/a 
 0  
761.4 26.6 n/a 
   
761.7 0 n/a 
761.8 0 n/a 
 0  
770.1 50 n/a 
770.2 40 n/a 
770.3 0 n/a 
 30  
770.4 21.8 n/a 
770.5 20.8 n/a 
770.6 20.4 n/a 
 21  
770.7 3.08 n/a 
770.8 40 n/a 
770.9 0 n/a 
 14.36  
772.1 20 n/a 
   
772.4 15.7 n/a 
   
772.7 16.3 n/a 
772.8 0 n/a 
772.9 0 n/a 
 5.433333333  
781.2 16.1 n/a 
782.1 16.3 n/a 
782.3 16.4 n/a 
 16.26666667  
782.4 15.9 n/a 
782.5 16 n/a 
782.6 9.23 n/a 
 13.71  
782.7 16.9 n/a 
144 
782.8 16.2 n/a 
782.9 14.3 n/a 
 15.8  
 
 
Samples Freq. of CD4+ CD4 Proliferation 
751.1 14.3 33.3 
751.2 0 0 
751.3 0 0 
 4.766666667  
751.4 15.6 17.9 
751.5 11.2 18 
 13.4  
752.1 5.56 9.09 
752.2 2.7 5.88 
 4.13  
752.4 40 40 
752.5 8.14 15.9 
 24.07  
753.1 9.09 13.3 
753.2 15.4 17.4 
753.3 18.8 30 
 14.43  
753.4 3.23 3.85 
753.5 9.52 12.5 
753.6 4.55 4.76 
 5.766666667  
754.1 3.41 7.14 
754.2 5.06 9.52 
754.3 5.63 12.1 
 4.7  
754.4 5.15 8.06 
754.5 6.82 11.8 
 5.985  
756.2 8.01 12.4 
756.3 8.06 12.9 
 8.035  
756.4 6.58 8.52 
756.5 9.03 11.8 
756.6 7.67 10.1 
 7.76  
757.1 4.4 12 
757.2 6.34 14.3 
145 
757.3 7.98 17.8 
 6.24  
757.4 8.16 14.8 
757.5 10 16.4 
757.6 10.2 16.6 
 9.453333333  
760.1 5 18.8 
760.2 4.89 17.2 
760.3 5.48 17.1 
 5.123333333  
760.4 9.24 15.9 
760.5 8.96 17.4 
760.6 8.65 17 
 8.95  
761.1 6.91 20.6 
761.2 6.32 20.2 
761.3 6.92 19.9 
 6.716666667  
761.4 7.26 16.8 
761.5 7.43 16.1 
761.6 7.64 17.7 
 7.443333333  
764.1 0.84 1.43 
764.2 1.06 1.86 
764.3 0.73 1.28 
 0.876666667  
764.4 0.56 0.81 
764.5 0.61 0.87 
764.6 0.9 1.31 
 0.69  
951.1 2.55 20 
951.2 2.52 20.3 
 2.535  
951.4 5.56 27.6 
951.5 5.68 26.3 
 5.62  
959.1 1.49 5.96 
959.2 0.93 3.55 
959.3 0.99 4.2 
 1.136666667  
959.4 1.91 5.09 
959.5 1.42 4.04 
959.6 1.97 4.22 
146 
 1.766666667  
972.1 15.3 25.1 
972.2 16 26.8 
972.3 13.4 22.6 
 14.9  
972.4 18.3 25.4 
972.5 16.6 23 
 17.45  
981.1 3.48 13 
981.2 3.12 11.8 
981.3 3.7 13.4 
 3.433333333  
981.5 5.54 10.7 
981.6 5.72 11.1 
 5.63  
982.1 6.23 14 
982.2 7.26 16.5 
982.3 6.6 14 
 6.696666667  
982.4 4 7.33 
982.5 4.97 9.05 
982.6 8.51 16.8 
 5.826666667  
985.1 7.73 23.1 
985.2 8.77 25.8 
985.3 7.87 24.2 
 8.123333333  
985.4 13.9 20.3 
985.5 14.5 22.4 
985.6 11.5 20 








726.1 0 0 
726.2 25.6 12.8 
762.3 31 31 
 18.86666667  
726.4 18.5 9.23 
726.5 21.1 13.2 
 19.8  
726.7 22.5 17.5 
147 
726.8 6.67 6.67 
 14.585  
728.1 16.9 3.08 
728.2 17.9 3.32 
728.3 16.9 2.82 
 17.23333333  
728.4 18.6 3.43 
728.5 19.2 2.9 
728.6 18.6 2.95 
 18.8  
728.7 17 3.35 
728.8 17.7 3.27 
728.9 19.4 3.97 
 18.03333333  
886.1 18.3 2.69 
886.2 19.6 2.57 
886.3 18.6 2.31 
 18.83333333  
886.4 19.1 2.59 
886.5 19.4 2.78 
886.6 20.4 3.1 
 19.63333333  
886.7 19.7 3.17 
886.8 19.3 2.67 
886.9 20.2 1.45 
 19.73333333  
887.1 19.2 0.77 
887.2 19.4 1.28 
887.3 18.8 1.38 
 19.13333333  
887.4 18.8 1.13 
887.55 21.2 0.39 
887.66 20.6 0.62 
 20.2  
887.7 19 0.46 
887.8 19.4 0.67 
887.9 18.9 0.57 
 19.1  
926.1 16.9 5.81 
926.2 13.8 2.3 
962.3 8.59 2.02 
 13.09666667  
926.4 17.2 6.06 
148 
926.5 32.4 23.9 
926.6 13.8 5.5 
 21.13333333  
926.7 14.3 3.8 
926.8 11 4.27 
926.9 44.7 38.3 
 23.33333333  
927.1 18.6 5.38 
927.2 16.8 5.23 
927.3 16.9 5.3 
 17.43333333  
927.4 16.4 4.71 
927.5 17.6 4.88 
927.6 17.3 5.34 
 17.1  
927.7 15.8 4.34 
927.8 19.7 8.02 
928.9 14.8 4.33 
  16.76666667  
948.1 16.6 6.27 
948.2 10.8 5.88 
 13.7  
948.4 9.38 4.69 
948.5 12.7 8.29 
 11.04  
948.7 22.8 15.7 
948.8 9.7 4.16 
 16.25  
954.1 16.4 4.32 
954.2 16.7 3.75 
954.3 15.9 3.49 
 16.33333333  
954.4 16 3.38 
954.5 17.5 3.42 
954.6 17 3.87 
 16.83333333  
954.7 52.4 34.6 
954.8 17.2 0.95 
954.9 16.2 2.25 
 28.6  
976.1 17.6 0.91 
976.2 17.8 0.94 
976.3 17.2 0.98 
149 
 17.53333333  
976.4 17.7 1.22 
976.5 17.8 1.05 
976.6 17.6 1.22 
 17.7  
976.7 17 1.15 
976.8 17.4 2.85 
976.9 16.7 2.47 
 17.03333333  
977.1 22.4 4.11 
977.2 18.4 3.54 
977.3 17.6 3.01 
 19.46666667  
977.4 17.1 2.54 
977.5 18.4 2.74 
977.6 18.8 2.85 
 18.1  
977.7 17.3 2.47 
977.8 18.2 3.15 
977.9 18 1.97 
 17.83333333  
 
 
Samples Freq. of CD4+ 
CD4 
Proliferation 
692.1 4.99 16.7 
692.2 5.25 17.2 
692.3 4.49 14.7 
 4.91  
692.4 5.52 16.9 
692.5 5.21 15.7 
692.6 4.81 15.3 
 5.18  
692.7 4.15 14.5 
692.8 5.53 17.4 
692.9 5.49 18 
 5.056666667  
693.1 4.38 17.7 
693.2 4.83 20 
693.3 4.84 20 
 4.683333333  
693.4 4.34 17.8 
693.5 4.87 19.1 
150 
693.6 3.95 16.1 
 4.386666667  
693.7 4.56 19.8 
693.8 4.88 19.8 
693.9 5.07 19.5 
 4.836666667  
694.1 3.87 18.7 
694.2 3.72 17.5 
694.3 3.84 18.5 
 3.81  
694.4 4.07 18.3 
694.5 4.26 19.1 
694.6 4.13 19 
 4.153333333  
694.7 3.73 17.5 
694.8 3.99 21 
694.9 4.28 20.1 
 4  
729.1 5.64 23.6 
729.2 6.45 22.8 
 6.045  
729.4 8.14 31.9 
729.5 0 0 
 4.07  
729.7 9.11 31 
729.9 6.42 29.5 
 7.765  
738.1 5.74 18.9 
738.2 7.32 21.6 
738.3 6.19 19.4 
 6.416666667  
738.4 6.45 21.6 
738.5 5.93 20.2 
738.6 7.38 24.7 
 6.586666667  
738.7 7.38 20.8 
738.8 6.84 21.6 
738.9 6.4 22.4 
 6.873333333  
758.1 5.1 19 
758.2 5.46 18.7 
758.3 5.18 19.5 
 5.246666667  
151 
758.4 5.54 17.6 
758.5 5.53 16.9 
758.6 5.61 18.5 
 5.56  
762.1 9.62 26.7 
762.2 10.6 32.3 
762.3 9.96 31.5 
 10.06  
762.4 11.1 25.1 
762.5 10.5 25.6 
762.6 11 27.3 
 10.86666667  
881.1 15 41.6 
881.2 16.6 42.8 
881.3 18.8 47.3 
 16.8  
881.4 15.4 41.6 
881.5 15.9 42.8 
881.6 15.8 42.9 
 15.7  
881.7 17.6 44.9 
881.8 16.3 43.6 
881.9 15.9 40.4 
 16.6  
883.1 8.86 27.2 
883.2 8.38 25 
883.3 9.28 26.2 
 8.84  
883.4 8.78 25.7 
883.5 9.48 27.9 
883.6 10.3 31.3 
 9.52  
883.7 9.63 27.4 
883.8 8.95 26.1 
883.9 10.1 28.6 
 9.56  
888.1 7.33 25.1 
888.2 7.33 25.5 
888.3 7.61 25.9 
 7.423333333  
888.4 7.78 25.9 
888.5 7.74 25.8 
888.6 7.21 24.2 
152 
 7.576666667  
888.7 7.34 21 
888.8 7.08 24.2 
888.9 6.34 21.4 
 6.92  
931.1 15.8 32.9 
931.2 14.8 34 
 15.3  
931.4 14.3 33 
931.5 15.9 36.6 
 15.1  
931.7 17.2 36.8 
931.8 14.5 33.2 
 15.85  
933.1 7.95 27.2 
933.2 8.32 27.2 
933.3 7.62 24.8 
 7.963333333  
933.4 8.36 26 
933.5 8.64 26.4 
933.6 8.19 26 
 8.396666667  
933.7 8.03 27 
933.8 7.61 23.6 
933.9 8.22 26.5 
 7.953333333  
949.1 7.18 42.9 
949.2 10.3 56.4 
949.3 8.7 48.6 
 8.726666667  
949.4 8.11 42.9 
949.5 9.52 42.1 
 8.815  
952.1 30.4 58.8 
952.2 31.7 58.6 
952.3 29.2 59.9 
 30.43333333  
952.4 26.5 59 
952.5 29.4 58.8 
952.6 27.2 59.7 
 27.7  
952.7 18.4 36.8 
952.8 29 58.5 
153 
952.9 32.6 59.8 
 26.66666667  
953.1 2.16 19.5 
953.2 6.42 24.3 
953.3 6.67 23.7 
 5.083333333  
953.4 6.54 27.8 
953.5 6.82 26.1 
953.6 6.69 25.8 
 6.683333333  
953.7 6.66 25.3 
953.8 6.36 25.7 
953.9 7.48 27.8 
 6.833333333  
956.1 10.4 36.8 
956.2 21.2 48.1 
956.3 12 40.5 
 14.53333333  
956.4 13.5 43.8 
956.5 13.6 38.2 
956.6 12.1 40.2 
 13.06666667  
956.7 14.8 40.3 
956.8 15.3 42.4 
956.9 13 36.3 
 14.36666667  
957.1 3.66 16.7 
957.2 0 0 
957.3 10.8 45.8 
 4.82  
957.4 2.27 15.4 
957.5 11.5 40 
 6.885  
957.7 62.5 78.9 
957.8 13.5 56.8 
957.9 7.69 36.4 
 27.89666667  
969.1 6 20.5 
969.2 6.61 22.6 
969.3 6.7 24.5 
 6.436666667  
969.4 6.98 21 
969.5 7.07 22 
154 
969.6 6.38 21.8 
 6.81  
969.7 6.23 22.1 
969.8 6.75 22.9 
969.9 6.68 20.1 
 6.553333333  
978.1 10.8 37 
978.2 10.7 35.7 
978.3 14 44.1 
 11.83333333  
978.4 12.3 40.4 
978.5 12.4 37.4 
 12.35  
978.7 8.81 31 
978.8 14.5 41.2 
978.9 10.4 32.5 
 11.23666667  
980.1 14.5 49.2 
980.2 16.8 51.7 
980.3 17.7 54.2 
 16.33333333  
980.4 16.6 51.9 
980.5 16.4 49.9 
980.6 17.9 51.4 
 16.96666667  
980.7 17.1 53.2 
980.8 17.7 53.1 
980.9 17.7 53 




Samples Freq. of CD4+ CD4 Proliferation 
700.1 7.02 22.9 
700.2 7.43 26.3 
700.3 7.77 25.5 
 7.406666667  
700.4 6.88 25.1 
700.5 7.49 28.4 
700.6 6.56 24 
 6.976666667  
700.7 6.67 24.2 
700.8 6.94 25.2 
155 
700.9 5.66 22 
 6.423333333  
730.1 4 26.7 
730.2 3.9 37.5 
 3.95  
730.4 5.84 34.8 
730.5 2.3 20 
 4.07  
730.7 4.64 32.4 
730.8 6.25 27.7 
 5.445  
732.1 1.53 8.7 
732.2 1.5 12.5 
 1.515  
732.4 4.2 26.3 
   
732.7 1.7 13 
732.8 5.43 27.8 
 3.565  
737.1 3.08 25 
737.2 0 0 
 1.54  
737.4 0 0 
737.5 1.59 10 
 0.795  
737.7 0 0 
737.8 0 0 
 0  
739.1 2.24 11.2 
739.2 2.62 12.7 
739.3 2.58 12.3 
 2.48  
739.4 3.64 17.2 
739.5 2.78 13.8 
739.6 3.03 14.1 
 3.15  
739.7 2.96 13.8 
739.8 2.99 13.5 
739.9 2.66 12.7 
 2.87  
740.1 1.94 10.4 
740.2 1.98 13.2 
740.3 2.17 13.7 
156 
 2.03  
740.4 2.67 16.2 
740.5 2.59 14.5 
740.6 2.63 13.6 
 2.63  
740.7 2.14 13.7 
740.8 2.2 13.9 
740.9 3 17.2 
 2.446666667  
882.1 4.37 16.6 
882.2 3.53 14.4 
882.3 4.47 16.3 
 4.123333333  
882.4 4.77 17.9 
882.5 4.51 18.2 
882.6 4.75 18.1 
 4.676666667  
882.7 4.9 19.4 
882.8 3.5 14.4 
882.9 5.77 22.8 
 4.723333333  
884.1 0.23 3.96 
884.2 4.46 17.2 
884.3 5.28 20.3 
 3.323333333  
884.4 4.97 20 
884.5 5.84 21.6 
884.6 5.12 20.6 
 5.31  
884.7 4.71 19.5 
884.8 4.34 17.8 
884.9 4.99 20.3 
 4.68  
885.1 7.36 27.9 
885.2 6.39 25.4 
885.3 6.17 21.4 
 6.64  
885.4 8.19 31 
885.5 6.97 26.2 
885.6 8.32 29.9 
 7.826666667  
885.7 7.71 26.5 
885.8 6.86 27 
157 
885.9 6.64 24.6 
 7.07  
971.1 0 0 
971.2 0 0 
 0  
971.4 0 0 
971.5 0 0 
 0  
971.7 0 0 
971.8 0 0 
 0  
 
 
Samples Freq. of CD4+ CD4 Proliferation 
380.1 6.29 20.2 
380.2 6.52 21.5 
380.3 5.95 19.7 
 6.253333333  
380.4 5.11 18.2 
380.5 6.33 20.9 
380.6 5.65 18.6 
 5.696666667  
380.7 6.39 21.1 
380.8 5.02 16.1 
380.9 5.89 20.2 
 5.766666667  
387.1 3.6 16 
387.2 4.71 18.6 
387.3 2.11 14.3 
 3.473333333  
387.4 4.55 26.7 
387.5 2.99 13.3 
387.6 3.9 16.7 
 3.813333333  
387.7 2.33 15.8 
387.8 1.31 9.3 
387.9 4.44 25 
 2.693333333  
411.1 4.19 14 
411.2 4.35 13.7 
411.3 4.57 14.8 
 4.37  
411.4 4.93 16.6 
158 
411.5 4.54 15.2 
411.6 6.13 19.9 
 5.2  
411.7 4.72 15.6 
411.8 4.99 16.7 
411.9 5.2 16.9 
 4.97  
417.1 8.85 22.8 
417.2 9.67 23.5 
417.3 11.5 25.6 
 10.00666667  
417.4 10.7 25 
417.5 13.6 31 
417.6 10.1 26.3 
 11.46666667  
417.7 9.49 25.7 
417.8 9.45 22.9 
417.9 9.84 21.6 
 9.593333333  
641.1 7.11 26.9 
641.2 6.5 22.1 
641.3 6.84 25.9 
 6.816666667  
641.4 7.41 25.2 
641.5 7.44 26.3 
641.6 7.3 24.6 
 7.383333333  
641.7 7.02 26.6 
641.8 6.82 24.7 
641.9 6.69 26.3 
 6.843333333  
642.1 9.04 27.4 
642.2 8.14 27.1 
642.3 8.65 28.5 
 8.61  
642.4 9.94 29.8 
642.5 9.54 30.3 
642.6 9.56 29.8 
 9.68  
642.7 8.7 29.3 
642.8 8.7 28 
642.9 8.07 27 
 8.49  
159 
643.1 17.2 41.6 
643.2 19 41 
643.3 18.7 38 
 18.3  
643.4 18.8 44.9 
643.5 17.7 43.7 
643.6 18.2 44.3 
 18.23333333  
643.7 15.7 41.3 
643.8 14.9 40.8 
643.9 15.5 41.1 
 15.36666667  
644.1 13.4 30.1 
644.2 15 30.2 
644.3 14.8 29.6 
 14.4  
644.4 15.3 26.8 
644.5 12.4 25.5 
644.6 12.2 25.5 
 13.3  
644.7 14 31.4 
644.8 13.2 30 
644.9 14.4 29.8 
 13.86666667  
780.1 5.51 24.5 
780.2 6.45 37.2 
780.3 6.36 27.7 
 6.106666667  
780.4 0 0 
780.5 6.33 21.7 
 3.165  
932.1 6.19 21.1 
932.2 4.86 18.7 
932.3 6.11 24.2 
 5.72  
932.4 6.39 21.9 
932.5 6 22.2 
932.6 6.08 20 
 6.156666667  
932.7 6.51 22.3 
932.8 5.25 20 
932.9 4.29 14.7 
 5.35  
160 
Samples Freq. of CD4+ CD4 Proliferation 
384.1 19.4 50 
384.2 33.3 80 
384.3 0 0 
 17.56666667  
384.4 27.3 85.7 
384.5 22.2 80 
384.6 21.9 66.7 
 23.8  
384.7 10.5 22.2 
384.8 23.1 50 
384.9 11.8 66.7 
 15.13333333  
394.1 6.67 16.7 
394.2 0 0 
394.3 3.12 12.5 
 3.263333333  
394.4 11.8 50 
394.5 0 0 
394.6 5.56 20 
 5.786666667  
394.7 5.17 33.3 
394.8 11.9 46.7 
394.9 7.69 25 
 8.253333333  
395.1 9.79 27.1 
395.2 8.95 24.5 
395.3 9.22 25.6 
 9.32  
395.4 8.82 22.8 
395.5 8.7 21.9 
395.6 10.5 25.4 
 9.34  
395.7 11.6 29.8 
395.8 11.3 29.3 
395.9 10.1 26.6 
 11  
396.1 8.16 36.4 
396.2 9.88 34.8 
396.3 8.04 34.6 
 8.693333333  
396.4 3.16 16.7 
396.5 5.93 33.3 
161 
396.6 7.69 25 
 5.593333333  
396.7 10.9 50 
396.8 9.68 42.9 
396.9 0 0 
 6.86  
397.1 7.54 22.1 
397.2 7.17 22.8 
397.3 7.39 21.7 
 7.366666667  
397.4 9.02 24.9 
397.5 7.6 22.5 
397.6 10.2 27.8 
 8.94  
397.7 8.39 29.2 
397.8 6.93 19.8 
397.9 7.22 23.6 
 7.513333333  
402.1 11.2 51.2 
402.2 14.8 63.9 
402.3 13.9 55.8 
 13.3  
402.4 22.5 57.4 
402.5 15 63.2 
402.6 13.2 50 
 16.9  
402.7 15.2 55.9 
402.8 14.6 56.4 
402.9 17.7 65.4 
 15.83333333  
407.1 6.91 26.4 
407.2 7.47 28.8 
407.3 9.13 36.9 
 7.836666667  
407.4 7.67 25.5 
407.5 6.54 20.3 
407.6 13.1 40.7 
 9.103333333  
407.7 6.09 22.6 
407.8 8.29 26.8 
407.9 6.82 27.6 
 7.066666667  
408.1 5.71 16.3 
162 
408.2 7.74 21.2 
408.3 7.25 19.2 
 6.9  
408.4 10 24.7 
408.5 6.34 15.4 
408.6 7.61 19.5 
 7.983333333  
408.7 13.3 33 
408.8 10.3 26.7 
408.9 9.71 25.2 
 11.10333333  
412.1 8.05 21.5 
412.2 9.13 24.4 
412.3 8.06 22.8 
 8.413333333  
412.4 9.26 24.6 
412.5 8.53 23.9 
412.6 9.19 24.7 
 8.993333333  
412.7 10.8 29.2 
412.8 16.8 42.8 
412.9 8.86 24.7 
 12.15333333  
418.1 6 27.8 
418.2 5.65 28.9 
418.3 7.53 27.3 
 6.393333333  
418.4 4.13 15.2 
418.5 8.16 32 
418.6 5.88 24.3 
 6.056666667  
418.7 4.84 21.4 
418.8 3.78 19.1 
418.9 4.01 19.4 
 4.21  
 
 
Samples Freq. of CD4+ 
CD4 
Proliferation 
381.1 4.77 15.7 
381.2 5.06 16.1 
381.3 5.09 15.4 
 4.973333333  
163 
381.4 5.49 16.6 
381.5 5.2 16.4 
381.6 5.47 16.4 
 5.386666667  
381.7 4.36 13.9 
381.8 4.51 14.1 
381.9 5.14 16.4 
 4.67  
382.1 3.87 29.6 
382.2 4.47 34.6 
382.33 2.1 5.52 
 3.48  
382.4 2.25 22.1 
382.5 3.38 25.4 
382.6 2.34 20.8 
 2.656666667  
382.7 2.85 33.3 
382.8 1.24 16.7 
382.9 1.75 24 
 1.946666667  
383.1 2.53 6.74 
383.2 3.25 8.73 
 2.89  
383.4 2.31 6.03 
383.5 3.28 9.06 
383.6 3.22 8.86 
 2.936666667  
383.7 2.48 7.05 
383.8 1.91 5.41 
383.9 2.82 8.49 
 2.403333333  
385.1 3.51 11.5 
385.2 3.98 12.8 
385.3 6.83 31.8 
 4.773333333  
385.4 2.69 10.1 
385.5 3.47 12.1 
385.6 3.75 11.7 
 3.303333333  
385.7 2.85 9.41 
385.8 4.03 13.9 
385.9 2.47 8.8 
 3.116666667  
164 
386.1 6.71 20.1 
386.2 7.01 21.8 
386.3 6.34 20.2 
 6.686666667  
386.4 6.5 20 
386.5 8.35 23.2 
386.6 6.71 18.6 
 7.186666667  
386.7 6.91 20.1 
386.8 6.96 20.6 
386.9 7.42 21.2 
 7.096666667  
391.1 3.23 14.3 
391.2 0.94 4.35 
391.3 4.23 13 
 2.8  
391.4 5.26 25 
391.5 3.85 20 
391.6 0 0 
 3.036666667  
391.7 0 0 
391.8 3.14 17.2 
391.9 2.27 10 
 1.803333333  
392.1 0 0 
392.2 4 20 
392.3 0 0 
 1.333333333  
392.4 7.69 50 
392.5 5.88 28.6 
392.6 0 0 
 4.523333333  
392.7 0 0 
392.8 0 0 
392.9 0 0 
 0  
403.1 4.11 19.5 
403.2 3.45 14.2 
403.3 10.7 50 
 6.086666667  
403.4 5.82 23.6 
403.5 3.14 12.5 
403.6 3.83 18.9 
165 
 4.263333333  
403.7 3.85 15.7 
403.8 5.73 19.7 
403.9 5.51 19.7 
 5.03  
405.1 2.86 10.6 
405.2 2.68 9.76 
405.3 3.57 100 
 3.036666667  
405.4 3.54 13.3 
405.5 2.13 7.99 
405.6 1.51 5.63 
 2.393333333  
405.7 3.51 12.6 
405.8 3.18 11.6 
405.9 3.96 14.8 
 3.55  
406.1 1.52 4.92 
406.2 0 0 
406.3 2.94 12.5 
 1.486666667  
406.4 2.13 7.69 
406.5 3.12 20 
406.6 0 0 
 1.75  
406.7 2.27 12.5 
406.8 0 0 
406.9 2.97 10.3 




Samples Freq. of CD4+ CD4 Proliferation 
390.1 0 0 
390.2 0 0 
 0  
390.4 0 0 
 0  
390.7 1.37 11.1 
390.8 0 0 
 0.685  
393.1 3.49 20.7 
393.2 3.21 14.7 
166 
393.3 2.1 10.9 
 2.933333333  
393.4 3.91 15.2 
393.5 6.32 28.2 
393.6 1.86 8.11 
 4.03  
393.7 3.23 13.6 
393.8 2.13 9.09 
393.9 3.4 18.5 
 2.92  
413.1 2.21 8.11 
413.2 5.38 22.2 
413.3 2.68 11.1 
 3.423333333  
413.4 2.82 13.3 
413.5 8.82 26.1 
413.6 5.45 21.6 
 5.696666667  
413.7 3.15 13.7 
413.8 4.23 17.4 
413.9 6.06 24.4 
 4.48  
419.1 4.36 16.9 
419.2 7.55 25.7 
419.3 5.14 19.2 
 5.683333333  
419.4 4.99 17.7 
419.5 4.26 15 
419.6 5.4 18.7 
 4.883333333  
419.7 6.88 24.5 
419.8 7.74 27.7 
419.9 3.79 13.7 
 6.136666667  
926.1 0 0 
926.2 0 0 
926.3 0 0 
 0  
926.4 0 0 
926.5 0 0 
926.6 0 0 
 0  
926.7 16.7 50 
167 
926.8 0 0 
926.9 14.3 100 
 10.33333333  
 
 
Samples Freq. of CD4+ 
CD4 
Proliferation 
345.1 1.49 7.43 
345.2 2.95 11.6 
345.3 1.03 4.66 
 1.823333333  
345.4 1.22 5.68 
345.5 1.18 7.07 
345.6 1.4 6.87 
 1.266666667  
345.7 0.61 2.89 
345.8 1.09 5.39 
345.9 1.6 7.99 
 1.1  
347.1 0.8 4.27 
347.2 0.92 4.88 
347.3 0.95 5.49 
 0.89  
347.4 0.48 2.77 
347.5 0.59 2.7 
347.6 0.44 2.01 
 0.503333333  
347.7 1.67 12.6 
347.8 0.55 2.66 
347.9 0.67 3.14 
 0.963333333  
363.1 0.45 3.1 
363.2 0.12 0.78 
363.3 0.46 2.77 
 0.343333333  
363.4 0.14 0.92 
363.5 0.33 2.19 
363.6 0.087 0.64 
 0.185666667  
363.7 0.14 0.91 
363.8 0.096 0.59 
363.9 0.15 0.99 
 0.128666667  
168 
364.1 0.32 1.79 
364.2 0.21 1.31 
364.3 0.37 2.1 
 0.3  
364.4 0 0 
364.5 0 0 
364.6 0 0 
 0  
364.7 0.079 0.55 
364.8 0.031 0.22 
364.9 0 0 
 0.036666667  
365.1 0.34 2.78 
365.2 0.48 3.64 
365.3 0 0 
 0.273333333  
365.4 0 0 
365.5 0 0 
365.6 0.44 2.56 
 0.146666667  
365.7 0 0 
365.8 0 0 
365.9 0.79 8 
 0.263333333  
366.1 0 0 
366.2 0 0 
366.3 3.36 21.1 
 1.12  
366.4 0 0 
366.5 0 0 
366.6 0 0 
 0  
366.7 0 0 
366.8 0 0 
366.9 0 0 
 0  
374.1 0.36 1.63 
374.2 0.44 1.87 
374.3 0.61 2.54 
 0.47  
374.4 0.27 1.05 
374.5 0.26 1.21 
374.6 0.14 0.5 
169 
 0.223333333  
374.7 1.11 5.37 
374.8 0.64 3.22 
374.9 1.08 4.83 
 0.943333333  
375.1 0.77 3.43 
375.2 1.09 4.57 
375.3 0.77 3.46 
 0.876666667  
375.4 0.65 2.4 
375.5 1.16 4.62 
375.6 0.96 3.72 
 0.923333333  
375.7 0.59 2.15 
375.8 0.79 3.42 
375.9 0.78 2.74 
 0.72  
 
 
Samples Freq. of CD4+ 
CD4 
Proliferation 
331.1 5.3 25.4 
331.2 5.03 22 
 5.165  
331.4 5.81 26.2 
331.5 0.64 10.9 
 3.225  
331.7 4.81 23.1 
331.8 4.88 22.7 
 4.845  
336.1 5.47 21.6 
336.2 6.21 25.2 
336.3 6.48 25.6 
 6.053333333  
336.4 6.57 24.8 
336.5 6.85 26.5 
336.6 7.62 28.4 
 7.013333333  
336.7 5.71 24.9 
336.8 5.33 23.4 
336.9 10.6 40.3 
 7.213333333  
337.1 13.3 36.4 
170 
337.2 3.86 15.9 
337.3 3.8 18.8 
 6.986666667  
337.4 5.04 22.8 
337.5 3.58 17.8 
337.6 4.84 22.1 
 4.486666667  
337.7 9.02 35.2 
337.8 4.37 19.7 
337.9 4.38 20 
 5.923333333  
340.1 5.62 30.8 
340.2 5.84 28.1 
340.3 5.92 30.4 
 5.793333333  
340.4 5.42 27.2 
340.5 4.83 28.1 
340.6 5.66 29.1 
 5.303333333  
340.7 4.62 27.4 
340.8 5.36 28.1 
340.9 5.51 27.4 
 5.163333333  
344.1 4.76 24.6 
344.2 4.33 23.7 
344.3 3.27 18 
 4.12  
344.4 3.9 21.8 
344.5 4.43 26.5 
344.6 2.85 17.1 
 3.726666667  
344.7 4.43 24.4 
344.8 4.51 26.1 
344.9 3.8 20 
 4.246666667  
346.1 4.12 20.9 
346.2 7.35 27.9 
346.3 3.35 16.7 
 4.94  
346.4 3.74 18.5 
346.5 4.35 20.8 
346.6 4.22 20.3 
 4.103333333  
171 
346.7 4.9 22.2 
346.8 4.15 20.9 
346.9 4.1 20.6 
 4.383333333  
367.1 7.01 24.5 
367.2 7.9 27.4 
367.3 7.31 25.9 
 7.406666667  
367.4 7.37 26.9 
367.5 6.55 22.8 
367.6 5.56 20.2 
 6.493333333  
367.7 7.19 24.8 
367.8 6.31 22.8 
367.9 8.18 30.3 
 7.226666667  
414.1 10.9 42.6 
414.2 11.1 42.3 
414.3 10.6 41.7 
 10.86666667  
414.4 5.4 25.7 
414.5 9.39 37.1 
414.6 12.2 48.1 
 8.996666667  
414.7 9.94 42.3 
414.8 9.2 37.5 
414.9 9.26 35.8 
 9.466666667  
 
 
Samples Freq. of CD4+ CD4 Proliferation 
330.1 5.26 19.7 
330.2 9.2 38.7 
330.3 4.27 16 
 6.243333333  
330.4 9.73 33.1 
330.5 11.4 35.8 
330.6 4.68 16.5 
 8.603333333  
330.7 2.4 8.35 
330.8 3.39 11.6 
330.9 1.78 9.03 
 2.523333333  
172 
332.1 2.75 11.7 
332.2 2.17 9.66 
332.3 1.89 8.1 
 2.27  
332.4 2.28 9.22 
332.5 1.69 8.38 
332.6 2.22 8.96 
 2.063333333  
332.7 2.83 13.3 
332.8 2.33 11.6 
332.9 0.084 0.64 
 1.748  
333.1 3.26 11.1 
333.2 6.38 23.2 
333.3 4.39 16.2 
 4.676666667  
333.4 0.45 10 
333.5 4.66 15.3 
333.6 3.44 11.6 
 2.85  
333.7 3.35 11.6 
333.8 3.99 15.7 
333.9 3.51 14.5 
 3.616666667  
334.1 2.96 11.9 
334.2 6.27 23.6 
334.3 6.66 24.6 
 5.296666667  
334.4 3.94 15.3 
334.5 7.41 28 
334.6 8.01 29.9 
 6.453333333  
334.7 7.11 25.7 
334.8 10.2 40.7 
334.9 10.9 43 
 9.403333333  
335.1 11.8 39.3 
335.2 10.7 36.1 
335.3 10.9 33.5 
 11.13333333  
335.4 15.9 47.7 
335.5 13.6 45.3 
335.6 19.4 58 
173 
 16.3  
335.7 2.48 32.5 
335.8 9.98 32.7 
335.9 13.7 45 
 8.72  
338.1 4.19 22.2 
338.2 6.32 33.8 
338.3 9.03 44.4 
 6.513333333  
338.4 8.34 39.4 
338.5 0.89 5.86 
338.6 2.99 15.5 
 4.073333333  
338.7 3.83 21.1 
338.8 3.12 17.1 
338.9 3.58 18.8 
 3.51  
339.1 11.1 33.6 
339.2 8.42 28.5 
339.3 8.21 26.1 
 9.243333333  
339.4 9.29 27.7 
339.5 11.9 32.1 
339.6 10.8 32.1 
 10.66333333  
339.7 12.1 36.5 
339.8 9.01 28.5 
339.9 11 33.3 
 10.70333333  
343.1 7.73 34.1 
343.2 9.03 38 
343.3 7.93 34.1 
 8.23  
343.4 10.6 44.1 
343.5 11 44.1 
343.6 10.4 37.7 
 10.66666667  
343.7 6.18 29.9 
343.8 9.01 36.3 
343.9 1.47 35.9 
 5.553333333  
350.1 17.3 47.5 
350.2 14.8 49.1 
174 
350.3 12 44.2 
 14.7  
350.4 13.3 47.6 
350.5 13.1 42.7 
350.6 11.2 39.1 
 12.53333333  
350.7 11.8 42.9 
350.8 12.2 38.6 
350.9 9.15 35 
 11.05  
357.1 9 41 
357.2 4.54 27.6 
357.3 17.1 50.4 
 10.21333333  
357.4 13 45.8 
357.5 13 45.6 
357.6 13.5 45.4 
 13.16666667  
357.7 15.5 47.7 
357.8 14.8 47.9 
357.9 13.8 47 
 14.7  
358.1 4.08 23 
358.2 4.09 22.3 
358.3 5.97 28.8 
 4.713333333  
358.4 3.53 20.6 
358.5 4.52 22 
358.6 2.79 16 
 3.613333333  
358.7 3.43 20.3 
358.8 0.98 6.71 
358.9 0.17 2.14 
 1.526666667  
359.1 7.94 31.1 
359.2 3.86 16.9 
359.3 6.15 25.1 
 5.983333333  
359.4 5.6 23.6 
359.5 9.97 36.6 
359.6 9.02 34.8 
 8.196666667  
359.7 4.54 20 
175 
359.8 5.22 24.1 
359.9 4.53 20.3 
 4.763333333  
361.1 0.92 7.49 
361.2 0.5 5.01 
361.3 0.22 2.73 
 0.546666667  
361.4 0.19 1.82 
361.5 0.2 2.38 
361.6 5.79 29.7 
 2.06  
361.7 4.51 23.4 
361.8 4.99 25.6 
361.9 4.58 25 
 4.693333333  
368.1 12.3 44 
368.2 9.63 36.1 
368.3 11.6 41 
 11.17666667  
368.4 8.86 31.3 
368.5 7.38 24.5 
368.6 9.42 33.9 
 8.553333333  
368.7 5.95 23.6 
368.8 10.8 41 
368.9 5.41 21.3 
 7.386666667  
369.1 4.88 19.2 
369.2 6.17 23.6 
369.3 4.55 19.4 
 5.2  
369.4 8.47 33.5 
369.5 7.52 27.2 
369.6 7.5 28.2 
 7.83  
369.7 6.51 27.9 
369.8 8.09 33.4 
369.9 6.33 27.4 
 6.976666667  
370.1 0.25 3.18 
370.2 0.2 2.61 
370.3 0.3 4.6 
 0.25  
176 
370.4 0.11 1.12 
370.5 2.33 25.2 
370.6 0.28 4.27 
 0.906666667  
370.7 0 0 
370.8 0.13 4.42 
370.9 0.34 4.43 
 0.156666667  
420.1 12.2 38 
420.2 18 55.8 
420.3 13.1 41.9 
 14.43333333  
420.4 9.28 32 
420.5 10.4 37.2 
420.6 12.6 41.3 
 10.76  
420.7 14.3 42.1 
420.8 11.1 37.1 
420.9 9.35 32.6 
 11.58333333  
421.1 13.7 51 
421.2 9.47 40.4 
421.3 8.55 41 
 10.57333333  
421.4 8.5 37.9 
421.5 15 57.5 
421.6 10.8 47.8 
 11.43333333  
421.7 8.43 38.3 
421.8 8.88 35.8 
 8.655  
 
 
Samples Freq. of CD8+ 
CD8 
Proliferation 
292.1 9.68 8.06 
292.2 0 0 
292.3 0 0 
 3.226666667 2.686666667 
292.4 3.85 0 
292.5 1.22 0.46 
 2.535 0.23 
292.7 11.2 4.41 
177 
292.8 6.56 2.49 
292.9 0 0 
 5.92 2.3 
293.1 6.45 6.45 
   
293.4 6.64 3.39 
   
293.7 0 0 
   
296.1 0 0 
   
296.4 5.19 3.36 
   
296.7 2.78 2.78 
   
721.1 2.33 1.55 
721.2 5.18 2.91 
721.3 7.82 3.63 
 5.11 2.696666667 
721.4 8.19 3.2 
721.5 7.53 3 
721.6 7.83 3.09 
 7.85 3.096666667 
721.7 6.14 3.17 
721.8 1.35 1.35 
721.9 4.55 0 
 4.013333333 1.506666667 
722.1 6.08 0.68 
722.2 13.6 4.55 
722.3 8.65 5.77 
 9.443333333 3.666666667 
722.4 10.5 10.5 
722.5 4.69 4.69 
722.6 0 0 
 5.063333333 5.063333333 
722.7 0 0 
722.8 23.5 17.6 
722.9 50 37.5 
 24.5 18.36666667 
756.1 1.28 1.28 
756.2 0 0 
 0.64 0.64 
756.4 0 0 
178 
   
756.7 0 0 
   
765.1 0 0 
765.2 3.76 1.57 
765.3 0 0 
 1.253333333 0.523333333 
765.4 2.66 1.14 
765.5 1.57 1.57 
 2.115 1.355 
765.7 0 0 
765.8 0 0 
765.9 1.94 0 
 0.646666667 0 
775.1 5.05 1.44 
   




Samples Freq. of CD8+ CD8 Proliferation 
297.1 0 n/a 
   
297.4 0 n/a 
   
297.7 0 n/a 
   
298.1 0 n/a 
   
298.4 33.3 n/a 
   
298.7 50 n/a 
   
723.1 0 n/a 
   
723.4 12.5 n/a 
   
723.7 16.4 n/a 
   
758.1 0 n/a 
   
758.7 0 n/a 
   
179 
761.1 50 n/a 
761.2 0 n/a 
 25  
761.4 0 n/a 
   
761.7 0 n/a 
761.8 0 n/a 
 0  
770.1 0 n/a 
770.2 0 n/a 
770.3 0 n/a 
 0  
770.4 7.84 n/a 
770.5 12.1 n/a 
770.6 29.5 n/a 
 16.48  
770.7 25 n/a 
770.8 0 n/a 
770.9 0 n/a 
 8.333333333  
772.1 13.5 n/a 
   
772.4 29.7 n/a 
   
772.7 0 n/a 
772.8 0 n/a 
772.9 0 n/a 
 0  
781.2 35.3 n/a 
782.1 30.6 n/a 
782.3 34.8 n/a 
 33.56666667  
782.4 31.9 n/a 
782.5 26 n/a 
782.6 5.85 n/a 
 21.25  
782.7 33.9 n/a 
782.8 35.2 n/a 
782.9 50 n/a 
 39.7  
 
 
Samples Freq. of CD8+ CD8 Proliferation 
180 
751.1 0 0 
751.2 0 0 
751.3 0 0 
 0  
751.4 0 0 
751.5 0 0 
 0  
752.1 0 0 
752.2 0 0 
 0  
752.4 0 0 
752.5 0 0 
 0  
753.1 0 0 
753.2 0 0 
753.3 0 0 
 0  
753.4 0 0 
753.5 0 0 
753.6 0 0 
 0  
754.1 0 0 
754.2 0 0 
754.3 0 0 
 0  
754.4 0 0 
754.5 0 0 
 0  
756.2 0 0 
756.3 0 0 
 0  
756.4 0 0 
756.5 0 0 
756.6 0 0 
 0  
757.1 0 0 
757.2 0 0 
757.3 0 0 
 0  
757.4 0 0 
757.5 0 0 
757.6 0 0 
 0  
181 
760.1 0 0 
760.2 0 0 
760.3 0 0 
 0  
760.4 0 0 
760.5 0 0 
760.6 0 0 
 0  
761.1 0 0 
761.2 0 0 
761.3 0 0 
 0  
761.4 0 0 
761.5 0 0 
761.6 0 0 
 0  
764.1 0 0 
764.2 0 0 
764.3 0 0 
 0  
764.4 0 0 
764.5 0 0 
764.6 0 0 
 0  
951.1 0 0 
951.2 0 0 
 0  
951.4 0 0 
951.5 0 0 
 0  
959.1 0 0 
959.2 0 0 
959.3 0 0 
 0  
959.4 0 0 
959.5 0 0 
959.6 0 0 
 0  
972.1 0 0 
972.2 0 0 
972.3 0 0 
 0  
972.4 0 0 
182 
972.5 0 0 
 0  
981.1 0 0 
981.2 0 0 
981.3 0 0 
 0  
981.5 0 0 
981.6 0 0 
 0  
982.1 0 0 
982.2 0 0 
982.3 0 0 
 0  
982.4 0 0 
982.5 0 0 
982.6 0 0 
 0  
985.1 0 0 
985.2 0 0 
985.3 0 0 
 0  
985.4 0 0 
985.5 0 0 
985.6 0.014 100 








726.1 10 3.33 
726.2 10.3 7.69 
762.3 13.8 13.8 
 11.36666667  
726.4 12.3 3.08 
726.5 10.5 0 
 11.4  
726.7 5 0 
726.8 6.67 6.67 
 5.835  
728.1 10.7 1.3 
728.2 11.3 1.8 
728.3 10.8 1.25 
 10.93333333  
183 
728.4 11.2 1.46 
728.5 12.1 1.36 
728.6 10.6 1.36 
 11.3  
728.7 10.4 1.69 
728.8 10.2 2.13 
728.9 11.5 1.92 
 10.7  
886.1 11 1.26 
886.2 12 1.47 
886.3 10.9 1.42 
 11.3  
886.4 11.3 1.2 
886.5 10.9 1.41 
886.6 11.1 1.31 
 11.1  
886.7 11 1.4 
886.8 10.5 1.15 
886.9 10.8 0.61 
 10.76666667  
887.1 10.8 0.21 
887.2 11.9 0.37 
887.3 11.1 0.37 
 11.26666667  
887.4 11.9 0.57 
887.55 11.4 0.37 
887.66 12.2 0.26 
 11.83333333  
887.7 11.5 0.15 
887.8 10.4 0.18 
887.9 10.9 0.28 
 10.93333333  
926.1 1.45 0.29 
926.2 4.15 0.46 
962.3 3.54 2.02 
 3.046666667  
926.4 2.02 0.51 
926.5 4.23 2.82 
926.6 1.83 0 
 2.693333333  
926.7 3.22 2.34 
926.8 2.44 1.83 
926.9 2.13 2.13 
184 
 2.596666667  
927.1 10.1 2.53 
927.2 9.78 2.85 
927.3 9.39 3.31 
 9.756666667  
927.4 9.69 2.92 
927.5 9.45 2.76 
927.6 9.47 2.47 
 9.536666667  
927.7 9.92 2.18 
927.8 7.31 2.95 
928.9 9.13 2.52 
  8.786666667  
948.1 2.89 0.24 
948.2 2.17 0.62 
 2.53  
948.4 1.56 0.67 
948.5 2.12 0.96 
 1.84  
948.7 0.79 0.79 
948.8 1.78 0.4 
 1.285  
954.1 7.45 1.29 
954.2 7.17 1.28 
954.3 6.58 1.16 
 7.066666667  
954.4 7.13 1.41 
954.5 6.4 1.23 
954.6 6.84 1.37 
 6.79  
954.7 4.07 3.66 
954.8 6.64 0.12 
954.9 7.49 0.72 
 6.066666667  
976.1 10.1 0.27 
976.2 9.48 0.27 
976.3 9 0.26 
 9.526666667  
976.4 9.08 0.24 
976.5 10.2 0.28 
976.6 10.4 0.41 
 9.893333333  
976.7 9.96 0.37 
185 
976.8 10.1 0.83 
976.9 10.1 1.05 
 10.05333333  
977.1 14.6 1.84 
977.2 11.6 1.28 
977.3 10.7 1.43 
 12.3  
977.4 12.3 0.99 
977.5 11.9 1.22 
977.6 11.4 1.01 
 11.86666667  
977.7 10.4 1 
977.8 11.2 1.13 
977.9 10.8 0.92 
 10.8  
 
 
Samples Freq. of CD8+ 
CD8 
Proliferation 
692.1 1.53 14.8 
692.2 1.21 11.8 
692.3 1.28 13 
 1.34  
692.4 0.64 6.36 
692.5 1.19 11.2 
692.6 1.29 12.5 
 1.04  
692.7 1.25 12.2 
692.8 1.33 12.1 
692.9 1.62 14.5 
 1.4  
693.1 1.53 15.8 
693.2 1.57 18.5 
693.3 1.47 16.2 
 1.523333333  
693.4 1.51 16.3 
693.5 0.78 10.1 
693.6 1.13 14.9 
 1.14  
693.7 1.47 17.9 
693.8 1.38 17.1 
693.9 1.24 15.2 
 1.363333333  
186 
694.1 1.09 13.2 
694.2 1.18 16.9 
694.3 1.03 13.4 
 1.1  
694.4 1.09 13 
694.5 1.45 16.9 
694.6 1.11 13.6 
 1.216666667  
694.7 0.92 11.1 
694.8 1.11 14.5 
694.9 0.9 11.6 
 0.976666667  
729.1 1.49 13 
729.2 2.54 19.7 
 2.015  
729.4 2.78 27.7 
729.5 0 0 
 1.39  
729.7 2.73 20.7 
729.9 2.72 19.7 
 2.725  
738.1 0.9 16 
738.2 1.33 23.6 
738.3 1.04 21.1 
 1.09  
738.4 1.64 24.4 
738.5 1.42 19.3 
738.6 1.22 18.2 
 1.426666667  
738.7 0.92 15.5 
738.8 1.58 25.1 
738.9 1.31 20.2 
 1.27  
758.1 1.11 15.1 
758.2 1.03 16.3 
758.3 1.13 17.5 
 1.09  
758.4 1.21 13.8 
758.5 1.45 14.5 
758.6 1.73 18.2 
 1.463333333  
762.1 2.15 22.9 
762.2 2.74 26.4 
187 
762.3 2.5 25.7 
 2.463333333  
762.4 2.12 19.9 
762.5 2.16 20.4 
762.6 2.36 21.9 
 2.213333333  
881.1 2.78 30.5 
881.2 2.5 32.1 
881.3 3.18 38.3 
 2.82  
881.4 3.18 36.1 
881.5 2.85 34.1 
881.6 2.83 33.5 
 2.953333333  
881.7 3.47 36.9 
881.8 2.93 33.5 
881.9 2.7 31.1 
 3.033333333  
883.1 1.79 20.6 
883.2 2.07 23.1 
883.3 2.28 22.9 
 2.046666667  
883.4 2.03 23.4 
883.5 1.9 22.3 
883.6 2.78 28.8 
 2.236666667  
883.7 2.39 25.1 
883.8 2.17 21.8 
883.9 2.72 27.8 
 2.426666667  
888.1 2.2 21.2 
888.2 2.25 22.8 
888.3 1.96 21.3 
 2.136666667  
888.4 2.47 26.4 
888.5 2.1 22.7 
888.6 1.88 20.3 
 2.15  
888.7 2.21 22.1 
888.8 2.09 18.9 
888.9 1.82 18.1 
 2.04  
931.1 4.99 27.7 
188 
931.2 5.06 28.2 
 5.025  
931.4 5.13 28.6 
931.5 5.97 32.4 
 5.55  
931.7 5.19 28.4 
931.8 5.22 29.8 
 5.205  
933.1 3.82 24 
933.2 3.02 20.4 
933.3 2.57 17.6 
 3.136666667  
933.4 3.51 21.7 
933.5 3.52 22.3 
933.6 3.44 21.3 
 3.49  
933.7 4.06 27.2 
933.8 3 19.3 
933.9 2.88 20.1 
 3.313333333  
949.1 0.96 50 
949.2 0.94 66.7 
949.3 0.48 100 
 0.793333333  
949.4 1.35 66.7 
949.5 0.4 25 
 0.875  
952.1 3.71 42.7 
952.2 3.99 44.1 
952.3 4.58 48.3 
 4.093333333  
952.4 5.14 47.8 
952.5 4.41 46.8 
952.6 4.87 44.7 
 4.806666667  
952.7 0 0 
952.8 4.51 42.9 
952.9 5.71 47.4 
 3.406666667  
953.1 1.3 20.3 
953.2 1.42 19.2 
953.3 1.78 25 
 1.5  
189 
953.4 1.31 21.7 
953.5 1.61 23.8 
953.6 1.05 18.7 
 1.323333333  
953.7 1.73 23.2 
953.8 1.24 19.8 
953.9 1.17 19.4 
 1.38  
956.1 1.17 31.5 
956.2 2.54 30 
956.3 1.33 34.2 
 1.68  
956.4 1.57 37.2 
956.5 1.08 26.4 
956.6 1.3 28.2 
 1.316666667  
956.7 1.36 36.8 
956.8 1.47 35.1 
956.9 1.1 26.7 
 1.31  
957.1 0 0 
957.2 0 0 
957.3 1.96 50 
 0.653333333  
957.4 1.14 100 
957.5 1.15 50 
 1.145  
957.7 4.17 100 
957.8 0 0 
957.9 0 0 
 1.39  
969.1 1.33 18.4 
969.2 1.52 20.9 
969.3 1.48 21.7 
 1.443333333  
969.4 1.61 23.3 
969.5 1.58 20.9 
969.6 1.24 18.2 
 1.476666667  
969.7 1.61 21.6 
969.8 1.82 22.3 
969.9 1.66 21.5 
 1.696666667  
190 
978.1 0.69 27.3 
978.2 0.52 22.2 
978.3 0.81 23.1 
 0.673333333  
978.4 0.84 37.5 
978.5 0.18 7.14 
 0.51  
978.7 0.34 7.14 
978.8 1.19 55.6 
978.9 0 0 
 0.51  
980.1 4.16 42.5 
980.2 4.35 42.5 
980.3 4.35 41.2 
 4.286666667  
980.4 3.09 33.1 
980.5 3.41 37.4 
980.6 4.13 40 
 3.543333333  
980.7 3.69 39.8 
980.8 4.48 40.1 
980.9 4.14 38.8 
 4.103333333  
 
 
Samples Freq. of CD8+ 
CD8 
Proliferation 
700.1 3.46 28.4 
700.2 3.83 30.4 
700.3 4 29.5 
 3.763333333  
700.4 3.34 30.4 
700.5 3.61 32.7 
700.6 3.18 29.4 
 3.376666667  
700.7 3.83 34.4 
700.8 3.63 30 
700.9 3.43 28.1 
 3.63  
730.1 1 33.3 
730.2 3.9 75 
 2.45  
730.4 0 0 
191 
730.5 1.72 23.1 
 0.86  
730.7 1.69 22.2 
730.8 2.4 38.5 
 2.045  
732.1 0 0 
732.2 0.75 14.3 
 0.375  
732.4 1.68 22.2 
   
732.7 1.14 50 
732.8 3.26 42.9 
 2.2  
737.1 1.54 33.3 
737.2 0 0 
 0.77  
737.4 0 0 
737.5 0 0 
 0  
737.7 0 0 
737.8 11.1 100 
 5.55  
739.1 1.7 16.3 
739.2 1.8 17.5 
739.3 1.81 17 
 1.77  
739.4 2.38 23.3 
739.5 2.03 19.3 
739.6 1.36 14 
 1.923333333  
739.7 2.32 19.5 
739.8 1.99 18.2 
739.9 2.11 17.6 
 2.14  
740.1 0.51 9.23 
740.2 1.25 21.4 
740.3 1.32 24 
 1.026666667  
740.4 1.6 24.6 
740.5 1.21 19.5 
740.6 1.42 22.5 
 1.41  
740.7 1.04 18.6 
192 
740.8 1.61 26.4 
740.9 1.32 22 
 1.323333333  
882.1 3.25 22.1 
882.2 2.81 18.7 
882.3 2.94 20.1 
 3  
882.4 3.61 23.5 
882.5 2.9 20.4 
882.6 3.85 24 
 3.453333333  
882.7 3.48 25.1 
882.8 3.19 20.8 
882.9 4.04 28.3 
 3.57  
884.1 0.33 6.07 
884.2 2.05 21.5 
884.3 2.18 24.4 
 1.52  
884.4 2.05 21.9 
884.5 2.09 22 
884.6 2.33 23.8 
 2.156666667  
884.7 2.21 21.5 
884.8 2.44 24 
884.9 2.21 23 
 2.286666667  
885.1 2.54 28.8 
885.2 2.86 30.2 
885.3 2.07 24 
 2.49  
885.4 2.98 33.5 
885.5 2.13 23.3 
885.6 2.25 25.8 
 2.453333333  
885.7 2.71 28.6 
885.8 3.09 32.7 
885.9 2.34 23.9 
 2.713333333  
971.1 0 0 
971.2 0 0 
 0  
971.4 0 0 
193 
971.5 0 0 
 0  
971.7 0 0 
971.8 0 0 
 0  
 
 
Samples Freq. of CD8+ 
CD8 
Proliferation 
380.1 2.5 18.2 
380.2 3.42 22.9 
380.3 3.24 20.8 
 3.053333333  
380.4 3.12 24.5 
380.5 2.39 19.7 
380.6 2.19 16.6 
 2.566666667  
380.7 3.74 24.5 
380.8 2.85 20.8 
380.9 2.65 18.3 
 3.08  
387.1 0.9 28.6 
387.2 0.36 9.09 
387.3 0.84 13.3 
 0.7  
387.4 1.14 25 
387.5 0 0 
387.6 0 0 
 0.38  
387.7 0 0 
387.8 0.66 13.3 
387.9 0 0 
 0.22  
411.1 1.64 23.9 
411.2 1.73 26.1 
411.3 1.51 22.7 
 1.626666667  
411.4 1.57 26 
411.5 1.85 28.1 
411.6 1.71 28.8 
 1.71  
411.7 1.57 25.4 
411.8 2.12 27.8 
194 
411.9 1.86 29.5 
 1.85  
417.1 3.94 37.4 
417.2 3.67 40 
417.3 3.13 31.1 
 3.58  
417.4 3.35 33.1 
417.5 3.63 36.6 
417.6 3.8 38.2 
 3.593333333  
417.7 3.04 32.1 
417.8 2.68 28.6 
417.9 3.37 30.1 
 3.03  
641.1 3.03 31.6 
641.2 2.4 25.8 
641.3 2.56 26.4 
 2.663333333  
641.4 2.82 26.2 
641.5 2.76 26.3 
641.6 2.5 27.4 
 2.693333333  
641.7 2.77 29.1 
641.8 2.36 25.2 
641.9 2.57 28.5 
 2.566666667  
642.1 2.56 26.4 
642.2 3.6 31.9 
642.3 2.7 25.6 
 2.953333333  
642.4 2.96 30.9 
642.5 3.31 30.8 
642.6 2.68 28.3 
 2.983333333  
642.7 3.39 31.2 
642.8 3.57 31.5 
642.9 3.38 33.7 
 3.446666667  
643.1 3.78 38.5 
643.2 4.57 40.4 
643.3 4.5 39.3 
 4.283333333  
643.4 4.06 45 
195 
643.5 4.34 43.9 
643.6 4.69 44.1 
 4.363333333  
643.7 4.11 40.5 
643.8 4.09 41.9 
643.9 4.53 42.3 
 4.243333333  
644.1 3.09 35 
644.2 3.23 33.5 
644.3 3.21 33.8 
 3.176666667  
644.4 2.65 28.1 
644.5 2.53 29.8 
644.6 2.58 31.7 
 2.586666667  
644.7 3.61 39 
644.8 2.82 34 
644.9 2.71 33.6 
 3.046666667  
780.1 2.54 35.3 
780.2 1.21 18.8 
780.3 2.12 33.3 
 1.956666667  
780.4 3.45 33.3 
780.5 1.27 16.7 
 2.36  
932.1 3.05 28.3 
932.2 2.95 26.1 
932.3 3.01 27.9 
 3.003333333  
932.4 2.87 25.7 
932.5 2.9 24.6 
932.6 1.27 10.2 
 2.346666667  
932.7 3.03 26.6 
932.8 2.79 21.2 
932.9 2.73 25.6 
 2.85  
 
 
Samples Freq. of CD8+ 
CD8 
Proliferation 
384.1 0 0 
196 
384.2 0 0 
384.3 0 0 
 0  
384.4 0 0 
384.5 0 0 
384.6 3.12 40 
 1.04  
384.7 0 0 
384.8 0 0 
384.9 17.6 75 
 5.866666667  
394.1 0 0 
394.2 7.41 40 
394.3 3.12 50 
 3.51  
394.4 0 0 
394.5 0 0 
394.6 0 0 
 0  
394.7 0 0 
394.8 0 0 
394.9 0 0 
 0  
395.1 3.87 23.1 
395.2 3.93 24.4 
395.3 3.41 21.5 
 3.736666667  
395.4 2.03 14.1 
395.5 2.61 20.9 
395.6 2.85 22.5 
 2.496666667  
395.7 4.63 29.6 
395.8 3.55 19.4 
395.9 3.95 25.9 
 4.043333333  
396.1 2.04 28.6 
396.2 0 0 
396.3 3.57 40 
 1.87  
396.4 2.11 33.3 
396.5 1.48 40 
396.6 1.28 25 
 1.623333333  
197 
396.7 0 0 
396.8 0 0 
396.9 0 0 
 0  
397.1 1.73 15.2 
397.2 2.16 19 
397.3 2.23 17.9 
 2.04  
397.4 0.93 11.1 
397.5 1.66 14.9 
397.6 1.56 16.7 
 1.383333333  
397.7 2.05 20.3 
397.8 2.57 20 
397.9 2.18 19 
 2.266666667  
402.1 2.6 47.6 
402.2 1.29 40 
402.3 2.89 47.6 
 2.26  
402.4 1.16 33.3 
402.5 1.25 28.6 
402.6 0.88 33.3 
 1.096666667  
402.7 3.2 50 
402.8 5.96 47.4 
402.9 1.04 20 
 3.4  
407.1 3.27 42.9 
407.2 2.9 28 
407.3 1.14 23.1 
 2.436666667  
407.4 1.6 20.8 
407.5 1.87 22.2 
407.6 3.18 50 
 2.216666667  
407.7 2.32 23.5 
407.8 1.69 21.4 
407.9 3.28 29.5 
 2.43  
408.1 1.47 10.7 
408.2 2.3 19.6 
408.3 2.86 19.3 
198 
 2.21  
408.4 0.93 8.7 
408.5 1.73 11.1 
408.6 1.95 13.8 
 1.536666667  
408.7 3.01 21.6 
408.8 2.73 18.1 
408.9 3.27 23.7 
 3.003333333  
412.1 4.56 22.4 
412.2 2.98 16.3 
412.3 4.3 21.8 
 3.946666667  
412.4 4.17 21.5 
412.5 4.87 24.1 
412.6 5.14 26.4 
 4.726666667  
412.7 5.17 24.2 
412.8 9.21 41.9 
412.9 3.4 18.1 
 5.926666667  
418.1 0 0 
418.2 1.3 15.8 
418.3 0.42 4.55 
 0.573333333  
418.4 0.83 20 
418.5 1.02 16.7 
418.6 0.65 9.09 
 0.833333333  
418.7 0 0 
418.8 1.68 16 
418.9 1.43 16.7 
 1.036666667  
 
 
Samples Freq. of CD8+ CD8 Proliferation 
381.1 2.68 15.8 
381.2 3.22 20.3 
381.3 2.62 18.9 
 2.84  
381.4 2.08 13.9 
381.5 2.04 12.8 
381.6 2.44 15.6 
199 
 2.186666667  
381.7 2.37 15.1 
381.8 2.62 16.1 
381.9 2.13 13.7 
 2.373333333  
382.1 0 0 
382.2 0.25 50 
382.33 0.97 5.38 
 0.406666667  
382.4 0.15 25 
382.5 0.21 20 
382.6 0.16 50 
 0.173333333  
382.7 0.15 12.5 
382.8 0 0 
382.9 0.29 33.3 
 0.146666667  
383.1 1.27 6.93 
383.2 1.23 6.97 
 1.25  
383.4 0.66 4.57 
383.5 0.83 5.84 
383.6 0.93 5.95 
 0.806666667  
383.7 0.73 4.76 
383.8 0.78 4.98 
383.9 1 6.41 
 0.836666667  
385.1 0.73 5.29 
385.2 1.89 11.8 
385.3 3.41 40 
 2.01  
385.4 0.82 6.19 
385.5 1.73 13.6 
385.6 0.35 2.73 
 0.966666667  
385.7 1.25 8.64 
385.8 1.51 12.5 
385.9 0.22 1.72 
 0.993333333  
386.1 1.7 14.5 
386.2 2 17.6 
386.3 2.22 18.8 
200 
 1.973333333  
386.4 1.55 16.3 
386.5 2.33 22.3 
386.6 1.93 18.4 
 1.936666667  
386.7 2.35 19.5 
386.8 3.08 25.4 
386.9 2.46 21.6 
 2.63  
391.1 0 0 
391.2 0.94 8.33 
391.3 0 0 
 0.313333333  
391.4 0 0 
391.5 3.85 50 
391.6 0 0 
 1.283333333  
391.7 2 33.3 
391.8 0.63 8.33 
391.9 0 0 
 0.876666667  
392.1 0 0 
392.2 0 0 
392.3 0 0 
 0  
392.4 0 0 
392.5 0 0 
392.6 0 0 
 0  
392.7 0 0 
392.8 0 0 
392.9 0 0 
 0  
403.1 1.64 16.7 
403.2 0.66 8.51 
403.3 2.29 37.5 
 1.53  
403.4 1.39 17.9 
403.5 0.63 7.14 
403.6 2.73 26.3 
 1.583333333  
403.7 2.45 21.2 
403.8 1.54 18.4 
201 
403.9 0.79 8 
 1.593333333  
405.1 0.46 6.17 
405.2 0.77 10.5 
405.3 0 0 
 0.41  
405.4 0.52 7.81 
405.5 0.37 7.84 
405.6 0.28 4.48 
 0.39  
405.7 0.32 6.67 
405.8 0.66 12 
405.9 1.1 16.7 
 0.693333333  
406.1 0.51 4.76 
406.2 0 0 
406.3 0 0 
 0.17  
406.4 0 0 
406.5 0 0 
406.6 0 0 
 0  
406.7 0 0 
406.8 0 0 
406.9 0 0 
 0  
 
 
Samples Freq. of CD8+ CD8 Proliferation 
390.1 0 0 
390.2 0 0 
 0  
390.4 0 0 
 0  
390.7 0 0 
390.8 0 0 
 0  
393.1 3.49 40 
393.2 0.64 14.3 
393.3 2.52 30 
 2.216666667  
393.4 0.56 12.5 
393.5 2.87 55.6 
202 
393.6 1.24 22.2 
 1.556666667  
393.7 5.91 68.8 
393.8 2.13 37.5 
393.9 2.04 50 
 3.36  
413.1 0 0 
413.2 2.69 26.3 
413.3 3.36 33.3 
 2.016666667  
413.4 2.11 42.9 
413.5 4.41 85.7 
413.6 3.47 58.3 
 3.33  
413.7 2.25 29.4 
413.8 2.46 41.2 
413.9 2.75 33.3 
 2.486666667  
419.1 4.02 33.3 
419.2 4.42 36.6 
419.3 4.66 42.4 
 4.366666667  
419.4 3.84 34.2 
419.5 4.93 40.7 
419.6 2.79 32.4 
 3.853333333  
419.7 3.54 32.4 
419.8 6.06 50.9 
419.9 3.05 30.7 
 4.216666667  
926.1 0 0 
926.2 0 0 
926.3 0 0 
 0  
926.4 0 0 
926.5 4.35 100 
926.6 0 0 
 1.45  
926.7 0 0 
926.8 3.7 50 
926.9 0 0 




Samples Freq. of CD8+ 
CD8 
Proliferation 
345.1 0.4 6.37 
345.2 0.58 15.1 
345.3 0.44 10.9 
 0.473333333  
345.4 0.37 10.4 
345.5 0.21 4.81 
345.6 0.47 7.69 
 0.35  
345.7 0.64 13.1 
345.8 0.42 8.43 
345.9 0.3 5.77 
 0.453333333  
347.1 0.18 3.42 
347.2 0.28 6.44 
347.3 0.33 7.1 
 0.263333333  
347.4 0.18 3.29 
347.5 0.15 3.03 
347.6 0.2 3.7 
 0.176666667  
347.7 0.055 3.64 
347.8 0.36 5.8 
347.9 0.22 6.02 
 0.211666667  
363.1 0.23 4.49 
363.2 0.24 3.97 
363.3 0.47 8.1 
 0.313333333  
363.4 0.25 4.03 
363.5 0.25 5.73 
363.6 0.14 2.14 
 0.213333333  
363.7 0.39 5.71 
363.8 0.37 5.61 
363.9 0.25 3.75 
 0.336666667  
364.1 0.37 5.3 
364.2 0.41 4.78 
364.3 0.32 4.21 
 0.366666667  
204 
364.4 0.38 3.27 
364.5 0.23 2.07 
364.6 0.38 3.15 
 0.33  
364.7 0.63 5.88 
364.8 0.44 3.51 
364.9 0.45 3.51 
 0.506666667  
365.1 0 0 
365.2 0 0 
365.3 0 0 
 0  
365.4 0 0 
365.5 0.27 5.88 
365.6 0.44 16.7 
 0.236666667  
365.7 0 0 
365.8 0 0 
365.9 0 0 
 0  
366.1 0 0 
366.2 0 0 
366.3 0 0 
 0  
366.4 0 0 
366.5 0 0 
366.6 0.11 3.45 
 0.036666667  
366.7 0.11 5.88 
366.8 0 0 
366.9 0 0 
 0.036666667  
374.1 0.28 2.3 
374.2 0.26 2.33 
374.3 0.35 3.34 
 0.296666667  
374.4 0.47 5.24 
374.5 0.18 1.48 
374.6 0.49 5.52 
 0.38  
374.7 0.52 5.3 
374.8 0.34 3.94 
374.9 0.21 2.14 
205 
 0.356666667  
375.1 0.2 1.83 
375.2 0.31 2.85 
375.3 0.1 1 
 0.203333333  
375.4 0.22 2.39 
375.5 0.21 2.37 
375.6 0.094 1.16 
 0.174666667  
375.7 0.48 5.41 
375.8 0.071 0.63 
375.9 0.22 3.05 
 0.257  
 
 
Samples Freq. of CD8+ CD8 Proliferation 
331.1 3.24 36.6 
331.2 2.55 35.4 
 2.895  
331.4 2.95 36.3 
331.5 2.46 32.2 
 2.705  
331.7 3.26 37 
331.8 2.63 31.8 
 2.945  
336.1 3.94 35.5 
336.2 4.3 42.2 
336.3 4.39 41.6 
 4.21  
336.4 3.57 33.2 
336.5 3.55 34.4 
336.6 3.75 41.7 
 3.623333333  
336.7 3.62 34.9 
336.8 4.43 40 
336.9 4.71 52.3 
 4.253333333  
337.1 3.33 33.3 
337.2 2.53 23.8 
337.3 2.44 26.3 
 2.766666667  
337.4 2.42 24.1 
337.5 2.18 22.3 
206 
337.6 1.96 22.1 
 2.186666667  
337.7 3.51 58.6 
337.8 2.99 26 
337.9 2.17 27.3 
 2.89  
340.1 2.31 36.6 
340.2 2.81 43.7 
340.3 1.81 29.3 
 2.31  
340.4 1.96 29.4 
340.5 2.23 34.5 
340.6 1.35 29.7 
 1.846666667  
340.7 2.6 45.8 
340.8 1.44 33.3 
340.9 1.24 23 
 1.76  
344.1 3.21 42.5 
344.2 2.88 50 
344.3 2.37 28.4 
 2.82  
344.4 1.83 25.9 
344.5 2.82 38.9 
344.6 2.16 37.9 
 2.27  
344.7 1.8 31 
344.8 1.38 23.4 
344.9 2.28 36 
 1.82  
346.1 3.76 45.7 
346.2 3.74 42.6 
346.3 3.38 38.3 
 3.626666667  
346.4 3.28 34.4 
346.5 2.83 32.1 
346.6 2.46 32.6 
 2.856666667  
346.7 3.05 38.8 
346.8 3.36 38.6 
346.9 3.03 34.8 
 3.146666667  
367.1 6.25 34.1 
207 
367.2 6.16 35.9 
367.3 8.32 47.7 
 6.91  
367.4 6.5 37.9 
367.5 6.1 35.6 
367.6 6.48 38.5 
 6.36  
367.7 7.6 42.5 
367.8 6.76 38.5 
367.9 6.75 44.7 
 7.036666667  
414.1 7.85 69.7 
414.2 6.68 68.6 
414.3 6.83 67.9 
 7.12  
414.4 6.52 49 
414.5 7 70.4 
414.6 6.42 74.8 
 6.646666667  
414.7 7.82 72.8 
414.8 7.19 70.3 
414.9 5.88 67.7 
 6.963333333  
 
 
Samples Freq. of CD8+ CD8 Proliferation 
330.1 3.99 48 
330.2 1.65 25.3 
330.3 3.01 35.8 
 2.883333333  
330.4 2.78 43.3 
330.5 3.51 59.4 
330.6 3.09 35.5 
 3.126666667  
330.7 1.71 16.3 
330.8 2.5 24.8 
330.9 1.78 17.7 
 1.996666667  
332.1 2.25 19.3 
332.2 2.37 20.9 
332.3 2.22 22.6 
 2.28  
332.4 2.11 23.4 
208 
332.5 1.79 22.9 
332.6 2.28 22.7 
 2.06  
332.7 2.54 29.7 
332.8 2.9 26.8 
332.9 0.22 2.06 
 1.886666667  
333.1 3.07 35.4 
333.2 1.76 32 
333.3 2.04 26.6 
 2.29  
333.4 0.27 5.08 
333.5 2.33 31.2 
333.6 1.97 25.2 
 1.523333333  
333.7 2.96 33.8 
333.8 2.2 27.1 
333.9 2.81 41.6 
 2.656666667  
334.1 2.51 25.4 
334.2 4.55 51.4 
334.3 5.61 53.1 
 4.223333333  
334.4 2.86 28.9 
334.5 3.95 47.4 
334.6 3.29 41.1 
 3.366666667  
334.7 4.39 48.4 
334.8 3.76 50.2 
334.9 3.82 46.8 
 3.99  
335.1 8.18 68.4 
335.2 5.48 53.2 
335.3 7.18 69.3 
 6.946666667  
335.4 7.75 68.1 
335.5 6.23 59.4 
335.6 8.96 74.9 
 7.646666667  
335.7 2.67 56.6 
335.8 6.57 61.5 
335.9 7.36 73.6 
 5.533333333  
209 
338.1 2.61 35.1 
338.2 2.49 37.8 
338.3 2.84 50.2 
 2.646666667  
338.4 2.8 46.4 
338.5 0.89 11.7 
338.6 2.96 37.9 
 2.216666667  
338.7 3.33 39.6 
338.8 2.63 31.4 
338.9 2.63 31.6 
 2.863333333  
339.1 5.8 48.8 
339.2 5.58 40.6 
339.3 5.61 44.4 
 5.663333333  
339.4 5.36 48.6 
339.5 7.58 56.1 
339.6 6.15 51 
 6.363333333  
339.7 7.47 57.6 
339.8 6.26 53 
339.9 6.08 49.8 
 6.603333333  
343.1 3.81 52.1 
343.2 3.13 51.5 
343.3 2.25 42.5 
 3.063333333  
343.4 3.39 63.2 
343.5 2.88 50.6 
343.6 3.56 58.3 
 3.276666667  
343.7 2.55 35.6 
343.8 2.11 36.3 
343.9 5.03 68.9 
 3.23  
350.1 3.4 77.8 
350.2 4.75 80.6 
350.3 3.67 68.1 
 3.94  
350.4 3.58 77.3 
350.5 3.87 80.3 
350.6 3.2 71.4 
210 
 3.55  
350.7 3.93 75.9 
350.8 4.9 71.3 
350.9 3.12 64.1 
 3.983333333  
357.1 3.26 57.1 
357.2 4.14 39.8 
357.3 8 74.3 
 5.133333333  
357.4 6.41 70.4 
357.5 6.3 71.1 
357.6 5.46 69.2 
 6.056666667  
357.7 7.53 75.9 
357.8 9.01 79.9 
357.9 6.87 71.7 
 7.803333333  
358.1 2.91 36.9 
358.2 2.39 33 
358.3 2.65 33.8 
 2.65  
358.4 2.44 34.1 
358.5 3.18 37.8 
358.6 2.52 28.7 
 2.713333333  
358.7 3.5 36.6 
358.8 1.14 10.4 
358.9 0.37 4.89 
 1.67  
359.1 2.64 38.8 
359.2 1.47 22.9 
359.3 2.1 31.7 
 2.07  
359.4 2.1 32.9 
359.5 3.71 56.9 
359.6 2.68 45.7 
 2.83  
359.7 1.55 21.6 
359.8 1.82 26 
359.9 1.96 27.7 
 1.776666667  
361.1 0.61 8.6 
361.2 0.5 7.6 
211 
361.3 0.24 3.74 
 0.45  
361.4 0.39 5.43 
361.5 0.36 5.1 
361.6 3.88 50.2 
 1.543333333  
361.7 3.69 45.2 
361.8 3.37 41.6 
361.9 3.14 39.7 
 3.4  
368.1 7.28 55.2 
368.2 6.87 50.9 
368.3 6.44 51.3 
 6.863333333  
368.4 6.16 51.3 
368.5 5.74 41.7 
368.6 5.26 47.3 
 5.72  
368.7 3.52 28.1 
368.8 6.75 50.6 
368.9 4.14 31.8 
 4.803333333  
369.1 5.64 43.9 
369.2 5.86 47.1 
369.3 4.94 42.1 
 5.48  
369.4 6.19 57 
369.5 7.29 62.1 
369.6 6.99 59 
 6.823333333  
369.7 5.3 48.6 
369.8 5.64 51.3 
369.9 5.82 47 
 5.586666667  
370.1 0.39 7.73 
370.2 0.23 6.6 
370.3 0.19 4.1 
 0.27  
370.4 0.17 4.08 
370.5 0.58 17.3 
370.6 0.14 3.5 
 0.296666667  
370.7 0.3 6.82 
212 
370.8 0.31 8.28 
370.9 0.29 6.99 
 0.3  
420.1 7.8 68.2 
420.2 9.06 71.9 
420.3 7.91 62.7 
 8.256666667  
420.4 4.44 47 
420.5 5.81 52 
420.6 5.62 50 
 5.29  
420.7 6.69 63.9 
420.8 5.48 57.3 
420.9 6.07 50.8 
 6.08  
421.1 5.92 65.9 
421.2 3.64 54.7 
421.3 4.09 66.7 
 4.55  
421.4 4.98 68.4 
421.5 5.35 72.1 
421.6 3.21 62.6 
 4.513333333  
421.7 4.91 62.3 
421.8 4.03 54.4 















































































































K7M2 Cell Culture 
 
     
Cells + Allo Serum 1_100.fcs                              197     15.1 
  
Cells + Allo 1_50.fcs                                             229      18 
  
Cells + Auto 1_50.fcs                                           80.9    6.69 
  
Cells + Auto 1_100.fcs                                        92.8     6.58                             
  
Cells+ CTL Serum 1_100.fcs                               70        9.22 
  
Cells.fcs                                                                  12.7    1.02   
Mean                                                                      114     9.44   









     
                                                                   Mean FITC Intensity               Antibody Bound 
Cells.fcs                                                                12.7                                         1.02     
Cells+ CTL Serum 1_100.fcs                              70                                             9.22     
Cells + Allo Serum 1_100.fcs                             197                                          15.1     
Cells + Auto 1_100.fcs                                        92.8                                          6.58   
 
 
 
 
 
 
 
 
 
 
 
 
217 
 
